EP0823941A4 - Human antibodies derived from immunized xenomice - Google Patents

Human antibodies derived from immunized xenomice

Info

Publication number
EP0823941A4
EP0823941A4 EP95918935A EP95918935A EP0823941A4 EP 0823941 A4 EP0823941 A4 EP 0823941A4 EP 95918935 A EP95918935 A EP 95918935A EP 95918935 A EP95918935 A EP 95918935A EP 0823941 A4 EP0823941 A4 EP 0823941A4
Authority
EP
European Patent Office
Prior art keywords
human antibodies
antibodies derived
immunized xenomice
xenomice
immunized
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP95918935A
Other languages
German (de)
French (fr)
Other versions
EP0823941A1 (en
Inventor
Raju Kucherlapati
Aya Jakobovits
Sue Klapholz
Daniel G Brenner
Daniel J Capon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Fremont Inc
Original Assignee
Abgenix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abgenix Inc filed Critical Abgenix Inc
Publication of EP0823941A1 publication Critical patent/EP0823941A1/en
Publication of EP0823941A4 publication Critical patent/EP0823941A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C07K16/2854—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72 against selectins, e.g. CD62
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EP95918935A 1995-04-28 1995-04-28 Human antibodies derived from immunized xenomice Withdrawn EP0823941A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CA002219486A CA2219486A1 (en) 1995-04-28 1995-04-28 Human antibodies derived from immunized xenomice
PCT/US1995/005500 WO1996034096A1 (en) 1995-04-28 1995-04-28 Human antibodies derived from immunized xenomice

Publications (2)

Publication Number Publication Date
EP0823941A1 EP0823941A1 (en) 1998-02-18
EP0823941A4 true EP0823941A4 (en) 2001-09-19

Family

ID=25679770

Family Applications (1)

Application Number Title Priority Date Filing Date
EP95918935A Withdrawn EP0823941A4 (en) 1995-04-28 1995-04-28 Human antibodies derived from immunized xenomice

Country Status (4)

Country Link
EP (1) EP0823941A4 (en)
AU (1) AU2466895A (en)
CA (1) CA2219486A1 (en)
WO (1) WO1996034096A1 (en)

Families Citing this family (1502)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6713610B1 (en) 1990-01-12 2004-03-30 Raju Kucherlapati Human antibodies derived from immunized xenomice
US5770429A (en) * 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US7084260B1 (en) 1996-10-10 2006-08-01 Genpharm International, Inc. High affinity human antibodies and human antibodies against human antigens
US7041871B1 (en) 1995-10-10 2006-05-09 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6300129B1 (en) * 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5795966A (en) † 1995-02-22 1998-08-18 Immunex Corp Antagonists of interleukin-15
US7888466B2 (en) 1996-01-11 2011-02-15 Human Genome Sciences, Inc. Human G-protein chemokine receptor HSATU68
US7964190B2 (en) 1996-03-22 2011-06-21 Human Genome Sciences, Inc. Methods and compositions for decreasing T-cell activity
US6635743B1 (en) 1996-03-22 2003-10-21 Human Genome Sciences, Inc. Apoptosis inducing molecule II and methods of use
EP0966971A1 (en) 1996-04-23 1999-12-29 Chugai Seiyaku Kabushiki Kaisha Cerebral stroke/cerebral edema preventive or remedy containing il-8 binding inhibitor as active ingredient
WO1998006431A2 (en) * 1996-08-16 1998-02-19 Osther Kurt B Method for treating diabetes
CA2273194C (en) 1996-12-03 2011-02-01 Abgenix, Inc. Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
AU2008200005B2 (en) * 1996-12-03 2012-05-17 Amgen Fremont Inc. Transgenic Mammals Having Human Ig Loci Including Plural Vh and Vk Regions and Antibodies Produced Therefrom
ATE547119T1 (en) 1997-03-21 2012-03-15 Chugai Pharmaceutical Co Ltd PREVENTIVE OR THERAPEUTIC AGENT CONTAINING AN IL-6 ANTAGONIST AS AN ACTIVE INGREDIENTS FOR SENSITIZED T CELL-MEDIATED DISEASES
US20020173629A1 (en) 1997-05-05 2002-11-21 Aya Jakobovits Human monoclonal antibodies to epidermal growth factor receptor
US6235883B1 (en) * 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
KR20010022846A (en) 1997-08-15 2001-03-26 나가야마 오사무 Preventives and/or remedies for systemic lupus erythematosus containing anti-il-6 receptor antibody as the active ingredient
AU6369399A (en) 1998-11-04 2000-05-22 Chugai Research Institute For Molecular Medicine, Inc. Novel trypsin family serine proteases
JP3579355B2 (en) * 1998-12-09 2004-10-20 プロテイン デザイン ラブス インコーポレイティド Psoriasis model animals for preventing and treating human psoriasis
JP3793693B2 (en) 1998-12-23 2006-07-05 ファイザー インコーポレーテッド Human monoclonal antibody against CTLA-4
US7109003B2 (en) 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
US6682736B1 (en) 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
JP2002537769A (en) 1999-02-26 2002-11-12 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド Human endokine alpha and method of use
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
AU3674000A (en) 1999-04-09 2000-11-14 Chugai Research Institute For Molecular Medicine, Inc. Novel fetal genes
JP2002544174A (en) 1999-05-07 2002-12-24 ジェネンテック・インコーポレーテッド Treatment of autoimmune diseases using antagonists that bind to B cell surface markers
NZ515686A (en) 1999-06-01 2005-01-28 Biogen Inc A blocking monoclonal antibody to integrin VLA-1 and its use for the treatment of inflammatory disorders such as arthritis
EP2135953B1 (en) 1999-06-02 2014-04-23 Chugai Seiyaku Kabushiki Kaisha Novel hemopoietin receptor protein, Nr. 10
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
AU783356B2 (en) * 1999-07-29 2005-10-20 Medarex, Inc. Human monoclonal antibodies to prostate specific membrane antigen
EP1213028B1 (en) 1999-08-23 2008-08-13 Chugai Seiyaku Kabushiki Kaisha Hm1.24 antigen expression potentiators
US6984720B1 (en) * 1999-08-24 2006-01-10 Medarex, Inc. Human CTLA-4 antibodies
WO2001018200A1 (en) 1999-09-06 2001-03-15 Chugai Seiyaku Kabushiki Kaisha Tsg-like gene
JP4838961B2 (en) 1999-09-21 2011-12-14 中外製薬株式会社 Transporter genes OATP-B, C, D, and E
IL148980A0 (en) 1999-10-01 2002-11-10 Chugai Pharmaceutical Co Ltd An antibody to human tissue factor and experimental animals having inserted cells with the gene encoding human tissue factor
BR0107799A (en) 2000-01-24 2002-10-22 Haruo Sugiyama Wt1 interaction protein wtip
EP1257585A2 (en) 2000-02-10 2002-11-20 Basf Aktiengesellschaft Antibodies that bind human interleukin-18 and methods of making and using
US6653448B1 (en) 2000-03-29 2003-11-25 Curagen Corporation Wnt-7B-like polypeptides and nucleic acids encoding same
GB0006398D0 (en) 2000-03-16 2000-05-03 Novartis Ag Organic compounds
CA2405557C (en) 2000-04-12 2013-09-24 Human Genome Sciences, Inc. Albumin fusion proteins
US7063845B2 (en) 2000-04-28 2006-06-20 Gemini Science, Inc. Human anti-CD40 antibodies
WO2001083755A2 (en) * 2000-04-28 2001-11-08 La Jolla Institute For Allergy And Immunology Human anti-cd40 antibodies and methods of making and using same
DK2990420T3 (en) 2000-05-26 2017-04-03 Immunex Corp USE OF INTERLEUKIN-4 RECEPTOR ANTIBODIES AND COMPOSITIONS THEREOF
US20030031675A1 (en) 2000-06-06 2003-02-13 Mikesell Glen E. B7-related nucleic acids and polypeptides useful for immunomodulation
WO2001096528A2 (en) 2000-06-15 2001-12-20 Human Genome Sciences, Inc. Human tumor necrosis factor delta and epsilon
WO2002002641A1 (en) 2000-06-16 2002-01-10 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to blys
MXPA02012867A (en) 2000-06-29 2003-09-05 Abbott Lab Dual specificity antibodies and methods of making and using.
UA81743C2 (en) 2000-08-07 2008-02-11 Центокор, Инк. HUMAN MONOCLONAL ANTIBODY WHICH SPECIFICALLY BINDS TUMOR NECROSIS FACTOR ALFA (TNFα), PHARMACEUTICAL MIXTURE CONTAINING THEREOF, AND METHOD FOR TREATING ARTHRITIS
US7288390B2 (en) 2000-08-07 2007-10-30 Centocor, Inc. Anti-dual integrin antibodies, compositions, methods and uses
US6902734B2 (en) 2000-08-07 2005-06-07 Centocor, Inc. Anti-IL-12 antibodies and compositions thereof
CA2424296A1 (en) * 2000-10-02 2002-04-11 Chiron Corporation Human anti-cd40 antibodies
EP2412384A1 (en) 2000-11-28 2012-02-01 MedImmune, LLC Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
DE60143544D1 (en) 2000-12-12 2011-01-05 Medimmune Llc MOLECULES WITH LONGER MID-TERM, COMPOSITIONS AND THEIR USE
BRPI0116728B1 (en) 2001-01-05 2018-10-30 Abgenix Inc insulin-like growth factor i receptor antibodies
JP2005510201A (en) * 2001-01-26 2005-04-21 アブジェニックス インコーポレイテッド Neutralizing human monoclonal antibodies against HIV-1, their production and use
EP1364657B1 (en) 2001-02-07 2016-12-28 Chugai Seiyaku Kabushiki Kaisha Remedies for myelocytic leukemia
CN1564826A (en) 2001-02-09 2005-01-12 人类基因组科学公司 Human G-protein chemokine receptor (CCR5) HDGNR10
US7087726B2 (en) * 2001-02-22 2006-08-08 Genentech, Inc. Anti-interferon-α antibodies
US8981061B2 (en) 2001-03-20 2015-03-17 Novo Nordisk A/S Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof
EP2294917A1 (en) 2001-03-22 2011-03-16 Abbott GmbH & Co. KG Transgenic animals expressing antibodies specific for genes of interest and uses thereof
UA80091C2 (en) 2001-04-02 2007-08-27 Chugai Pharmaceutical Co Ltd Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
AU2002303261A1 (en) 2001-04-06 2002-10-21 Georgetown University Gene brcc2 and diagnostic and therapeutic uses thereof
AU2002258728A1 (en) 2001-04-06 2002-10-21 Georgetown University Gene brcc-3 and diagnostic and therapeutic uses thereof
WO2002081641A2 (en) 2001-04-06 2002-10-17 Georgetown University Gene scc-112 and diagnostic and therapeutic uses thereof
DK1385864T3 (en) 2001-04-13 2010-08-16 Human Genome Sciences Inc Anti-VEGF-2 antibodies
KR100927670B1 (en) 2001-04-13 2009-11-20 바이오겐 아이덱 엠에이 인코포레이티드 Antibodies Against ZAL-1
PT1391464E (en) 2001-04-27 2007-11-15 Kirin Pharma Kk Anti-cd40 monoclonal antibody
JP2005519580A (en) 2001-05-16 2005-07-07 アルバート アインシュタイン カレッジ オブ メディシン オブ イエシバ ユニバーシティ Human anti-pneumococcal antibody derived from non-human animals
WO2002097033A2 (en) 2001-05-25 2002-12-05 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to trail receptors
US7247304B2 (en) 2001-08-23 2007-07-24 Genmab A/S Methods of treating using anti-IL-15 antibodies
HU229776B1 (en) 2001-08-23 2014-07-28 Genmab As Human antibodies specific for interleukin 15 (il-15)
US7329405B2 (en) 2001-08-23 2008-02-12 Genmab A/S Human antibodies specific for interleukin 15 (IL-15)
US7981863B2 (en) 2001-09-19 2011-07-19 Neuronova Ab Treatment of Parkinson's disease with PDGF
WO2003029296A1 (en) * 2001-10-02 2003-04-10 Chiron Corporation Human anti-cd40 antibodies
AR039067A1 (en) 2001-11-09 2005-02-09 Pfizer Prod Inc ANTIBODIES FOR CD40
ES2645698T3 (en) 2001-11-30 2017-12-07 Amgen Fremont Inc. Transgenic animals that carry human Ig light chain genes
EP2261250B1 (en) 2001-12-21 2015-07-01 Human Genome Sciences, Inc. GCSF-Albumin fusion proteins
SI1475101T1 (en) 2002-02-14 2011-03-31 Chugai Pharmaceutical Co Ltd Antibody-containing solution pharmaceuticals
WO2003083116A1 (en) 2002-03-29 2003-10-09 Chugai Seiyaku Kabushiki Kaisha Emthod of screening transporter inhibitor
CN1326879C (en) 2002-03-29 2007-07-18 先灵公司 Human monoclonal antibodies to interleukin-5 and methods and compositions comprising same
US7244565B2 (en) 2002-04-10 2007-07-17 Georgetown University Gene shinc-3 and diagnostic and therapeutic uses thereof
SI1503794T1 (en) 2002-04-12 2012-09-28 Medarex Inc Methods of treatement using ctla-4 antibodies
AU2003226065B2 (en) 2002-04-12 2009-02-26 Ludwig Institute For Cancer Research, Ltd Recombinant anti-interleukin-9 antibodies
US20040005671A1 (en) 2002-05-17 2004-01-08 Amrad Operations Pty Ltd. Immunointeractive molecules
CN101613406A (en) 2002-06-06 2009-12-30 肿瘤疗法科学股份有限公司 Gene relevant and polypeptide with human colon carcinoma
KR101031025B1 (en) 2002-06-06 2011-04-25 온코세라피 사이언스 가부시키가이샤 Genes and polypeptides relating to human colon cancers
EP2070949B1 (en) 2002-06-10 2013-01-16 Vaccinex, Inc. C35 antibodies and their use in the treatment of cancer
US7425618B2 (en) 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
CN1688340A (en) 2002-07-15 2005-10-26 韦思公司 Methods and compositions for modulating T helper (TH) cell development and function
US7425620B2 (en) 2002-08-14 2008-09-16 Scott Koenig FcγRIIB-specific antibodies and methods of use thereof
EP1541165A4 (en) 2002-08-27 2009-06-24 Chugai Pharmaceutical Co Ltd Method of stabilizing protein solution preparation
AU2003267124A1 (en) 2002-09-09 2004-03-29 Dana-Farber Cancer Institute, Inc. Bh3 peptides and method of use thereof
CN100522989C (en) 2002-09-11 2009-08-05 中外制药株式会社 Method of purifying protein
TW200418988A (en) 2002-09-30 2004-10-01 Oncotherapy Science Inc Method for diagnosing prostate cancer
TW200413725A (en) 2002-09-30 2004-08-01 Oncotherapy Science Inc Method for diagnosing non-small cell lung cancers
CN1891826B (en) 2002-10-22 2011-09-14 卫材R&D管理有限公司 Gene specifically expressed in postmitotic dopaminergic neuron precursor cells
JPWO2004039981A1 (en) 2002-10-30 2006-03-02 中外製薬株式会社 Mast cell-derived membrane protein
JP2006520584A (en) 2002-11-08 2006-09-14 アブリンクス エン．ヴェー． Stabilized single domain antibody
US20060034845A1 (en) 2002-11-08 2006-02-16 Karen Silence Single domain antibodies directed against tumor necrosis factor alpha and uses therefor
US9320792B2 (en) 2002-11-08 2016-04-26 Ablynx N.V. Pulmonary administration of immunoglobulin single variable domains and constructs thereof
EP1572106B1 (en) 2002-11-15 2010-05-05 Novartis Vaccines and Diagnostics, Inc. Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis
CA2537263C (en) 2002-11-27 2017-05-30 Minerva Biotechnologies Corporation Techniques and compositions for the diagnosis and treatment of cancer (muc1)
ES2347239T3 (en) 2002-12-02 2010-10-27 Amgen Fremont Inc. ANTIBODIES DIRECTED TO THE TUMOR NECROSIS FACTOR AND USES OF THE SAME.
EP2141235B1 (en) 2002-12-29 2014-06-11 Toudai Tlo, Ltd. Adiponectin receptor and gene coding for the same
ES2897506T3 (en) 2003-01-09 2022-03-01 Macrogenics Inc Identification and modification of antibodies with variant Fc regions and methods of using them
DE10303974A1 (en) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid β (1-42) oligomers, process for their preparation and their use
EP1638587A4 (en) 2003-02-14 2007-04-18 Univ Missouri Contraceptive methods and compositions related to proteasomal interference
AU2004213053C1 (en) 2003-02-20 2009-07-16 Seagen Inc. Anti-CD70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
WO2004085648A2 (en) 2003-03-19 2004-10-07 Biogen Idec Ma Inc. Nogo receptor binding protein
ES2557769T3 (en) 2003-03-19 2016-01-28 Amgen Fremont Inc. Antibodies against the T cell immunoglobulin domain antigen and mucin domain 1 (TIM-1) and uses thereof
WO2004091510A2 (en) 2003-04-11 2004-10-28 Medimmune, Inc. Recombinant il-9 antibodies and uses thereof
EP1615956A1 (en) * 2003-04-14 2006-01-18 Board Of Regents The University Of Texas System Methods for ex vivo hybridoma-free production of polyclonal and monoclonal antibodies and generation of immortalized cell populations
GB2401040A (en) 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases
US9708410B2 (en) 2003-05-30 2017-07-18 Janssen Biotech, Inc. Anti-tissue factor antibodies and compositions
DE602004028249D1 (en) 2003-06-18 2010-09-02 Chugai Pharmaceutical Co Ltd FUCOSETRANSPORTER
EP1639092B1 (en) 2003-06-27 2016-01-06 Amgen Fremont Inc. Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
WO2005010040A1 (en) 2003-07-15 2005-02-03 Barros Research Institute Eimeria tenella antigen for immunotherapy of coccidiosis
HN2004000285A (en) 2003-08-04 2006-04-27 Pfizer Prod Inc ANTIBODIES DIRECTED TO c-MET
JP2007511738A (en) 2003-08-08 2007-05-10 ジーンニュース インコーポレーテッド Biomarkers for osteoarthritis and uses thereof
AU2003282780A1 (en) 2003-08-08 2005-03-07 Abgenix, Inc. Antibodies directed to parathyroid hormone (pth) and uses thereof
JP4643450B2 (en) 2003-08-08 2011-03-02 株式会社ペルセウスプロテオミクス Cancer high expression gene
EP1654383A1 (en) 2003-08-08 2006-05-10 Licentia, Ltd. Materials and methods for colorectal cancer screening, diagnosis, and therapy
AR045563A1 (en) 2003-09-10 2005-11-02 Warner Lambert Co ANTIBODIES DIRECTED TO M-CSF
WO2005035753A1 (en) 2003-10-10 2005-04-21 Chugai Seiyaku Kabushiki Kaisha Double specific antibodies substituting for functional protein
EP2311945A1 (en) 2003-10-14 2011-04-20 Chugai Seiyaku Kabushiki Kaisha Bispecific antibodies substituting for functional proteins
EP1692184B1 (en) 2003-11-07 2012-03-07 Immunex Corporation Antibodies that bind interleukin-4 receptor
US20050100965A1 (en) 2003-11-12 2005-05-12 Tariq Ghayur IL-18 binding proteins
US8454963B2 (en) * 2003-11-13 2013-06-04 Musc Foundation For Research Development Tissue targeted complement modulators
US7750123B2 (en) 2003-11-25 2010-07-06 Dana Farber Cancer Institute, Inc. Antibodies against SARS-CoV and methods of use thereof
ES2484340T3 (en) 2003-12-05 2014-08-11 Multimmune Gmbh Therapeutic and diagnostic anti hsp70 antibodies
US7312320B2 (en) 2003-12-10 2007-12-25 Novimmune Sa Neutralizing antibodies and methods of use thereof
HUE064610T2 (en) 2003-12-23 2024-04-28 Genentech Inc Novel anti-il 13 antibodies and uses thereof
ES2689328T3 (en) 2004-01-07 2018-11-13 Novartis Vaccines And Diagnostics, Inc. M-CSF-specific monoclonal antibody and uses thereof
PE20051053A1 (en) 2004-01-09 2005-12-12 Pfizer ANTIBODIES AGAINST MADCAM
EP1729795B1 (en) 2004-02-09 2016-02-03 Human Genome Sciences, Inc. Albumin fusion proteins
US7625549B2 (en) 2004-03-19 2009-12-01 Amgen Fremont Inc. Determining the risk of human anti-human antibodies in transgenic mice
US20050260679A1 (en) 2004-03-19 2005-11-24 Sirid-Aimee Kellerman Reducing the risk of human anti-human antibodies through V gene manipulation
TW200600785A (en) 2004-03-23 2006-01-01 Oncotherapy Science Inc Method for diagnosing non-small cell lung cancer
WO2005097184A2 (en) 2004-03-26 2005-10-20 Human Genome Sciences, Inc. Antibodies against nogo receptor
JP4879884B2 (en) 2004-04-12 2012-02-22 メディミューン，エルエルシー Anti-IL-9 antibody preparation and use thereof
EP1761784B1 (en) 2004-05-24 2016-10-26 Universität Zu Köln Identification of ergothioneine transporter and therapeutic uses thereof
WO2006083286A2 (en) 2004-06-01 2006-08-10 Mount Sinai School Of Medicine Of New York University Genetically engineered swine influenza virus and uses thereof
EA012622B1 (en) 2004-06-01 2009-10-30 Домэнтис Лимитед Bispecific fusion antibodies with enhanced serum half-life
EP1602926A1 (en) 2004-06-04 2005-12-07 University of Geneva Novel means and methods for the treatment of hearing loss and phantom hearing
PT1776136E (en) 2004-06-24 2012-12-05 Biogen Idec Inc Treatment of conditions involving demyelination
EP1791868B1 (en) 2004-07-01 2011-02-23 Novo Nordisk A/S Antibodies binding to receptors kir2dl1, -2, 3 but not kir2ds4 and their therapeutic use
EP2322217A3 (en) 2004-07-16 2011-09-28 Pfizer Products Inc. Combination treatment for non-hematologic malignancies using an anti-IGF-1R antibody
KR101375603B1 (en) 2004-07-22 2014-04-01 에자이 알앤드디 매니지먼트 가부시키가이샤 Lrp4/Corin DOPAMINERGIC NEURON PROGENITOR CELL MARKERS
CA2576193A1 (en) 2004-08-03 2006-02-16 Biogen Idec Ma Inc. Taj in neuronal function
MX2007002043A (en) 2004-08-16 2007-10-11 Quark Biotech Inc Therapeutic uses of inhibitors of rtp801.
CA2478458A1 (en) 2004-08-20 2006-02-20 Michael Panzara Treatment of pediatric multiple sclerosis
CA2486285C (en) 2004-08-30 2017-03-07 Viktor S. Goldmakher Immunoconjugates targeting syndecan-1 expressing cells and use thereof
US20060051347A1 (en) 2004-09-09 2006-03-09 Winter Charles M Process for concentration of antibodies and therapeutic products thereof
CA2580921C (en) 2004-09-21 2016-04-12 Medimmune, Inc. Antibodies against and methods for producing vaccines for respiratory syncytial virus
WO2006037604A1 (en) 2004-10-01 2006-04-13 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Novel antibodies directed to the mammalian eag1 ion channel protein
KR20070072608A (en) 2004-10-22 2007-07-04 레비비코르 인코포레이션 Ungulates with genetically modified immune systems
US20080026457A1 (en) 2004-10-22 2008-01-31 Kevin Wells Ungulates with genetically modified immune systems
EP2422811A2 (en) 2004-10-27 2012-02-29 MedImmune, LLC Modulation of antibody specificity by tailoring the affinity to cognate antigens
WO2006055638A2 (en) 2004-11-17 2006-05-26 Abgenix, Inc. Fully human monoclonal antibodies to il-13
CN101102792A (en) 2004-11-19 2008-01-09 比奥根艾迪克Ma公司 Treatment for multiple sclerosis
GB0426146D0 (en) 2004-11-29 2004-12-29 Bioxell Spa Therapeutic peptides and method
CN101128487B (en) 2004-12-02 2012-10-10 杜门蒂斯有限公司 Bispecific domain antibodies targeting serum albumin and GLP-1 or PYY
AU2005313026B2 (en) 2004-12-06 2011-09-08 Kyowa Hakko Kirin Co., Ltd. Human monoclonal antibodies to influenza M2 protein and methods of making and using same
EP1838737B1 (en) 2004-12-20 2011-04-06 Amgen Fremont Inc. Binding proteins specific for human matriptase
CN105085678B (en) 2004-12-21 2019-05-07 阿斯利康公司 The antibody of angiopoietin-2 and its application
US20090061485A1 (en) 2004-12-22 2009-03-05 Chugai Seiyaku Kabushiki Kaisha Method of Producing an Antibody Using a Cell in Which the Function of Fucose Transporter Is Inhibited
US7449184B2 (en) 2005-01-21 2008-11-11 Genentech, Inc. Fixed dosing of HER antibodies
EP1851245B1 (en) 2005-01-26 2012-10-10 Amgen Fremont Inc. Antibodies against interleukin-1 beta
JP5265923B2 (en) 2005-02-07 2013-08-14 ジーンニュース インコーポレーテッド Biomarkers for mild osteoarthritis and uses thereof
CN101175862A (en) 2005-02-10 2008-05-07 肿瘤疗法科学股份有限公司 Method of diagnosing bladder cancer
AU2006214473A1 (en) 2005-02-14 2006-08-24 Wyeth Interleukin-17F antibodies and other IL-17F signaling antagonists and uses therefor
AU2006214384A1 (en) 2005-02-14 2006-08-24 University Of Pittsburgh Of The Commonwealth System Of Higher Education Use of IL-17F in diagnosis and therapy of airway inflammation
WO2006089133A2 (en) 2005-02-15 2006-08-24 Duke University Anti-cd19 antibodies and uses in oncology
US20090124993A1 (en) 2005-02-17 2009-05-14 Burkly Linda C Treating neurological disorders
CA2597717C (en) 2005-02-18 2014-10-21 Dana-Farber Cancer Institute Antibodies against cxcr4 and methods of use thereof
TWI406870B (en) 2005-02-21 2013-09-01 Chugai Pharmaceutical Co Ltd A method of making a protein using hamster IGF-1
EP1850874B1 (en) 2005-02-23 2013-10-16 Genentech, Inc. Extending time to disease progression or survival in ovarian cancer patients using pertuzumab
ATE478707T1 (en) 2005-03-02 2010-09-15 Biogen Idec Inc KIM-1 ANTIBODIES FOR THE TREATMENT OF TH2-MEDIATED DISEASES
US8211430B2 (en) 2005-03-04 2012-07-03 Curedm Group Holdings, Llc Methods and pharmaceutical compositions for treating type 1 diabetes mellitus and other conditions
AR053026A1 (en) 2005-03-08 2007-04-18 Pharmacia & Upjohn Co Llc COMPOSITIONS OF ANTIBODIES ANTI FACTOR OF STIMULATION OF COLONIES OF MACROFAGOS (ANTI-M CSF)
ES2720288T3 (en) 2005-03-30 2019-07-19 Minerva Biotechnologies Corp Proliferation of cells expressing MUC1
JP2008543276A (en) 2005-03-30 2008-12-04 ミネルバ バイオテクノロジーズ コーポレーション Proliferation of MUC1-expressing cells
EP1870459B1 (en) 2005-03-31 2016-06-29 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
KR20070119710A (en) 2005-03-31 2007-12-20 더 제너럴 하스피탈 코포레이션 Monitoring and modulating hgf/hgfr activity
EP1872136B9 (en) 2005-04-04 2023-02-08 Biogen MA Inc. Methods and products for evaluating an immune response to a therapeutic protein
CA2603264C (en) 2005-04-08 2017-03-21 Chugai Seiyaku Kabushiki Kaisha Antibody substituting for function of blood coagulation factor viii
GT200600148A (en) 2005-04-14 2006-11-22 METHODS FOR THE TREATMENT AND PREVENTION OF FIBROSIS
US9889197B2 (en) 2005-04-15 2018-02-13 Macrogenics, Inc. Covalently-associated diabody complexes that possess charged coil domains and that are capable of enhanced binding to serum albumin
AU2006236439B2 (en) 2005-04-15 2012-05-03 Macrogenics, Inc. Covalent diabodies and uses thereof
US8604174B2 (en) 2005-04-20 2013-12-10 Amgen Inc. High affinity fully human monoclonal antibodies to interleukin-8
US7807159B2 (en) 2005-04-25 2010-10-05 Amgen Fremont Inc. Antibodies to myostatin
GEP20115226B (en) 2005-04-26 2011-06-10 Pfizer P-cadherin antibodies
JO3058B1 (en) 2005-04-29 2017-03-15 Applied Molecular Evolution Inc Anti-IL-6 Antibodies,Compositions,Methods and uses
CA2607281C (en) 2005-05-05 2023-10-03 Duke University Anti-cd19 antibody therapy for autoimmune disease
WO2006124269A2 (en) * 2005-05-16 2006-11-23 Amgen Fremont Inc. Human monoclonal antibodies that bind to very late antigen-1 for the treatment of inflammation and other disorders
PL3263581T3 (en) 2005-05-17 2021-05-04 University Of Connecticut Compositions and methods for immunomodulation in an organism
US7393919B2 (en) 2005-05-25 2008-07-01 Cure Dm, Inc. Peptides, derivatives and analogs thereof, and methods of using same
SI2460831T1 (en) 2005-05-27 2017-01-31 Biogen Ma Inc. Tweak binding antibodies
CA2610987C (en) 2005-06-10 2013-09-10 Chugai Seiyaku Kabushiki Kaisha Stabilizer for protein preparation comprising meglumine and use thereof
CA2612378A1 (en) * 2005-06-22 2007-01-04 Genentech, Inc. Methods and compositions for targeting ifnar2
US20070110757A1 (en) 2005-06-23 2007-05-17 Ziping Wei Antibody formulations having optimized aggregation and fragmentation profiles
CN101252951B (en) 2005-06-30 2011-12-21 森托科尔公司 Anti-IL-23 antibodies, compositions, methods and uses
CN101495509B (en) 2005-07-08 2015-04-22 比奥根艾迪克Ma公司 SP35 antibodies and uses thereof
CN101273271A (en) 2005-07-27 2008-09-24 肿瘤疗法科学股份有限公司 Genes and polypeptides relating to prostate cancers
EP2311876A3 (en) 2005-07-28 2011-04-27 Novartis AG M-CSF-specific monoclonal antibody and uses thereof
WO2007021841A2 (en) 2005-08-10 2007-02-22 Macrogenics, Inc. Identification and engineering of antibodies with variant fc regions and methods of using same
JP5230420B2 (en) 2005-08-18 2013-07-10 ゲンマブ エー／エス Treatment with CD4 binding peptides and radiation
EP2495257A3 (en) 2005-08-19 2012-10-17 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
EP2500356A3 (en) 2005-08-19 2012-10-24 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
SI1915397T1 (en) 2005-08-19 2015-05-29 Wyeth Llc Antagonist antibodies against gdf-8 and uses in treatment of als and other gdf-8-associated disorders
ES2546069T3 (en) 2005-09-07 2015-09-18 Amgen Fremont Inc. Human monoclonal antibodies to activin receptor type kinase-1 (ALK-1)
US9062126B2 (en) 2005-09-16 2015-06-23 Raptor Pharmaceuticals Inc. Compositions comprising receptor-associated protein (RAP) variants specific for CR-containing proteins and uses thereof
NZ566395A (en) 2005-09-26 2012-03-30 Medarex Inc Human monoclonal antibodies to CD70
US8906864B2 (en) 2005-09-30 2014-12-09 AbbVie Deutschland GmbH & Co. KG Binding domains of proteins of the repulsive guidance molecule (RGM) protein family and functional fragments thereof, and their use
CA2625773C (en) 2005-10-14 2015-05-12 Fukuoka University Inhibition of interleukin-6 (il-6) receptor promotes pancreatic islet transplantation
KR101239051B1 (en) 2005-10-21 2013-03-04 추가이 세이야쿠 가부시키가이샤 Agents for treating cardiopathy
ATE518007T1 (en) 2005-10-21 2011-08-15 Genenews Inc METHOD AND APPARATUS FOR CORRELING LEVELS OF BIOMARKER PRODUCTS WITH DISEASES
UA99591C2 (en) 2005-11-04 2012-09-10 Дженентек, Инк. Use of complement pathway inhibitors to treat ocular diseases
JP2009517340A (en) 2005-11-04 2009-04-30 バイオジェン・アイデック・エムエイ・インコーポレイテッド Methods for promoting neurite outgrowth and survival of dopaminergic neurons
EA014900B1 (en) 2005-11-07 2011-02-28 Зе Скрипс Ресеч Инститьют Compositions and methods for controlling tissue factor signaling specificity
CA2629453C (en) 2005-11-10 2018-03-06 Curagen Corporation Method of treating ovarian and renal cancer using antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen
EP1964574B1 (en) 2005-11-14 2016-09-07 Cellmid Limited Method for treatment or prevention of disease associated with functional disorder of regulatory t cell
AR057582A1 (en) 2005-11-15 2007-12-05 Nat Hospital Organization AGENTS TO DELETE INDUCTION OF CYTOTOXIC T LYMPHOCYTES
TWI461436B (en) 2005-11-25 2014-11-21 Kyowa Hakko Kirin Co Ltd Human monoclonal antibody human cd134 (ox40) and methods of making and using same
EP1967209B1 (en) 2005-11-25 2012-06-06 Keio University Therapeutic agent for prostate cancer
ES2409835T3 (en) 2005-11-28 2013-06-28 Zymogenetics, Inc. IL-21 antagonists
DK1976877T4 (en) 2005-11-30 2017-01-16 Abbvie Inc Monoclonal antibodies to amyloid beta protein and uses thereof
PL1954718T3 (en) 2005-11-30 2015-04-30 Abbvie Inc Anti-a globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies
WO2007065027A2 (en) 2005-12-02 2007-06-07 Dana Farber Cancer Institute Carbonic anhydrase ix (g250) antibodies and methods of use thereof
HUE037460T2 (en) 2005-12-02 2018-08-28 Icahn School Med Mount Sinai Chimeric Newcastle Disease viruses presenting non-native surface proteins and uses thereof
WO2007064882A2 (en) 2005-12-02 2007-06-07 Biogen Idec Ma Inc. Treatment of conditions involving demyelination
RU2426742C2 (en) 2005-12-02 2011-08-20 Дженентек, Инк. Compositions and methods of treating diseases and disorders associating cytokine signal transmission
CN101325971A (en) 2005-12-07 2008-12-17 米德列斯公司 CTLA-4 antibody dose escalation regimens
RS52357B (en) 2005-12-13 2012-12-31 Medimmune Limited Binding proteins specific for insulin-like growth factors and uses thereof
EP3309170B1 (en) 2005-12-15 2019-05-22 Genentech, Inc. Polyubiquitin antibodies
EP1977763A4 (en) 2005-12-28 2010-06-02 Chugai Pharmaceutical Co Ltd Antibody-containing stabilizing preparation
AR056857A1 (en) 2005-12-30 2007-10-24 U3 Pharma Ag DIRECTED ANTIBODIES TO HER-3 (RECEIVER OF THE HUMAN EPIDERMAL GROWTH FACTOR-3) AND ITS USES
AU2006332713B2 (en) 2005-12-30 2013-01-17 Takeda Pharmaceutical Company Limited Metalloproteinase binding proteins
NZ599035A (en) 2006-01-12 2013-12-20 Alexion Pharma Inc Antibodies to ox-2/cd200 and uses thereof
TWI428143B (en) 2006-01-18 2014-03-01 Gen Hospital Corp Methods of increasing lymphatic function
DOP2007000015A (en) 2006-01-20 2007-08-31 Quark Biotech Inc THERAPEUTIC USES OF RTP801 INHIBITORS
KR101481843B1 (en) 2006-01-25 2015-01-12 에라스무스 유니버시티 메디컬 센터 로테르담 Generation of heavy-chain only antibodies in transgenic animals
AU2007208678B2 (en) 2006-01-27 2013-01-10 Chugai Seiyaku Kabushiki Kaisha Therapeutic agents for diseases involving choroidal neovascularization
WO2007089601A2 (en) 2006-01-27 2007-08-09 Biogen Idec Ma Inc. Nogo receptor antagonists
WO2007092431A2 (en) 2006-02-06 2007-08-16 Rhode Island Hospital Gpr30 estrogen receptor in breast cancers
TW200744634A (en) 2006-02-21 2007-12-16 Wyeth Corp Methods of using antibodies against human IL-22
TWI417301B (en) 2006-02-21 2013-12-01 Wyeth Corp Antibodies against human il-22 and uses therefor
JP2009529915A (en) 2006-03-20 2009-08-27 ゾーマ テクノロジー リミテッド Human antibodies and methods specific for gastrin substances
US8252547B2 (en) 2006-03-20 2012-08-28 Japan Science And Technology Agency In vitro control of protein synthesis in mammalian cells by IP3 receptor-binding protein
EP2008106A2 (en) 2006-03-31 2008-12-31 Dana-Farber Cancer Institute Methods of determining cellular chemosensitivity
DK2009101T3 (en) 2006-03-31 2018-01-15 Chugai Pharmaceutical Co Ltd Antibody modification method for purification of a bispecific antibody
JP5514539B2 (en) 2006-03-31 2014-06-04 メダレックス・リミテッド・ライアビリティ・カンパニー Transgenic animals expressing chimeric antibodies for use in preparing human antibodies
DK2006381T3 (en) 2006-03-31 2016-02-22 Chugai Pharmaceutical Co Ltd PROCEDURE FOR REGULATING ANTIBODIES BLOOD PHARMACOKINETICS
CA2647277A1 (en) 2006-04-05 2007-11-08 Genentech, Inc. Method for using boc/cdo to modulate hedgehog signaling
EP2010567A2 (en) 2006-04-07 2009-01-07 The Government of the United States of America as Represented by The Department of Health and Human Services Antibody compositions and methods for treatment of neoplastic disease
US9260516B2 (en) 2006-04-07 2016-02-16 Osaka University Method for promoting muscle regeneration by administering an antibody to the IL-6 receptor
TW200813091A (en) 2006-04-10 2008-03-16 Amgen Fremont Inc Targeted binding agents directed to uPAR and uses thereof
US20100080794A1 (en) 2006-04-14 2010-04-01 Takashi Tsuji Mutant polypeptide having effector function
JP5496658B2 (en) 2006-05-25 2014-05-21 バイオジェン・アイデック・エムエイ・インコーポレイテッド How to treat a stroke
EP2447282B1 (en) 2006-05-30 2016-01-27 Genentech, Inc. Anti-CD22 Antibodies, their Immunoconjugates and uses thereof
AU2007319672B2 (en) 2006-06-06 2011-06-30 Genentech, Inc. Anti-DLL4 antibodies and methods using same
AU2007255753B2 (en) 2006-06-08 2013-01-17 Chugai Seiyaku Kabushiki Kaisha Preventive or remedy for inflammatory disease
CA2655080A1 (en) 2006-06-14 2007-12-21 Macrogenics, Inc. Methods for the treatment of autoimmune disorders using monoclonal antibodies with reduced toxicity
ES2599319T3 (en) 2006-06-26 2017-02-01 Macrogenics, Inc. Fc RIIB specific antibodies and their methods of use
US7572618B2 (en) 2006-06-30 2009-08-11 Bristol-Myers Squibb Company Polynucleotides encoding novel PCSK9 variants
EP2471809B1 (en) 2006-07-11 2015-09-02 University Of Medicine And Dentistry Of New Jersey Proteins, nucleic acids encoding the same and associated methods of use
JPWO2008007755A1 (en) 2006-07-13 2009-12-10 中外製薬株式会社 Cell death inducer
MX2009000709A (en) 2006-07-18 2009-02-04 Sanofi Aventis Antagonist antibody against epha2 for the treatment of cancer.
EP2047862B9 (en) 2006-07-21 2013-04-10 Chugai Seiyaku Kabushiki Kaisha Remedy for renal disease
WO2008112004A2 (en) 2006-08-03 2008-09-18 Astrazeneca Ab ANTIBODIES DIRECTED TO αVβ6 AND USES THEREOF
CL2007002225A1 (en) 2006-08-03 2008-04-18 Astrazeneca Ab SPECIFIC UNION AGENT FOR A RECEIVER OF THE GROWTH FACTOR DERIVED FROM PLATES (PDGFR-ALFA); NUCLEIC ACID MOLECULA THAT CODIFIES IT; VECTOR AND CELL GUESTS THAT UNDERSTAND IT; CONJUGADO UNDERSTANDING THE AGENT; AND USE OF THE AGENT OF A
PT2511301T (en) 2006-08-04 2018-03-08 Medimmune Ltd Human antibodies to erbb 2
US8586716B2 (en) 2006-08-04 2013-11-19 Novartis Ag EPHB3-specific antibody and uses thereof
AU2007285217B2 (en) 2006-08-14 2013-02-07 Forerunner Pharma Research Co., Ltd Diagnosis and treatment of cancer using anti-desmoglein-3 antibodies
EA201201533A1 (en) 2006-08-18 2014-11-28 Новартис Аг PRLR-SPECIFIC ANTIBODY AND ITS APPLICATIONS
US8058402B2 (en) 2006-08-28 2011-11-15 Kyowa Hakko Kirin Antagonistic human LIGHT-specific human monoclonal antibodies
EP2471816A1 (en) 2006-08-30 2012-07-04 Genentech, Inc. Multispecific antibodies
CA2661848C (en) 2006-09-01 2015-02-03 Therapeutic Human Polyclonals, Inc. Enhanced expression of human or humanized immunoglobulin in non-human transgenic animals
US7915388B2 (en) 2006-09-08 2011-03-29 Abbott Laboratories Interleukin-13 binding proteins
ES2372217T3 (en) 2006-09-12 2012-01-17 Genentech, Inc. PROCEDURES AND COMPOSITIONS FOR THE DIAGNOSIS AND TREATMENT OF LUNG CANCER USING THE GENE OF PDGFRA, KIT OR KDR AS A GENETIC MARKER.
JPWO2008032833A1 (en) 2006-09-14 2010-01-28 株式会社医学生物学研究所 Antibody with enhanced ADCC activity and method for producing the same
CN101557818A (en) 2006-10-03 2009-10-14 新泽西医科和牙科大学 ATAP peptides, nucleic acids encoding the same and associated methods of use
KR101493779B1 (en) 2006-10-12 2015-02-16 츄가이 세이야꾸 가부시키가이샤 Diagnosis and treatment of cancer using anti-ereg antibody
KR20090069330A (en) 2006-10-12 2009-06-30 와이어쓰 Modification of ionic strength in antibody-solutions to reduce opalescence/aggregates
WO2008048545A2 (en) 2006-10-16 2008-04-24 Medimmune, Llc. Molecules with reduced half-lives, compositions and uses thereof
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
WO2008047925A1 (en) 2006-10-20 2008-04-24 Forerunner Pharma Research Co., Ltd. Pharmaceutical composition comprising anti-hb-egf antibody as active ingredient
JP5676849B2 (en) 2006-10-20 2015-02-25 中外製薬株式会社 Cancer therapeutic agent comprising anti-HB-EGF antibody as active ingredient
US7846434B2 (en) 2006-10-24 2010-12-07 Trubion Pharmaceuticals, Inc. Materials and methods for improved immunoglycoproteins
PL2845866T3 (en) 2006-10-27 2017-10-31 Genentech Inc Antibodies and immunoconjugates and uses therefor
CA2666317C (en) 2006-11-03 2013-08-06 Wyeth Glycolysis-inhibiting substances in cell culture
US8394927B2 (en) 2006-11-03 2013-03-12 U3 Pharma Gmbh FGFR4 antibodies
US8785400B2 (en) 2006-11-22 2014-07-22 Curedm Group Holdings, Llc Methods and compositions relating to islet cell neogenesis
EP2101813B1 (en) 2006-11-27 2014-04-02 Patrys Limited Novel glycosylated peptide target in neoplastic cells
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
CN101678100A (en) 2006-12-06 2010-03-24 米迪缪尼有限公司 methods of treating systemic lupus erythematosus
EA200900767A1 (en) 2006-12-07 2009-12-30 Новартис Аг ANTAGONISTIC ANTIBODIES AGAINST EPHB3
EP2103628A4 (en) 2006-12-14 2012-02-22 Forerunner Pharma Res Co Ltd Anti-claudin-3 monoclonal antibody, and treatment and diagnosis of cancer using the same
KR20150004933A (en) 2006-12-18 2015-01-13 제넨테크, 인크. Antagonist anti-notch3 antibodies and their use in the prevention and treatment of notch3-related diseases
CA2673592C (en) 2006-12-20 2014-03-25 Xoma Technology Ltd. Methods for the treatment of il-1.beta. related diseases
EP2123676A4 (en) 2007-01-05 2011-01-05 Univ Tokyo Diagnosis and treatment of cancer by using anti-prg-3 antibody
AU2008203703C1 (en) 2007-01-05 2014-04-03 University Of Zurich Method of providing disease-specific binding molecules and targets
ES2673153T3 (en) 2007-01-09 2018-06-20 Biogen Ma Inc. Sp35 antibodies and uses thereof
US8128926B2 (en) 2007-01-09 2012-03-06 Biogen Idec Ma Inc. Sp35 antibodies and uses thereof
CN104524567A (en) 2007-01-16 2015-04-22 阿布维公司 Methods for treating psoriasis
EP2123302B1 (en) 2007-01-23 2015-12-09 Shinshu University Il-6 inhibitors to treat chronic rejection
NZ578701A (en) 2007-02-09 2012-02-24 Genentech Inc Anti-robo4 antibodies and uses therefor
EP3246407B1 (en) 2007-02-09 2019-04-03 Eisai R&D Management Co., Ltd. Gaba neuron progenitor cell marker 65b13
US8685666B2 (en) 2007-02-16 2014-04-01 The Board Of Trustees Of Southern Illinois University ARL-1 specific antibodies and uses thereof
WO2008101184A2 (en) 2007-02-16 2008-08-21 The Board Of Trustees Of Southern Illinois University Arl-1 specific antibodies
AU2008218199B2 (en) 2007-02-22 2013-10-31 Genentech, Inc. Methods for detecting inflammatory bowel disease
US20100311767A1 (en) 2007-02-27 2010-12-09 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
JP5374360B2 (en) 2007-02-27 2013-12-25 中外製薬株式会社 Pharmaceutical composition comprising anti-GRP78 antibody as an active ingredient
CN103432580A (en) 2007-03-02 2013-12-11 健泰科生物技术公司 Predicting response to a HER dimerisation inhibitor based on low HER3 expression
CL2008000719A1 (en) 2007-03-12 2008-09-05 Univ Tokushima Chugai Seiyaku THERAPEUTIC AGENT FOR CANCER RESISTANT TO CHEMOTHERAPEUTIC AGENTS THAT UNDERSTAND AN ANTIBODY THAT RECOGNIZES IT CLASS I AS ACTIVE INGREDIENT; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH ANTIBODY; AND METHOD TO TREAT CANCER RESISTANT TO
US8519106B2 (en) 2007-03-13 2013-08-27 University Of Zurich Monoclonal human tumor-specific antibody
JP5721951B2 (en) 2007-03-22 2015-05-20 バイオジェン アイデック マサチューセッツ インコーポレイテッド Binding proteins that specifically bind to CD154, including antibodies, antibody derivatives, and antibody fragments, and uses thereof
US7960139B2 (en) 2007-03-23 2011-06-14 Academia Sinica Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
WO2008118324A2 (en) 2007-03-26 2008-10-02 Macrogenics, Inc. Composition and method of treating cancer with an anti-uroplakin ib antibody
US20110130544A1 (en) 2007-03-30 2011-06-02 Medimmune, Llc Antibodies with decreased deamidation profiles
GT200800034A (en) 2007-04-02 2010-03-16 ANTI-IGE ANTIBODIES
TW200902708A (en) 2007-04-23 2009-01-16 Wyeth Corp Methods of protein production using anti-senescence compounds
SI3072525T1 (en) 2007-05-14 2018-06-29 Astrazeneca Ab Methods of reducing basophil levels
EP2158335A2 (en) 2007-05-21 2010-03-03 Genetech, Inc. Methods and compositions for identifying and treating lupus
JP5117765B2 (en) 2007-05-28 2013-01-16 国立大学法人 東京大学 Tumor diagnostic agent for PET containing anti-ROBO1 antibody
WO2008154249A2 (en) 2007-06-08 2008-12-18 Genentech, Inc. Gene expression markers of tumor resistance to her2 inhibitor treatment
CN101778640A (en) 2007-06-14 2010-07-14 比奥根艾迪克Ma公司 antibody formulations
AU2008265984B2 (en) 2007-06-21 2014-07-17 Macrogenics, Inc. Covalent diabodies and uses thereof
US20090053786A1 (en) 2007-07-09 2009-02-26 Yung-Hsiang Kao Prevention of disulfide bond reduction during recombinant production of polypeptides
JP5424330B2 (en) 2007-07-26 2014-02-26 国立大学法人大阪大学 A therapeutic agent for ocular inflammatory diseases comprising an interleukin 6 receptor inhibitor as an active ingredient
MX2010001307A (en) 2007-08-02 2010-07-30 Novimmune Sa Anti-rantes antibodies and methods of use thereof.
MX2010002018A (en) 2007-08-20 2010-05-27 Oncotherapy Science Inc Cdh3 peptide and medicinal agent comprising the same.
BRPI0815578B8 (en) 2007-08-20 2023-01-03 Oncotherapy Science Inc CDCA1 PEPTIDE, ITS USE AND IMMUNOGENIC COMPOSITION INCLUDING THE SAME TO INDUCE IMMUNITY, TREAT AND/OR PREVENT CANCER, AS WELL AS IN VITRO METHOD TO INDUCE AN ANTIGEN-PRESENTING CELL AND A CYTOTOXIC T-CELL (KILLER)
AU2008290049B2 (en) 2007-08-20 2013-08-29 Oncotherapy Science, Inc. FOXM1 peptide and medicinal agent comprising the same
EP2615113A3 (en) 2007-08-23 2013-11-13 Amgen Inc. Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)
JOP20080381B1 (en) 2007-08-23 2023-03-28 Amgen Inc Antigen Binding Proteins to Proprotein Convertase subtillisin Kexin type 9 (pcsk9)
MX346172B (en) 2007-08-29 2017-03-10 Sanofi - Aventis Humanized anti-cxcr5 antibodies, derivatives thereof and their uses.
KR20100080519A (en) 2007-08-30 2010-07-08 큐어디엠 인코포레이티드 Compositions and methods of using proislet peptides and analogs thereof
US20100239570A1 (en) 2007-09-13 2010-09-23 Roger Nitsch Moncolonal amyloid beta (abeta) - specific antibody and uses thereof
HUE029635T2 (en) 2007-09-26 2017-03-28 Chugai Pharmaceutical Co Ltd Method of modifying isoelectric point of antibody via amino acid substitution in cdr
SG187477A1 (en) 2007-09-26 2013-02-28 U3 Pharma Gmbh Heparin-binding epidermal growth factor-like growth factor antigen binding proteins
AU2008304111B2 (en) 2007-09-27 2014-04-24 Amgen Inc. Pharmaceutical formulations
NZ584769A (en) 2007-09-28 2011-09-30 Chugai Pharmaceutical Co Ltd Anti-glypican-3 antibody having improved kinetics in plasma
BRPI0817482B8 (en) 2007-10-02 2021-05-25 Chugai Pharmaceutical Co Ltd use of an interleukin-6 (il-6) receptor antibody in the treatment of graft versus host disease (gvhd)
BRPI0818674B1 (en) 2007-10-15 2023-01-17 Chugai Seiyaku Kabushiki Kaisha METHODS FOR THE PRODUCTION OF A WHOLE ANTIBODY OR A FRAGMENT THEREOF AND FOR THE PREPARATION OF DRUGS, AS WELL AS A RECOMBINANT VECTOR
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
SG185316A1 (en) 2007-10-19 2012-11-29 Immunas Pharma Inc ANTIBODY CAPABLE OF SPECIFICALLY BINDING TO Aβ OLIGOMER, AND USE THEREOF
WO2009054435A1 (en) 2007-10-24 2009-04-30 Otsuka Chemical Co., Ltd. Polypeptide having enhanced effector function
PE20091163A1 (en) 2007-11-01 2009-08-09 Wyeth Corp ANTIBODIES FOR GDF8
AU2008324800B2 (en) 2007-11-05 2014-03-27 Astrazeneca Ab Methods of treating scleroderma
ES2662845T3 (en) 2007-11-07 2018-04-10 Genentech, Inc. IL-22 for use in the treatment of microbial disorders
MX2010005080A (en) 2007-11-07 2010-07-28 Genentech Inc Methods and compositions for assessing responsiveness of b-cell lymphoma to treatment with anti-cd40 antibodies.
CN101939336B (en) 2007-11-12 2014-05-14 U3制药有限公司 AXL antibodies
CN102112492B (en) 2007-11-14 2015-02-25 中外制药株式会社 Diagnosis and treatment of cancer using anti-GPR49 antibody
EP3381445B1 (en) 2007-11-15 2023-10-25 Amgen Inc. Aqueous formulation of antibody stablised by antioxidants for parenteral administration
JP5554993B2 (en) 2007-11-15 2014-07-23 中外製薬株式会社 Monoclonal antibody binding to nexelekto and use thereof
JP5490714B2 (en) 2007-11-28 2014-05-14 メディミューン，エルエルシー Protein preparation
AR069501A1 (en) 2007-11-30 2010-01-27 Genentech Inc ANTI-VEGF ANTIBODIES (VASCULAR ENDOTELIAL GROWTH FACTOR)
KR101643005B1 (en) 2007-12-05 2016-07-28 추가이 세이야쿠 가부시키가이샤 Anti-NR10 antibody and use thereof
BRPI0821145B8 (en) 2007-12-05 2021-05-25 Chugai Pharmaceutical Co Ltd use of an anti-nr10 antibody as a preventive or therapeutic agent for pruritus
CN101970483A (en) 2007-12-06 2011-02-09 达纳-法伯癌症研究公司 Antibodies against influenza virus and methods of use thereof
JPWO2009075344A1 (en) 2007-12-12 2011-04-28 独立行政法人国立がん研究センター MLL leukemia and MOZ leukemia therapeutic agent using M-CSF receptor as molecular target, and use thereof
DK2391650T3 (en) 2007-12-20 2015-01-12 Xoma Us Llc Methods of treating gout
MX2010007101A (en) 2007-12-26 2011-07-01 Biotest Ag Methods and agents for improving targeting of cd138 expressing tumor cells.
DK2238168T3 (en) 2007-12-26 2014-08-25 Biotest Ag Means targeted to CD138 AND APPLICATIONS THEREOF
PT2242772E (en) 2007-12-26 2015-02-09 Biotest Ag Immunoconjugates targeting cd138 and uses thereof
EP2238169A1 (en) 2007-12-26 2010-10-13 Biotest AG Method of decreasing cytotoxic side-effects and improving efficacy of immunoconjugates
PE20091174A1 (en) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd LIQUID FORMULATION WITH HIGH CONCENTRATION OF ANTIBODY CONTENT
WO2009086514A1 (en) 2007-12-28 2009-07-09 Dana-Farber Cancer Institute, Inc. Humanized monoclonal antibodies and methods of use
EP2244729B1 (en) 2008-01-18 2016-11-02 MedImmune, LLC Cysteine engineered antibodies for site-specific conjugation
US9175078B2 (en) 2008-01-25 2015-11-03 Amgen Inc. Ferroportin antibodies and methods of use
CA2714413C (en) 2008-02-08 2017-01-24 Immunas Pharma, Inc. Antibody capable of binding specifically to ab-oligomer, and use thereof
CA2713981C (en) 2008-02-08 2016-11-01 Medimmune, Llc Anti-ifnar1 antibodies with reduced fc ligand affinity
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
RU2497545C2 (en) 2008-03-18 2013-11-10 Эбботт Лэборетриз Method of treating psoriasis (versions)
WO2009118300A1 (en) 2008-03-25 2009-10-01 Novartis Forschungsstiftung Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Treating cancer by down-regulating frizzled-4 and/or frizzled-1
KR20100131003A (en) 2008-03-31 2010-12-14 제넨테크, 인크. Compositions and methods for treating and diagnosing asthma
WO2009124109A1 (en) 2008-04-04 2009-10-08 The Government Of The U.S. A. As Represented By The Secretary Of The Dept. Of Health &Human Services Human monoclonal antibodies specific for cd22
CL2009000647A1 (en) 2008-04-04 2010-06-04 Chugai Pharmaceutical Co Ltd Pharmaceutical composition for treating or preventing liver cancer comprising a combination of a chemotherapeutic agent and an anti-glypican 3 antibody; agent for attenuating a side effect comprising said antibody; method of treating or preventing liver cancer of a subject.
DK2708559T3 (en) 2008-04-11 2018-06-14 Chugai Pharmaceutical Co Ltd Antigen-binding molecule capable of repeatedly binding two or more antigen molecules
CA2722082C (en) 2008-04-25 2021-11-09 Christopher Tenhoor Fc receptor binding proteins
EP2282769A4 (en) 2008-04-29 2012-04-25 Abbott Lab Dual variable domain immunoglobulins and uses thereof
JP2011519279A (en) 2008-05-01 2011-07-07 アムジエン・インコーポレーテツド Anti-hepcidin antibodies and methods of use
CA2723197C (en) 2008-05-02 2017-09-19 Seattle Genetics, Inc. Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
EP2500361B1 (en) 2008-05-09 2016-03-30 AbbVie Deutschland GmbH & Co KG Antibodies to receptor of advanced glycation end products (RAGE) and uses thereof
EP2304439A4 (en) 2008-05-29 2012-07-04 Nuclea Biotechnologies Llc Anti-phospho-akt antibodies
EP2283862B1 (en) 2008-06-02 2018-08-08 The University of Tokyo Combination treatment of cancer comprising anti-mfg-e8 antibody
JP5723769B2 (en) 2008-06-03 2015-05-27 アッヴィ・インコーポレイテッド Dual variable domain immunoglobulins and uses thereof
EP2297209A4 (en) 2008-06-03 2012-08-01 Abbott Lab Dual variable domain immunoglobulins and uses thereof
TW201503898A (en) 2008-06-05 2015-02-01 Chugai Pharmaceutical Co Ltd Neuroinvasion inhibitor
EP2303924B1 (en) 2008-06-16 2016-07-27 Patrys Limited Lm-antibodies, functional fragments, lm-1 target antigen, and methods for making and using same
WO2009154025A1 (en) 2008-06-20 2009-12-23 国立大学法人岡山大学 ANTIBODY AGAINST OXIDIZED LDL/β2GPI COMPLEX AND USE OF THE SAME
EP2313435A4 (en) 2008-07-01 2012-08-08 Aveo Pharmaceuticals Inc Fibroblast growth factor receptor 3 (fgfr3) binding proteins
SG192496A1 (en) 2008-07-08 2013-08-30 Abbott Lab Prostaglandin e2 binding proteins and uses thereof
EP2321422A4 (en) 2008-07-08 2013-06-19 Abbvie Inc Prostaglandin e2 dual variable domain immunoglobulins and uses thereof
US8058406B2 (en) 2008-07-09 2011-11-15 Biogen Idec Ma Inc. Composition comprising antibodies to LINGO or fragments thereof
US8680020B2 (en) 2008-07-15 2014-03-25 Academia Sinica Glycan arrays on PTFE-like aluminum coated glass slides and related methods
JP5623401B2 (en) 2008-08-14 2014-11-12 テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド Anti-IL-12 / IL-23 antibody
BRPI0916973A2 (en) 2008-08-18 2016-07-26 Amgen Fremont Inc antibodies to ccr2
CA2736799A1 (en) 2008-08-25 2010-03-11 Burnham Institute For Medical Research Conserved hemagglutinin epitope, antibodies to the epitope, and methods of use
WO2010027981A1 (en) 2008-09-03 2010-03-11 Genentech, Inc. Multispecific antibodies
EP2324060B1 (en) 2008-09-07 2015-07-22 Glyconex Inc. Anti-extended type i glycosphingolipid antibody, derivatives thereof and use
US8192738B2 (en) 2008-09-19 2012-06-05 Medimmune, Llc Targeted antibodies directed to DLL4
JP2012504939A (en) 2008-09-23 2012-03-01 ワイス・エルエルシー Method for predicting the generation of activation signals by cross-linked proteins
LT2346994T (en) 2008-09-30 2022-03-10 Ablexis, Llc Knock-in mice for the production of chimeric antibodies
JP2012505636A (en) 2008-10-09 2012-03-08 ミネルバ バイオテクノロジーズ コーポレーション Methods for inducing pluripotency in cells
JP2012505900A (en) 2008-10-14 2012-03-08 ダイアクス コーポレーション Use of an IGF-II / IGF-IIE binding protein for the treatment and prevention of pulmonary fibrosis associated with systemic scleroderma
PE20110707A1 (en) 2008-10-14 2011-10-11 Genentech Inc IMMUNOGLOBULIN VARIANTS
WO2010048615A2 (en) 2008-10-24 2010-04-29 The Government Of The United States Of America As Represented By The Secretary, Department Of Health & Human Services, Center For Disease Control And Prevention Human ebola virus species and compositions and methods thereof
DK2348827T3 (en) 2008-10-27 2015-07-20 Revivicor Inc IMMUNICIPLY COMPROMATED PETS
JP6113404B2 (en) 2008-10-29 2017-04-12 アブリンクス エン．ヴェー． Purification method of single domain antigen binding molecule
CN104740631B (en) 2008-10-29 2019-04-16 阿布林克斯公司 The preparation of single domain antigen-binding molecule
US8642280B2 (en) 2008-11-07 2014-02-04 Novartis Forschungsstiftung Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Teneurin and cancer
CA2742802C (en) 2008-11-10 2019-11-26 Alexion Pharmaceuticals, Inc. Methods and compositions for treating complement-associated disorders
EP2191841A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and vincristine
EP2191843A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and cyclophosphamide
EP2191840A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan
EP2191842A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and cytarabine
CN102245640B (en) 2008-12-09 2014-12-31 霍夫曼-拉罗奇有限公司 Anti-PD-L1 antibodies and their use to enhance T-cell function
CA2746778C (en) 2008-12-19 2019-04-23 University Of Zurich Human anti-alpha-synuclein autoantibodies
BRPI0918122A8 (en) 2008-12-19 2017-01-24 Macrogenics Inc diabody, diabody, and dart molecule
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
WO2010073972A1 (en) 2008-12-22 2010-07-01 エーザイ・アール・アンド・ディー・マネジメント株式会社 Method for obtaining pancreatic progenitor cell using neph3
EP3318573A1 (en) 2008-12-23 2018-05-09 F. Hoffmann-La Roche AG Mmunoglobulin variants with altered binding to protein a
US20120114667A1 (en) 2008-12-23 2012-05-10 Medimmune Limited TARGETED BINDING AGENTS DIRECTED TO a5BETA1 AND USES THEREOF
CA2748990A1 (en) 2008-12-26 2010-07-01 The University Of Tokyo Diagnosis and treatment of cancer using anti-lgr7 antibody
CN102341411A (en) 2008-12-31 2012-02-01 比奥根艾迪克Ma公司 Anti-lymphotoxin antibodies
EP2387584A1 (en) 2009-01-14 2011-11-23 IQ Therapeutics BV Combination antibodies for the treatment and prevention of disease caused by bacillus anthracis and related bacteria and their toxins
KR101245929B1 (en) 2009-01-20 2013-03-22 호메이욘 에이치. 자데흐 Antibody mediated osseous regeneration
WO2010087927A2 (en) 2009-02-02 2010-08-05 Medimmune, Llc Antibodies against and methods for producing vaccines for respiratory syncytial virus
EP2394159B1 (en) 2009-02-04 2018-09-26 Molecular Innovations Assays for detecting prorenin, and antibodies used therein
US8309530B2 (en) 2009-02-04 2012-11-13 Washington State University Compositions and methods for modulating ghrelin-mediated conditions
WO2010093993A2 (en) 2009-02-12 2010-08-19 Human Genome Sciences, Inc. Use of b lymphocyte stimulator protein antagonists to promote transplantation tolerance
RU2015132478A (en) 2009-03-05 2015-12-10 Эббви Инк. BINDING IL-17 PROTEINS
EP2405920A1 (en) 2009-03-06 2012-01-18 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Novel therapy for anxiety
JP2010210772A (en) 2009-03-13 2010-09-24 Dainippon Screen Mfg Co Ltd Method of manufacturing liquid crystal display device
MX2011009729A (en) 2009-03-20 2011-10-14 Genentech Inc Bispecific anti-her antibodies.
CA2756186A1 (en) 2009-03-24 2010-09-30 Teva Biopharmaceuticals Usa, Inc. Humanized antibodies against light and uses thereof
JP2012521786A (en) 2009-03-30 2012-09-20 モウント シナイ スクール オフ メディシネ Influenza virus vaccine and use thereof
EP2413967A1 (en) 2009-04-01 2012-02-08 F. Hoffmann-La Roche AG Treatment of insulin-resistant disorders
WO2010118243A2 (en) 2009-04-08 2010-10-14 Genentech, Inc. Use of il-27 antagonists to treat lupus
EP2417984B1 (en) 2009-04-10 2016-03-30 Kyowa Hakko Kirin Co., Ltd. Method for treatment of blood tumor using anti-tim-3 antibody
EP2241323A1 (en) 2009-04-14 2010-10-20 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Tenascin-W and brain cancers
WO2010121140A1 (en) 2009-04-16 2010-10-21 Facet Biotech Corporation ANTI-TNF-α ANTIBODIES AND THEIR USES
EP2419447B1 (en) 2009-04-17 2017-08-23 Immunas Pharma, Inc. Antibodies that specifically bind to a beta oligomers and use thereof
CA2758523C (en) 2009-04-18 2019-03-12 Genentech, Inc. Methods for assessing responsiveness of b-cell lymphoma to treatment with anti-cd40 antibodies
CN104558179A (en) 2009-04-27 2015-04-29 协和发酵麒麟株式会社 Anti-iL-3R[alpha] antibody for use in treatment of blood tumor
AU2010241706B2 (en) 2009-04-29 2015-07-09 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. ERG monoclonal antibodies
EP2426149A4 (en) 2009-05-01 2013-01-23 Univ Tokyo Anti-cadherin antibody
RU2605318C2 (en) 2009-05-05 2016-12-20 Новиммун С.А. Anti-il-17f antibodies and methods for use thereof
AU2010254136B2 (en) 2009-05-26 2016-09-29 Mount Sinai School Of Medicine Monoclonal antibodies against influenza virus generated by cyclical administration and uses thereof
EP2436397B1 (en) 2009-05-29 2017-05-10 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition containing antagonist of egf family ligand as component
US20100316639A1 (en) 2009-06-16 2010-12-16 Genentech, Inc. Biomarkers for igf-1r inhibitor therapy
ES2534355T3 (en) 2009-06-17 2015-04-21 Abbvie Biotherapeutics Inc. Anti-VEGF antibodies and their uses
MX2012000121A (en) 2009-06-22 2012-03-07 Medimmune Llc ENGINEERED Fc REGIONS FOR SITE-SPECIFIC CONJUGATION.
WO2011006001A1 (en) 2009-07-09 2011-01-13 Genentech, Inc. Animal model for the evaluation of adjuvant therapies of cancer
US20120226119A1 (en) 2009-07-09 2012-09-06 Hoffmann-La Roche Inc. Vivo tumor vasculature imaging
JP6095367B2 (en) 2009-07-13 2017-03-15 ジェネンテック， インコーポレイテッド Diagnostic methods and compositions for cancer treatment
TW201106972A (en) 2009-07-27 2011-03-01 Genentech Inc Combination treatments
WO2011014504A1 (en) 2009-07-27 2011-02-03 Mount Sinai School Of Medicine Of New York University Recombinant influenza virus vectors and uses thereof
US8828406B2 (en) 2009-07-30 2014-09-09 Icahn School Of Medicine At Mount Sinai Influenza viruses and uses thereof
EP2459591B1 (en) 2009-07-31 2014-08-20 Genentech, Inc. Inhibition of tumor metastasis using anti-g-csf-antibodies
TWI523661B (en) 2009-07-31 2016-03-01 Shin Maeda Anti-IL-6 receptor antibody in the manufacture of inhibitors of metastatic inhibition of lung cancer metastasis to the liver
EP2462451B1 (en) 2009-08-05 2016-02-17 Nexigen GmbH Human hcv-interacting proteins and methods of use
WO2011016238A1 (en) 2009-08-06 2011-02-10 Immunas Pharma, Inc. Antibodies that specifically bind to a beta oligomers and use thereof
WO2011016239A1 (en) 2009-08-06 2011-02-10 Immunas Pharma, Inc. Antibodies that specifically bind to a beta oligomers and use thereof
US20110039300A1 (en) 2009-08-10 2011-02-17 Robert Bayer Antibodies with enhanced adcc functions
LT2464725T (en) 2009-08-11 2020-06-10 F. Hoffmann-La Roche Ag Production of proteins in glutamine-free cell culture media
EP2464664B1 (en) 2009-08-13 2015-09-23 Crucell Holland B.V. Antibodies against human respiratory syncytial virus (rsv) and methods of use
EP2464744A1 (en) 2009-08-14 2012-06-20 F. Hoffmann-La Roche AG Biological markers for monitoring patient response to vegf antagonists
WO2011019622A1 (en) 2009-08-14 2011-02-17 Genentech, Inc. Cell culture methods to make antibodies with enhanced adcc function
US20120282173A1 (en) 2009-08-17 2012-11-08 Forerunner Pharma Research Co., Ltd. Pharmaceutical composition comprising anti-hb-egf antibody as active ingredient
WO2011024114A1 (en) 2009-08-25 2011-03-03 Ecole Polytechnique Federale De Lausanne (Epfl) Targeting extracellular matrix molecules for the treatment of cancer
EP2292266A1 (en) 2009-08-27 2011-03-09 Novartis Forschungsstiftung, Zweigniederlassung Treating cancer by modulating copine III
CN102741288B (en) 2009-08-29 2015-08-19 Abbvie公司 DLL4 associated proteins is used in treatment
SG178602A1 (en) 2009-09-01 2012-04-27 Abbott Lab Dual variable domain immunoglobulins and uses thereof
US9321823B2 (en) 2009-09-02 2016-04-26 Genentech, Inc. Mutant smoothened and methods of using the same
WO2011028945A1 (en) 2009-09-03 2011-03-10 Genentech, Inc. Methods for treating, diagnosing, and monitoring rheumatoid arthritis
CN102597776A (en) 2009-09-11 2012-07-18 霍夫曼-拉罗奇有限公司 Method to identify a patient with an increased likelihood of re sponding to an anti-cancer agent
AU2010291927A1 (en) 2009-09-14 2012-04-12 AbbVie Deutschland GmbH & Co. KG Methods for treating psoriasis
CN102612566B (en) 2009-09-17 2016-02-17 霍夫曼-拉罗奇有限公司 For the method and composition of diagnostics purposes in cancer patients
WO2011036118A1 (en) 2009-09-22 2011-03-31 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Treating cancer by modulating mex-3
TW201118166A (en) 2009-09-24 2011-06-01 Chugai Pharmaceutical Co Ltd HLA class I-recognizing antibodies
CA2772945A1 (en) 2009-09-25 2011-03-31 Xoma Technology Ltd. Screening methods
US8926976B2 (en) 2009-09-25 2015-01-06 Xoma Technology Ltd. Modulators
EP2305285A1 (en) 2009-09-29 2011-04-06 Julius-Maximilians-Universität Würzburg Means and methods for treating ischemic conditions
RU2012117619A (en) 2009-09-30 2013-11-10 Дженентек, Инк. TREATMENT OF MALIGNANT TUMORS RESISTANT TO THE ACTION OF AN NOTCH1 ANTAGONIST USING THE NOTCH3 ANTAGONIST
UY32914A (en) 2009-10-02 2011-04-29 Sanofi Aventis ANTIBODIES SPECIFICALLY USED TO THE EPHA2 RECEIVER
AU2010303415B2 (en) 2009-10-07 2015-02-19 Macrogenics, Inc. Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and methods for their use
WO2011044205A1 (en) 2009-10-07 2011-04-14 Genentech, Inc. Methods for treating, diagnosing, and monitoring lupus
CA2776756A1 (en) 2009-10-11 2011-04-14 Biogen Idec Ma Inc. Anti-vla-4 related assays
WO2011045352A2 (en) 2009-10-15 2011-04-21 Novartis Forschungsstiftung Spleen tyrosine kinase and brain cancers
WO2011047262A2 (en) 2009-10-15 2011-04-21 Abbott Laboratories Dual variable domain immunoglobulins and uses thereof
WO2011056494A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations
JP6139885B2 (en) 2009-10-26 2017-05-31 ジェネンテック， インコーポレイテッド Assays for detecting antibodies specific for therapeutic anti-IgE antibodies and their use in anaphylaxis
WO2011056497A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor type iib compositions and methods of use
WO2011056502A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Bone morphogenetic protein receptor type ii compositions and methods of use
UY32979A (en) 2009-10-28 2011-02-28 Abbott Lab IMMUNOGLOBULINS WITH DUAL VARIABLE DOMAIN AND USES OF THE SAME
ES2639056T3 (en) 2009-10-28 2017-10-25 Abbvie Biotherapeutics Inc. Anti-EGFR antibodies and their uses
US20120213801A1 (en) 2009-10-30 2012-08-23 Ekaterina Gresko Phosphorylated Twist1 and cancer
WO2011053707A1 (en) 2009-10-31 2011-05-05 Abbott Laboratories Antibodies to receptor for advanced glycation end products (rage) and uses thereof
EP2496604B1 (en) 2009-11-06 2017-08-23 IDEXX Laboratories, Inc. Canine anti-cd20 antibodies
WO2011060015A1 (en) 2009-11-11 2011-05-19 Genentech, Inc. Methods and compositions for detecting target proteins
BR112012012160B1 (en) 2009-11-13 2022-04-26 Amgen, Inc. Material and methods to treat or prevent diseases associated with her-3
US9260517B2 (en) 2009-11-17 2016-02-16 Musc Foundation For Research Development Human monoclonal antibodies to human nucleolin
MX359551B (en) 2009-11-24 2018-10-02 Medimmune Ltd Targeted binding agents against b7-h1.
US11377485B2 (en) 2009-12-02 2022-07-05 Academia Sinica Methods for modifying human antibodies by glycan engineering
US10087236B2 (en) 2009-12-02 2018-10-02 Academia Sinica Methods for modifying human antibodies by glycan engineering
ES2562832T3 (en) 2009-12-08 2016-03-08 Abbvie Deutschland Gmbh & Co Kg Monoclonal antibodies against the RGM protein for use in the treatment of degeneration of the retinal nerve fiber layer
ES2565208T3 (en) 2009-12-11 2016-04-01 F. Hoffmann-La Roche Ag Anti-VEGF-C antibodies and methods of use thereof
WO2011084496A1 (en) 2009-12-16 2011-07-14 Abbott Biotherapeutics Corp. Anti-her2 antibodies and their uses
RU2609658C2 (en) 2009-12-21 2017-02-02 Дженентек, Инк. Composition containing antibody
CN103068849B (en) 2009-12-23 2016-04-06 霍夫曼-拉罗奇有限公司 Anti-Bv8 antibody and uses thereof
JP6037841B2 (en) 2010-01-06 2016-12-07 ダイアックス コーポレーション Plasma kallikrein binding protein
MX2012008108A (en) 2010-01-11 2012-10-03 Alexion Pharma Inc Biomarkers of immunomodulatory effects in humans treated with anti-cd200 antibodies.
TWI609698B (en) 2010-01-20 2018-01-01 Chugai Pharmaceutical Co Ltd Stabilized antibody-containing solution preparation
KR101762467B1 (en) 2010-01-29 2017-07-27 도레이 카부시키가이샤 Polylactic acid-based resin sheet
WO2011099524A1 (en) 2010-02-10 2011-08-18 富士フイルムＲｉファーマ株式会社 Radioactive metal-labeled anti-cadherin antibody
WO2011100403A1 (en) 2010-02-10 2011-08-18 Immunogen, Inc Cd20 antibodies and uses thereof
JP2013520172A (en) 2010-02-18 2013-06-06 モウント シナイ スクール オフ メディシネ Vaccines for use in the prevention and treatment of influenza virus diseases
US8859736B2 (en) 2010-02-19 2014-10-14 The Board Of Regents Of The University Of Oklahoma Monoclonal antibodies that inhibit the wnt signaling pathway and methods of production and use thereof
JP5964249B2 (en) 2010-03-02 2016-08-03 アッヴィ・インコーポレイテッド Therapeutic DLL4 binding protein
WO2011108714A1 (en) 2010-03-04 2011-09-09 中外製薬株式会社 Antibody constant region variant
EP2542578A1 (en) 2010-03-05 2013-01-09 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Smoc1, tenascin-c and brain cancers
US9708373B2 (en) 2010-03-30 2017-07-18 Icahn School Of Medicine At Mount Sinai Influenza virus vaccine and uses thereof
TWI667257B (en) 2010-03-30 2019-08-01 中外製藥股份有限公司 Antibodies with modified affinity to fcrn that promote antigen clearance
LT3248462T (en) 2010-03-31 2024-05-27 Ablexis, Llc Genetic engineering of mice for the production of chimeric antibodies
WO2011130332A1 (en) 2010-04-12 2011-10-20 Academia Sinica Glycan arrays for high throughput screening of viruses
WO2011130434A2 (en) 2010-04-13 2011-10-20 Celldex Therapeutics Inc. Antibodies that bind human cd27 and uses thereof
JP2013523182A (en) 2010-04-15 2013-06-17 アボット・ラボラトリーズ Amyloid beta-binding protein
PL2558499T3 (en) 2010-04-16 2017-10-31 Biogen Ma Inc Anti-vla-4 antibodies
WO2011131611A1 (en) 2010-04-19 2011-10-27 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Modulating xrn1
WO2011133931A1 (en) 2010-04-22 2011-10-27 Genentech, Inc. Use of il-27 antagonists for treating inflammatory bowel disease
WO2011137395A1 (en) 2010-04-30 2011-11-03 Rother Russell P Anti-c5a antibodies and methods for using the antibodies
IL208820A0 (en) 2010-10-19 2011-01-31 Rachel Teitelbaum Biologic female contraceptives
DK2568976T3 (en) 2010-05-10 2016-01-11 Academia Sinica Zanamivir-phosphonate congener with the anti-influenza activity, and determining the sensitivity oseltamivir in influenza viruses
AR081246A1 (en) 2010-05-14 2012-07-18 Abbott Lab PROTEINS OF UNION TO IL-1
EP2569335B1 (en) 2010-05-14 2018-08-22 Orega Biotech Methods of treating and/or preventing cell proliferation disorders with il-17 antagonists
WO2011146568A1 (en) 2010-05-19 2011-11-24 Genentech, Inc. Predicting response to a her inhibitor
DK2578231T3 (en) 2010-05-28 2022-12-12 Chugai Pharmaceutical Co Ltd ANTI-TUMOR T-CELL RESPONSE AMPLIFIER
US20130149302A1 (en) 2010-05-28 2013-06-13 Chugai Seiyaku Kabushiki Kaisha Therapeutic agents for pancreatic cancer
ES2648885T3 (en) 2010-06-02 2018-01-08 Dana-Farber Cancer Institute, Inc. Humanized monoclonal antibodies and methods of use
WO2011153224A2 (en) 2010-06-02 2011-12-08 Genentech, Inc. Diagnostic methods and compositions for treatment of cancer
EP2577310B1 (en) 2010-06-03 2018-11-14 F.Hoffmann-La Roche Ag Immuno-pet imaging of antibodies and immunoconjugates and uses therefor
EP2580239A1 (en) 2010-06-10 2013-04-17 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Treating cancer by modulating mammalian sterile 20-like kinase 3
NZ603581A (en) 2010-06-19 2015-05-29 Sloan Kettering Inst Cancer Anti-gd2 antibodies
EA201291328A1 (en) 2010-06-22 2013-10-30 Дзе Риджентс Оф Дзе Юниверсити Оф Колорадо, Э Боди Корпорейт ANTIBODIES TO C3d FRAGMENT OF COMPONENT 3
US20130143797A1 (en) 2010-06-25 2013-06-06 Michael J. Tisdale Glycoproteins Having Lipid Mobilizing Properties an Therapeutic Uses Thereof
WO2012006500A2 (en) 2010-07-08 2012-01-12 Abbott Laboratories Monoclonal antibodies against hepatitis c virus core protein
UY33492A (en) 2010-07-09 2012-01-31 Abbott Lab IMMUNOGLOBULINS WITH DUAL VARIABLE DOMAIN AND USES OF THE SAME
NZ703035A (en) 2010-07-09 2016-06-24 Crucell Holland Bv Anti-human respiratory syncytial virus (rsv) antibodies and methods of use
US20120100166A1 (en) 2010-07-15 2012-04-26 Zyngenia, Inc. Ang-2 Binding Complexes and Uses Thereof
CN108314733A (en) 2010-07-16 2018-07-24 埃博灵克斯股份有限公司 The single domain antigen binding molecules of modification and its application
WO2012010549A1 (en) 2010-07-19 2012-01-26 F. Hoffmann-La Roche Ag Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy
KR20130091745A (en) 2010-07-19 2013-08-19 에프. 호프만-라 로슈 아게 Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy
KR102080704B1 (en) 2010-07-29 2020-02-24 세센 바이오, 아이엔씨. Chimeric IL-1 Receptor Type 1 Agonists and Antagonists
JP2013537415A (en) 2010-08-03 2013-10-03 アッヴィ・インコーポレイテッド Dual variable domain immunoglobulins and uses thereof
CA2815154A1 (en) 2010-08-06 2012-02-09 U3 Pharma Gmbh Use of her3 binding agents in prostate treatment
EP2420250A1 (en) 2010-08-13 2012-02-22 Universitätsklinikum Münster Anti-Syndecan-4 antibodies
EP2603524A1 (en) 2010-08-14 2013-06-19 AbbVie Inc. Amyloid-beta binding proteins
ES2665954T3 (en) 2010-08-19 2018-04-30 Zoetis Belgium S.A. Anti-NGF antibodies and their use
CA2809433A1 (en) 2010-08-26 2012-03-01 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
WO2012025636A1 (en) 2010-08-27 2012-03-01 University Of Zurich Method for target and drug validation in inflammatory and/or cardiovascular diseases
WO2012028697A1 (en) 2010-09-01 2012-03-08 Eth Zürich, Institute Of Molecular Biology And Biophysics Affinity purification system based on donor strand complementation
US20130171159A1 (en) 2010-09-10 2013-07-04 Brian Arthur Hemmings Phosphorylated twist1 and metastasis
CN103282042B (en) 2010-09-17 2014-12-10 巴克斯特国际公司 Stabilization of immunoglobulins through aqueous formulation with histidine at weak acidic to neutral pH
CA2813738A1 (en) 2010-10-05 2012-04-12 Genentech, Inc. Mutant smoothened and methods of using the same
WO2012049570A1 (en) 2010-10-11 2012-04-19 Panima Pharmaceuticals Ag Human anti-tau antibodies
US9272052B2 (en) 2010-10-22 2016-03-01 Seattle Genetics, Inc. Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the PI3K-AKT mTOR pathway
EP2632481A1 (en) 2010-10-25 2013-09-04 Regents Of The University Of Minnesota Therapeutic composition for treatment of glioblastoma
EP3708586A1 (en) 2010-10-29 2020-09-16 Perseus Proteomics Inc. Anti-cdh3 antibody having high internalization capacity
WO2012065937A1 (en) 2010-11-15 2012-05-24 Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research Anti-fungal agents
RU2620071C2 (en) 2010-11-17 2017-05-22 Чугаи Сеияку Кабушики Каиша Multispecific antigen-binding molecule with alternate function to blood coagulation factor viii function
TWI812066B (en) 2010-11-30 2023-08-11 日商中外製藥股份有限公司 Antibody having calcium-dependent antigen-binding ability
TW202323302A (en) 2010-11-30 2023-06-16 日商中外製藥股份有限公司 Cytotoxicity-inducing therapeutic agent
UA112170C2 (en) 2010-12-10 2016-08-10 Санофі ANTI-TUMOR COMBINATION CONTAINING AN ANTIBODY SPECIFICALLY RECOGNIZING CD38 AND BORTESOMB
EP3628689A1 (en) 2010-12-17 2020-04-01 Neurimmune Holding AG Human anti-sod1 antibodies
BR112013015944A2 (en) 2010-12-21 2018-06-19 Abbvie Inc Bispecific double-domain alpha and beta variable domain immunoglobulins and their uses.
WO2012088094A2 (en) 2010-12-21 2012-06-28 Abbott Laboratories Il-1 binding proteins
HUE037992T2 (en) 2010-12-21 2018-09-28 Selexys Pharmaceuticals Corp Anti-p-selectin antibodies and methods of their use and identification
CN103429261A (en) 2010-12-22 2013-12-04 塞法隆澳大利亚股份有限公司 Modified antibody with improved half-life
WO2012092539A2 (en) 2010-12-31 2012-07-05 Takeda Pharmaceutical Company Limited Antibodies to dll4 and uses thereof
CN105924519B (en) 2010-12-31 2019-08-23 生物蛋白有限公司 Comprehensive monoclonal antibody generates
US20120171195A1 (en) 2011-01-03 2012-07-05 Ravindranath Mepur H Anti-hla-e antibodies, therapeutic immunomodulatory antibodies to human hla-e heavy chain, useful as ivig mimetics and methods of their use
US20140050743A1 (en) 2011-01-19 2014-02-20 Bayer Intellectual Property Gmbh Binding proteins to inhibitors of coagulation factors
SG10201600531TA (en) 2011-01-24 2016-02-26 Univ Singapore Pathogenic mycobacteria-derived mannose-capped lipoarabinomannan antigen binding proteins
WO2012103240A2 (en) 2011-01-25 2012-08-02 Eleven Biotherapeutics, Inc. Receptor binding agents
DK2668210T3 (en) 2011-01-26 2020-08-24 Celldex Therapeutics Inc ANTI-KIT ANTIBODIES AND USES THEREOF
JP6150734B2 (en) 2011-02-03 2017-06-21 アレクシオン ファーマシューティカルズ， インコーポレイテッド Use of anti-CD200 antibodies to prolong allograft survival
WO2012104824A1 (en) 2011-02-04 2012-08-09 Ecole polytechnique fédérale de Lausanne (EPFL) Therapeutic antibodies targeting app-c99
WO2012113775A1 (en) 2011-02-21 2012-08-30 University Of Zurich Ankyrin g and modulators thereof for the treatment of neurodegenerative disorders
KR20230005405A (en) 2011-02-25 2023-01-09 추가이 세이야쿠 가부시키가이샤 FcγRIIb-specific Fc antibody
BR112013021725A2 (en) 2011-02-28 2016-11-01 Genentech Inc biological markers and methods for predicting response to b-cell antagonists
PL3235508T3 (en) 2011-03-16 2021-07-12 Sanofi Compositions comprising a dual v region antibody-like protein
EP2686418A4 (en) 2011-03-17 2015-04-22 Minerva Biotechnologies Corp Method for making pluripotent stem cells
EP2500073A1 (en) 2011-03-17 2012-09-19 ChromaCon AG Method for identification and purification of multi-specific polypeptides
EP2687231A4 (en) 2011-03-18 2014-10-22 Univ Kagoshima Composition for treatment and diagnosis of pancreatic cancer
US9555108B2 (en) 2011-03-24 2017-01-31 Texas Tech University System TCR mimic antibodies as vascular targeting tools
DK2698431T3 (en) 2011-03-30 2020-11-30 Chugai Pharmaceutical Co Ltd Maintenance of antigen-binding molecules in blood plasma and method of modifying immunogenicity
CN106039306A (en) 2011-03-30 2016-10-26 埃博灵克斯股份有限公司 Methods of treating immune disorders with single domain antibodies against TNF-alpha
MX356426B (en) 2011-04-04 2018-05-29 Univ Iowa Res Found Methods of improving vaccine immunogenicity.
AU2012239997A1 (en) 2011-04-07 2013-10-17 Amgen Inc. Novel EGFR binding proteins
US9150644B2 (en) 2011-04-12 2015-10-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies that bind insulin-like growth factor (IGF) I and II
EP2699264B1 (en) 2011-04-20 2018-03-14 Medlmmune, LLC Antibodies and other molecules that bind b7-h1 and pd-1
US9062106B2 (en) 2011-04-27 2015-06-23 Abbvie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
JOP20200043A1 (en) 2011-05-10 2017-06-16 Amgen Inc Methods of treating or preventing cholesterol related disorders
JP6400470B2 (en) 2011-05-16 2018-10-03 ジェネロン（シャンハイ）コーポレイション リミテッド Multispecific Fab fusion proteins and methods of use
SG195073A1 (en) 2011-05-21 2013-12-30 Macrogenics Inc Deimmunized serum-binding domains and their use for extending serum half-life
CA2837169C (en) 2011-05-24 2021-11-09 Zyngenia, Inc. Multispecific complexes comprising angiopoietin-2-binding peptide and their uses
AR086543A1 (en) 2011-05-25 2014-01-08 Bg Medicine Inc GALECTIN-3 INHIBITORS AND METHODS OF USE OF THE SAME, PHARMACEUTICAL COMPOSITION
EP2530088A1 (en) 2011-05-30 2012-12-05 Klinikum rechts der Isar der Technischen Universität München Means and methods for diagnosing and treating multiple sclerosis
JP6104897B2 (en) 2011-06-02 2017-04-05 ダイアックス コーポレーション Fc receptor binding protein
KR102051014B1 (en) 2011-06-03 2019-12-04 조마 테크놀로지 리미티드 Antibodies specific for tgf-beta
US9574002B2 (en) 2011-06-06 2017-02-21 Amgen Inc. Human antigen binding proteins that bind to a complex comprising β-Klotho and an FGF receptor
EP2717911A1 (en) 2011-06-06 2014-04-16 Novartis Forschungsstiftung, Zweigniederlassung Protein tyrosine phosphatase, non-receptor type 11 (ptpn11) and triple-negative breast cancer
JP6305919B2 (en) 2011-06-06 2018-04-04 プロセナ バイオサイエンシーズ リミテッド MCAM antagonists and methods of treatment
US9561274B2 (en) 2011-06-07 2017-02-07 University Of Hawaii Treatment and prevention of cancer with HMGB1 antagonists
WO2012170740A2 (en) 2011-06-07 2012-12-13 University Of Hawaii Biomarker of asbestos exposure and mesothelioma
WO2012170807A2 (en) 2011-06-10 2012-12-13 Medimmune, Llc Anti-pseudomonas psl binding molecules and uses thereof
US20140120555A1 (en) 2011-06-20 2014-05-01 Pierre Fabre Medicament Anti-cxcr4 antibody with effector functions and its use for the treatment of cancer
CA2839563C (en) 2011-06-23 2019-10-29 Biogen Idec International Neuroscience Gmbh Anti-alpha synuclein binding molecules
CA2839539C (en) 2011-06-30 2021-06-08 Chugai Seiyaku Kabushiki Kaisha Heterodimerized polypeptide
JP2013040160A (en) 2011-07-01 2013-02-28 Genentech Inc Use of anti-cd83 agonist antibody for treating autoimmune disease
DE202011103324U1 (en) 2011-07-12 2012-01-02 Nekonal S.A.R.L. Therapeutic anti-TIRC7 antibodies for use in immune and other diseases
KR20140061403A (en) 2011-07-13 2014-05-21 애브비 인코포레이티드 Methods and compositions for treating asthma using anti-il-13 antibodies
US9574005B2 (en) 2011-07-19 2017-02-21 Chugai Seiyaku Kabushiki Kaisha Stable Protein-containing preparation containing argininamide or analogous compound thereof
TW202114735A (en) 2011-08-01 2021-04-16 美商建南德克公司 Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors
WO2013017656A1 (en) 2011-08-02 2013-02-07 Medizinische Universität Wien Antagonists of ribonucleases for treating obesity
WO2013017691A1 (en) 2011-08-04 2013-02-07 Medizinische Universität Innsbruck Cahgt1p inhibitors for use in the treatment of candidiasis
JP6120848B2 (en) 2011-08-15 2017-04-26 メディミューン，エルエルシー Anti-B7-H4 antibody and use thereof
MX2014001736A (en) 2011-08-17 2014-03-31 Genentech Inc Inhibition of angiogenesis in refractory tumors.
JP6101205B2 (en) 2011-08-23 2017-03-22 中外製薬株式会社 Novel anti-DDR1 antibody having antitumor activity
US9447192B2 (en) 2011-09-09 2016-09-20 Medimmune Limited Anti-Siglec-15 antibodies and uses thereof
EA201490659A1 (en) 2011-09-20 2014-11-28 Маунт Синай Скул Оф Медсин VACCINES AGAINST FLU VIRUS AND THEIR USE
US9599608B2 (en) 2011-09-21 2017-03-21 Fujirebio Inc. Antibody against affinity complex
MX2014003313A (en) 2011-09-23 2014-07-09 Amgen Res Munich Gmbh Bispecific binding molecules for 5t4 and cd3.
CN110680920A (en) 2011-09-30 2020-01-14 中外制药株式会社 Antigen binding molecules that induce an immune response against a target antigen
SG11201401102VA (en) 2011-09-30 2014-09-26 Chugai Pharmaceutical Co Ltd Ion concentration-dependent binding molecule library
TW201817744A (en) 2011-09-30 2018-05-16 日商中外製藥股份有限公司 Therapeutic antigen-binding molecule with a FcRn-binding domain that promotes antigen clearance
WO2013047752A1 (en) 2011-09-30 2013-04-04 中外製薬株式会社 Antigen-binding molecule for promoting loss of antigens
EP3939996A1 (en) 2011-09-30 2022-01-19 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities
US20140248294A1 (en) 2011-10-05 2014-09-04 University Of Bremen Wnt4 and med12 for use in the diagnosis and treatment of tumor diseases
US9663573B2 (en) 2011-10-05 2017-05-30 Genentech, Inc. Methods of treating liver conditions using Notch2 antagonists
EP2765192A4 (en) 2011-10-05 2015-04-15 Chugai Pharmaceutical Co Ltd Antigen-binding molecule for promoting clearance from plasma of antigen comprising saccharide chain receptor-binding domain
AU2012326137B2 (en) 2011-10-17 2018-11-29 Minerva Biotechnologies Corporation Media for stem cell proliferation and induction
BR112014009536A2 (en) 2011-10-21 2017-04-18 Augurex Life Sciences Corp 14-3-3 xitrulinated derivatives and their uses in the diagnosis of rheumatoid arthritis
CA2853357A1 (en) 2011-10-24 2013-05-02 Abbvie Inc. Immunobinders directed against tnf
MX2014004977A (en) 2011-10-24 2014-09-11 Abbvie Inc Immunobinders directed against sclerostin.
US9272002B2 (en) 2011-10-28 2016-03-01 The Trustees Of The University Of Pennsylvania Fully human, anti-mesothelin specific chimeric immune receptor for redirected mesothelin-expressing cell targeting
KR102168733B1 (en) 2011-10-31 2020-10-23 추가이 세이야쿠 가부시키가이샤 Antigen-binding molecule having regulated conjugation between heavy-chain and light-chain
MX363226B (en) 2011-10-31 2019-03-15 Genentech Inc Antibody formulations.
CN104053671A (en) 2011-11-01 2014-09-17 生态学有限公司 Antibodies and methods of treating cancer
ES2697674T3 (en) 2011-11-01 2019-01-25 Bionomics Inc Procedures to block the growth of cancer stem cells
EP2773667A1 (en) 2011-11-01 2014-09-10 Bionomics, Inc. Anti-gpr49 antibodies
WO2013067057A1 (en) 2011-11-01 2013-05-10 Bionomics, Inc. Anti-gpr49 antibodies
WO2013067492A1 (en) 2011-11-03 2013-05-10 The Trustees Of The University Of Pennsylvania Isolated b7-h4 specific compositions and methods of use thereof
WO2013070468A1 (en) 2011-11-08 2013-05-16 The Trustees Of The University Of Pennsylvania Glypican-3-specific antibody and uses thereof
AU2012335247A1 (en) 2011-11-08 2014-05-29 Pfizer Inc. Methods of treating inflammatory disorders using anti-M-CSF antibodies
WO2013068432A1 (en) 2011-11-08 2013-05-16 Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research Early diagnostic of neurodegenerative diseases
WO2013068431A1 (en) 2011-11-08 2013-05-16 Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research New treatment for neurodegenerative diseases
EP2776565A1 (en) 2011-11-08 2014-09-17 Quark Pharmaceuticals, Inc. Methods and compositions for treating diseases, disorders or injury of the nervous system
TWI679212B (en) 2011-11-15 2019-12-11 美商安進股份有限公司 Binding molecules for e3 of bcma and cd3
SG11201402365RA (en) 2011-11-16 2014-06-27 Amgen Inc Methods of treating epidermal growth factor deletion mutant viii related disorders
PT2785375T (en) 2011-11-28 2020-10-29 Merck Patent Gmbh Anti-pd-l1 antibodies and uses thereof
KR20140100532A (en) 2011-11-30 2014-08-14 추가이 세이야쿠 가부시키가이샤 Drug containing carrier into cell for forming immune complex
EP2602621A1 (en) 2011-12-08 2013-06-12 Julius-Maximilians-Universität Würzburg LASP-1, a novel urinary marker for transitional cell carcinoma detection
ES2684950T3 (en) 2011-12-08 2018-10-05 Biotest Ag Uses of immunoconjugates directed to CD138
JP6342812B2 (en) 2011-12-14 2018-06-13 アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー Compositions and methods for diagnosing and treating iron-related disorders
CA2855570A1 (en) 2011-12-14 2013-06-20 AbbVie Deutschland GmbH & Co. KG Composition and method for the diagnosis and treatment of iron-related disorders
JP6320300B2 (en) 2011-12-19 2018-05-09 ゾーマ （ユーエス） リミテッド ライアビリティ カンパニー Methods for treating acne
ES2721882T3 (en) 2011-12-23 2019-08-06 Pfizer Constant regions of genetically engineered antibody for site-specific conjugation and procedures and uses thereof
WO2013093122A2 (en) 2011-12-23 2013-06-27 Phenoquest Ag Antibodies for the treatment and diagnosis of affective and anxiety disorders
PL2797951T3 (en) 2011-12-28 2018-07-31 Immunoqure Ag Method of isolating human antibodies
TWI593705B (en) 2011-12-28 2017-08-01 Chugai Pharmaceutical Co Ltd Humanized anti-epiregulin antibody and cancer therapeutic agent containing the antibody as an active ingredient
US9120870B2 (en) 2011-12-30 2015-09-01 Abbvie Inc. Dual specific binding proteins directed against IL-13 and IL-17
US20140363448A1 (en) 2012-01-02 2014-12-11 Novartis Ag Cdcp1 and breast cancer
AU2013208007A1 (en) 2012-01-09 2014-07-31 The Scripps Research Institute Humanized antibodies with ultralong CDR3
CA2863224A1 (en) 2012-01-09 2013-07-18 The Scripps Research Institute Ultralong complementarity determining regions and uses thereof
US10800847B2 (en) 2012-01-11 2020-10-13 Dr. Mepur Ravindranath Anti-HLA class-IB antibodies mimic immunoreactivity and immunomodulatory functions of intravenous immunoglobulin (IVIG) useful as therapeutic IVIG mimetics and methods of their use
US20130177574A1 (en) 2012-01-11 2013-07-11 Paul I. Terasaki Foundation Laboratory ANTI-HLA CLASS-Ib ANTIBODIES MIMIC IMMUNOREACTIVITY AND IMMUNOMODULATORY FUNCTIONS OF INTRAVENOUS IMMUNOGLOBULIN (IVIg) USEFUL AS THERAPEUTIC IVIg MIMETICS AND METHODS OF THEIR USE
SG11201403927XA (en) 2012-01-13 2014-08-28 Genentech Inc Biological markers for identifying patients for treatment with vegf antagonists
WO2013107290A1 (en) 2012-01-20 2013-07-25 The Government of the Hong Kong Special Administrative Region of the People's Republic of China A novel paramyxovirus and uses thereof
CN107880124B (en) 2012-01-27 2021-08-13 艾伯维德国有限责任两合公司 Compositions and methods for diagnosing and treating diseases associated with neural mutations
EP2809684A1 (en) 2012-01-31 2014-12-10 Genentech, Inc. Anti-ig-e m1' antibodies and methods using same
KR102338833B1 (en) 2012-02-06 2021-12-13 인히브릭스, 인크. Cd47 antibodies and methods of use thereof
CN113527469A (en) 2012-02-09 2021-10-22 中外制药株式会社 Fc region variants of antibodies
EP2812702B1 (en) 2012-02-10 2019-04-17 Seattle Genetics, Inc. Diagnosis and management of CD30-expressing cancers
PL2814842T3 (en) 2012-02-15 2018-12-31 Novo Nordisk A/S Antibodies that bind peptidoglycan recognition protein 1
US9550830B2 (en) 2012-02-15 2017-01-24 Novo Nordisk A/S Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
EP3196214B1 (en) 2012-02-15 2019-07-31 Novo Nordisk A/S Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (trem-1)
ES2732243T3 (en) 2012-02-16 2019-11-21 Santarus Inc Pharmaceutical compositions of ANTI-VLA1 antibodies (CD49A)
CA2865158C (en) 2012-02-24 2022-11-01 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule for promoting disappearance of antigen via fc.gamma.riib
JP6407726B2 (en) 2012-03-01 2018-10-24 アムゲン リサーチ （ミュンヘン） ゲーエムベーハーＡＭＧＥＮ Ｒｅｓｅａｒｃｈ（Ｍｕｎｉｃｈ）ＧｍｂＨ Long-life polypeptide binding molecule
US20140013456A1 (en) 2012-03-16 2014-01-09 Regeneron Pharmaceuticals, Inc. Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
BR112014022855A2 (en) 2012-03-16 2017-07-18 Regeneron Pharma genetically modified nonhuman animal, genetically modified mammal, and method for making a nonhuman animal
MX2014011047A (en) 2012-03-16 2015-04-08 Regeneron Pharma Mice that produce antigen-binding proteins with ph-dependent binding characteristics.
RU2644684C2 (en) 2012-03-16 2018-02-13 Регенерон Фармасьютикалз, Инк. Antibodies with built in the light circuit by hystidine and genetically modified excellent from human animals for their obtaining
US9592289B2 (en) 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
WO2013148315A1 (en) 2012-03-27 2013-10-03 Genentech, Inc. Diagnosis and treatments relating to her3 inhibitors
RU2014139546A (en) 2012-03-27 2016-05-20 Дженентек, Инк. METHODS FOR THE FORECASTING, DIAGNOSTICS AND TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS
AU2013237929B2 (en) 2012-03-29 2017-09-14 Novimmune S.A. Anti-TLR4 antibodies and uses thereof
EP2832856A4 (en) 2012-03-29 2016-01-27 Chugai Pharmaceutical Co Ltd Anti-lamp5 antibody and utilization thereof
WO2013144240A1 (en) 2012-03-29 2013-10-03 Friedrich Miescher Institute For Biomedical Research Inhibition of interleukin- 8 and/or its receptor cxcrl in the treatment her2/her3 -overexpressing breast cancer
SG11201406184XA (en) 2012-03-30 2014-10-30 Genentech Inc Diagnostic methods and compositions for treatment of cancer
WO2013151649A1 (en) 2012-04-04 2013-10-10 Sialix Inc Glycan-interacting compounds
CA2869704A1 (en) 2012-04-04 2013-10-10 Perseus Proteomics Inc. Drug conjugate comprising anti-cdh3 (pcadherin) antibody
WO2013155447A1 (en) 2012-04-13 2013-10-17 Children's Medical Center Corporation Tiki inhibitors
US10130714B2 (en) 2012-04-14 2018-11-20 Academia Sinica Enhanced anti-influenza agents conjugated with anti-inflammatory activity
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
US9980942B2 (en) 2012-05-02 2018-05-29 Children's Hospital Medical Center Rejuvenation of precursor cells
US9480449B2 (en) 2012-05-03 2016-11-01 Fibrogen, Inc. Methods for treating idiopathic pulmonary fibrosis
EA039663B1 (en) 2012-05-03 2022-02-24 Амген Инк. Use of an anti-pcsk9 antibody for lowering serum cholesterol ldl and treating cholesterol related disorders
WO2013166290A1 (en) 2012-05-04 2013-11-07 Abbvie Biotherapeutics Inc. P21 biomarker assay
CA2871751C (en) 2012-05-04 2021-08-24 Dana-Farber Cancer Institute, Inc. Affinity matured anti-ccr4 humanized monoclonal antibodies and methods of use
CA2873623C (en) 2012-05-14 2021-11-09 Biogen Idec Ma Inc. Lingo-2 antagonists for treatment of conditions involving motor neurons
KR20220051197A (en) 2012-05-17 2022-04-26 익스텐드 바이오사이언시즈, 인크. Carriers for improved drug delivery
WO2013177386A1 (en) 2012-05-24 2013-11-28 Abbvie Biotherapeutics Inc. Biomarkers for predicting response to tweak receptor (tweakr) agonist therapy
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
ES2856272T3 (en) 2012-05-30 2021-09-27 Chugai Pharmaceutical Co Ltd Antigen-binding molecule to remove aggregated antigens
TWI797443B (en) 2012-05-30 2023-04-01 日商中外製藥股份有限公司 Screening or production method of antigen-binding molecule
BR112014029887A8 (en) 2012-05-31 2021-09-14 Genentech Inc Method to treat or slow the progression of cancer, kits and use of a pd-1 axis binding antagonist, oxaliplatin, leucovorin and 5-fu
WO2013184871A1 (en) 2012-06-06 2013-12-12 Zoetis Llc Caninized anti-ngf antibodies and methods thereof
US11142563B2 (en) 2012-06-14 2021-10-12 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule containing modified Fc region
PE20150223A1 (en) 2012-06-15 2015-02-11 Pfizer ANTIBODIES ENHANCED ANTIBODIES AGAINST GROWTH AND DIFFERENTIATION FACTOR-8 AND THE USES OF THEM
PE20150643A1 (en) 2012-06-22 2015-05-29 Cytomx Therapeutics Inc ANTI-JAGGED 1 / JAGGED 2 CROSS-REACTIVE ANTIBODIES ACTIVABLE ANTI-JAGGED ANTIBODIES AND METHODS OF USE OF THEM
EP2866831A1 (en) 2012-06-29 2015-05-06 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Treating diseases by modulating a specific isoform of mkl1
US20150184154A1 (en) 2012-07-05 2015-07-02 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Resear New treatment for neurodegenerative diseases
US10656156B2 (en) 2012-07-05 2020-05-19 Mepur Ravindranath Diagnostic and therapeutic potential of HLA-E monospecific monoclonal IgG antibodies directed against tumor cell surface and soluble HLA-E
WO2014006115A1 (en) 2012-07-06 2014-01-09 Novartis Ag Combination of a phosphoinositide 3-kinase inhibitor and an inhibitor of the il-8/cxcr interaction
US9670276B2 (en) 2012-07-12 2017-06-06 Abbvie Inc. IL-1 binding proteins
ES2786263T3 (en) 2012-07-13 2020-10-09 Univ Pennsylvania Enhancement of T-lymphocyte CAR activity by co-introduction of a bispecific antibody
WO2014031498A1 (en) 2012-08-18 2014-02-27 Academia Sinica Cell-permeable probes for identification and imaging of sialidases
CA2883168A1 (en) 2012-08-21 2014-02-27 Academia Sinica Benzocyclooctyne compounds and uses thereof
JP6774164B2 (en) 2012-08-24 2020-10-21 中外製薬株式会社 Mouse FcγRII specific Fc antibody
EP3721900A1 (en) 2012-08-24 2020-10-14 Chugai Seiyaku Kabushiki Kaisha Fcgammariib-specific fc region variant
AU2013308409A1 (en) 2012-08-31 2015-03-26 University Of Birmingham Target peptides for immunotherapy and diagnostics
NZ726258A (en) 2012-08-31 2019-07-26 Immunogen Inc Antibodies and uses thereof to detect folate receptor 1
BR112015004467A2 (en) 2012-09-02 2017-03-21 Abbvie Inc method for controlling protein heterogeneity
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
EP4088737A3 (en) 2012-09-05 2023-02-08 University Of Virginia Patent Foundation Target peptides for colorectal cancer therapy and diagnostics
TWI660972B (en) 2012-09-10 2019-06-01 愛爾蘭商尼歐托普生物科學公司 Anti-mcam antibodies and associated methods of use
WO2014047342A1 (en) 2012-09-19 2014-03-27 Dana-Farber Cancer Institute, Inc. Dynamic bh3 profiling
EP2711016A1 (en) 2012-09-21 2014-03-26 Covagen AG Novel IL-17A binding molecules and medical uses thereof
AU2013320972B2 (en) 2012-09-27 2018-08-30 Chugai Seiyaku Kabushiki Kaisha FGFR3 fusion gene and pharmaceutical drug targeting same
TWI609083B (en) 2012-09-28 2017-12-21 Chugai Pharmaceutical Co Ltd Blood coagulation reaction assessment method
NO2760138T3 (en) 2012-10-01 2018-08-04
WO2014055442A2 (en) 2012-10-01 2014-04-10 The Trustees Of The University Of Pennsylvania Compositions and methods for targeting stromal cells for the treatment of cancer
CN107892719B (en) 2012-10-04 2022-01-14 达纳－法伯癌症研究所公司 Human monoclonal anti-PD-L1 antibodies and methods of use
WO2014055771A1 (en) 2012-10-05 2014-04-10 The Trustees Of The University Of Pennsylvania Human alpha-folate receptor chimeric antigen receptor
AU2013334493B2 (en) 2012-10-26 2018-11-29 The University Of Queensland Use of endocytosis inhibitors and antibodies for cancer therapy
BR112015009961B1 (en) 2012-11-01 2020-10-20 Abbvie Inc. binding protein capable of binding to dll4 and vegf, as well as a composition comprising it as a composition comprising it
PT2918603T (en) 2012-11-08 2018-10-30 Univ Miyazaki Antibody capable of specifically recognizing transferrin receptor
US20140154255A1 (en) 2012-11-30 2014-06-05 Abbvie Biotherapeutics Inc. Anti-vegf antibodies and their uses
CA2892585C (en) 2012-12-03 2022-07-05 Novimmune S.A. Anti-cd47 antibodies and methods of use thereof
UA118255C2 (en) 2012-12-07 2018-12-26 Санофі Compositions comprising anti-cd38 antibodies and lenalidomide
US10342869B2 (en) 2012-12-07 2019-07-09 The Regents Of The University Of California Compositions comprising anti-CD38 antibodies and lenalidomide
US9902775B2 (en) 2012-12-10 2018-02-27 Biogen Ma Inc. Anti-blood dendritic cell antigen 2 antibodies and uses thereof
US20160000893A1 (en) 2012-12-13 2016-01-07 University Of Virginia Patent Foundation Target peptides for ovarian cancer therapy and diagnostics
JP2016508133A (en) 2012-12-18 2016-03-17 アイカーン スクール オブ メディシン アット マウント サイナイ Influenza virus vaccine and use thereof
EP2934575A2 (en) 2012-12-19 2015-10-28 Amplimmune, Inc. B7-h4 specific antibodies, and compositions and methods of use thereof
LT2935326T (en) 2012-12-21 2020-12-10 Biogen Ma Inc. Human anti-tau antibodies
JP6359031B2 (en) 2012-12-21 2018-07-18 メディミューン，エルエルシー Anti-H7CR antibody
CN105102618B (en) 2012-12-27 2018-04-17 中外制药株式会社 heterodimerization polypeptide
EP2938631B1 (en) 2012-12-31 2018-12-19 Neurimmune Holding AG Recombinant human antibodies for therapy and prevention of polyomavirus-related diseases
US10717965B2 (en) 2013-01-10 2020-07-21 Gloriana Therapeutics, Inc. Mammalian cell culture-produced neublastin antibodies
EP2948478B1 (en) 2013-01-25 2019-04-03 Amgen Inc. Antibodies targeting cdh19 for melanoma
JO3519B1 (en) 2013-01-25 2020-07-05 Amgen Inc Antibody constructs for CDH19 and CD3
US9834610B2 (en) 2013-01-31 2017-12-05 Thomas Jefferson University Fusion proteins for modulating regulatory and effector T cells
BR112015018851A2 (en) 2013-02-06 2017-07-18 Inhibrx Llc platelet non-depleting and non-depleting red blood cell cd47 antibodies, and methods of use thereof
CN105247072B (en) 2013-02-25 2019-10-15 基因泰克公司 The method and composition of detection and treatment drug resistance AKT mutant
AU2013381687A1 (en) 2013-03-12 2015-09-24 Abbvie Inc. Human antibodies that bind human TNF-alpha and methods of preparing the same
SG10201705525VA (en) 2013-03-13 2017-08-30 Genentech Inc Formulations with reduced oxidation
BR112015022210A8 (en) 2013-03-13 2018-01-23 Genentech Inc antibody formulations
SG10201707464SA (en) 2013-03-13 2017-10-30 Sanofi Sa Compositions comprising anti-cd38 antibodies and carfilzomib
SI2968467T1 (en) 2013-03-13 2020-11-30 F. Hoffmann-La Roche Ag Formulations with reduced oxidation
JP6450364B2 (en) 2013-03-13 2019-01-09 セセン バイオ， インコーポレイテッド Chimeric cytokine formulations for ocular delivery
US20140314778A1 (en) 2013-03-13 2014-10-23 Genentech, Inc. Formulations with reduced oxidation
US10653779B2 (en) 2013-03-13 2020-05-19 Genentech, Inc. Formulations with reduced oxidation
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
WO2014153056A2 (en) 2013-03-14 2014-09-25 Parkash Gill Cancer treatment using antibodies that bing cell surface grp78
WO2014159579A1 (en) 2013-03-14 2014-10-02 Abbvie Inc. MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE
MX2015012825A (en) 2013-03-14 2016-06-10 Abbott Lab Hcv core lipid binding domain monoclonal antibodies.
AU2014244444A1 (en) 2013-03-14 2015-09-24 Amgen Inc. CHRDL-1 antigen binding proteins and methods of treatment
JP6505076B2 (en) 2013-03-14 2019-04-24 アボット・ラボラトリーズＡｂｂｏｔｔ Ｌａｂｏｒａｔｏｒｉｅｓ HCV antigen-antibody combination assay and methods and compositions for use therein
WO2014159960A1 (en) 2013-03-14 2014-10-02 Icahn School Of Medicine At Mount Sinai Antibodies against influenza virus hemagglutinin and uses thereof
JP2016512241A (en) 2013-03-14 2016-04-25 アボット・ラボラトリーズＡｂｂｏｔｔ Ｌａｂｏｒａｔｏｒｉｅｓ HCVNS3 recombinant antigen for improved antibody detection and mutants thereof
WO2014159242A1 (en) 2013-03-14 2014-10-02 Novartis Ag Notch 3 mutants and uses thereof
JP2016514690A (en) 2013-03-15 2016-05-23 アッヴィ バイオテクノロジー リミテッド Anti-CD25 antibodies and their use
US10167341B2 (en) 2013-03-15 2019-01-01 Memorial Sloan Kettering Cancer Center High affinity anti-GD2 antibodies
SG11201507359SA (en) 2013-03-15 2015-10-29 Dana Farber Cancer Inst Inc Flavivirus neutralizing antibodies and methods of use thereof
AR095374A1 (en) 2013-03-15 2015-10-14 Amgen Res (Munich) Gmbh UNION MOLECULES FOR BCMA AND CD3
SI2970449T1 (en) 2013-03-15 2019-11-29 Amgen Res Munich Gmbh Single chain binding molecules comprising n-terminal abp
AR095348A1 (en) 2013-03-15 2015-10-07 Genentech Inc CELL CULTURE MEDIA AND ANTIBODY PRODUCTION METHODS
BR112015023752B1 (en) 2013-03-15 2023-11-14 Zyngenia, Inc. MODULAR RECOGNITION DOMAIN (MRD), COMPLEX COMPRISING MRD AND CETUXIMAB, USES OF THE COMPLEX TO INHIBIT ANGIOGENESIS AND TREAT CANCER AND PHARMACEUTICAL COMPOSITION COMPRISING SAID COMPLEX
CA2903596C (en) 2013-03-15 2023-10-03 Genentech, Inc. Cell culture compositions with antioxidants and methods for polypeptide production
US9505849B2 (en) 2013-03-15 2016-11-29 Amgen Research (Munich) Gmbh Antibody constructs for influenza M2 and CD3
CN105377892A (en) 2013-03-15 2016-03-02 艾伯维生物技术有限公司 Anti-CD25 antibodies and their uses
US9469686B2 (en) 2013-03-15 2016-10-18 Abbott Laboratories Anti-GP73 monoclonal antibodies and methods of obtaining the same
ES2699599T3 (en) 2013-03-15 2019-02-11 Abbvie Biotherapeutics Inc Fc variants
EA201591806A1 (en) 2013-03-15 2016-01-29 Байоджен Ма Инк. TREATMENT AND PREVENTION OF ACUTE RENAL FAILURE WITH THE USE OF ANTI-ALPHA-V-BETA-5 ANTIBODIES
WO2014144280A2 (en) 2013-03-15 2014-09-18 Abbvie Inc. DUAL SPECIFIC BINDING PROTEINS DIRECTED AGAINST IL-1β AND / OR IL-17
US10160797B2 (en) 2013-03-15 2018-12-25 Sanofi Pasteur Biologics, Llc Antibodies against Clostridium difficile toxins and methods of using the same
TWI636062B (en) 2013-04-02 2018-09-21 中外製藥股份有限公司 Fc region variant
WO2014165818A2 (en) 2013-04-05 2014-10-09 T Cell Therapeutics, Inc. Compositions and methods for preventing and treating prostate cancer
EP2983710B1 (en) 2013-04-09 2019-07-31 Annexon, Inc. Methods of treatment for neuromyelitis optica
TWI679019B (en) 2013-04-29 2019-12-11 法商賽諾菲公司 Anti-il-4/anti-il-13 bispecific antibody formulations
AU2014262843B2 (en) 2013-05-06 2017-06-22 Scholar Rock, Inc. Compositions and methods for growth factor modulation
WO2014182972A2 (en) 2013-05-10 2014-11-13 The Regents Of The University Of California Diagnostic and monitoring system for huntington's disease
CN105264381B (en) 2013-05-16 2018-06-01 国立大学法人京都大学 For determining the method for cancer prognosis
KR20160129698A (en) 2013-05-24 2016-11-09 메디뮨 엘엘씨 Anti-b7-h5 antibodies and their uses
WO2014197866A1 (en) 2013-06-06 2014-12-11 Igenica Biotherapeutics, Inc. Modified antibodies and related compounds, compositions, and methods of use
SG10201708143QA (en) 2013-06-06 2017-11-29 Pierre Fabre Médicament Anti-c10orf54 antibodies and uses thereof
CA2914566A1 (en) 2013-06-07 2014-12-11 Duke University Inhibitors of complement factor h
JP6442404B2 (en) 2013-06-11 2018-12-19 国立研究開発法人国立精神・神経医療研究センター Method for predicting treatment prognosis in patients with relapsing-remitting multiple sclerosis (RRMS), and method for determining new treatment indication
US9499628B2 (en) 2013-06-14 2016-11-22 Children's Hospital Medical Center Method of boosting the immune response in neonates
EP3015115A4 (en) 2013-06-24 2017-02-22 Chugai Seiyaku Kabushiki Kaisha Therapeutic agent comprising humanized anti-epiregulin antibody as active ingredient for non-small-cell lung carcinoma excluding adenocarcinoma
WO2014210397A1 (en) 2013-06-26 2014-12-31 Academia Sinica Rm2 antigens and use thereof
US9981030B2 (en) 2013-06-27 2018-05-29 Academia Sinica Glycan conjugates and use thereof
EP3013422A1 (en) 2013-06-28 2016-05-04 Amgen Inc. Methods for treating homozygous familial hypercholesterolemia
US10112995B2 (en) 2013-07-03 2018-10-30 Immunoqure Ag Human anti-IFN-α antibodies
CA2916521C (en) 2013-07-09 2023-03-07 Annexon, Inc. Anti-complement factor c1q antibodies and uses thereof
JP6636920B2 (en) 2013-07-16 2020-01-29 ジェネンテック， インコーポレイテッド Method of treating cancer using PD-1 axis binding antagonist and TIGIT inhibitor
EP3022224A2 (en) 2013-07-18 2016-05-25 Fabrus, Inc. Antibodies with ultralong complementarity determining regions
CN105814074B (en) 2013-07-18 2020-04-21 图鲁斯生物科学有限责任公司 Humanized antibodies with ultralong complementarity determining regions
BR112016002685A2 (en) 2013-08-07 2018-01-30 Astute Medical Inc timp2 assays that perform better on biological samples
WO2015019286A1 (en) 2013-08-07 2015-02-12 Friedrich Miescher Institute For Biomedical Research New screening method for the treatment friedreich's ataxia
WO2015023851A1 (en) 2013-08-14 2015-02-19 The Governing Council Of The University Of Toronto Antibodies against frizzled proteins and methods of use thereof
PL3036320T5 (en) 2013-08-19 2024-06-10 Biogen Ma Inc. Control of protein glycosylation by culture medium supplementation and cell culture process parameters
US10456470B2 (en) 2013-08-30 2019-10-29 Genentech, Inc. Diagnostic methods and compositions for treatment of glioblastoma
US10617755B2 (en) 2013-08-30 2020-04-14 Genentech, Inc. Combination therapy for the treatment of glioblastoma
WO2015035044A2 (en) 2013-09-04 2015-03-12 Abbvie Biotherapeutics Inc. Fc VARIANTS WITH IMPROVED ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY
CA2923579C (en) 2013-09-06 2023-09-05 Academia Sinica Human inkt cell activation using glycolipids with altered glycosyl groups
NZ714555A (en) 2013-09-17 2020-03-27 Obi Pharma Inc Compositions of a carbohydrate vaccine for inducing immune responses and uses thereof in cancer treatment
JP6663852B2 (en) 2013-09-19 2020-03-13 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド BH3 profiling method
WO2015041310A1 (en) 2013-09-20 2015-03-26 中外製薬株式会社 Treatment for hemorrhagic diseases by anti-protein-c antibody
CA2925256C (en) 2013-09-27 2023-08-15 Chugai Seiyaku Kabushiki Kaisha Method for producing polypeptide heteromultimer
PT3049441T (en) 2013-09-27 2020-01-21 Hoffmann La Roche Anti-pdl1 antibody formulations
WO2015051293A2 (en) 2013-10-04 2015-04-09 Abbvie, Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
CN105934252B (en) 2013-10-10 2020-11-10 贝思以色列女会吏医学中心公司 TM4SF1 binding proteins and methods of use thereof
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
AU2014342528A1 (en) 2013-10-28 2016-04-28 Dots Technology Corp. Allergen detection
EP3063173B1 (en) 2013-10-31 2020-07-29 Sanofi Specific anti-cd38 antibodies for treating human cancers
CA3185700A1 (en) 2013-11-06 2015-05-14 Astute Medical, Inc. Assays for igfbp7 having improved performance in biological samples
BR112016010025A2 (en) 2013-11-11 2017-12-05 Chugai Pharmaceutical Co Ltd antigen binding molecule containing modified antibody variable region
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
JP7060317B2 (en) 2013-12-04 2022-04-26 中外製薬株式会社 Antigen-binding molecule and its library whose antigen-binding ability changes according to the concentration of the compound
KR20160097294A (en) 2013-12-09 2016-08-17 뉴욕 유니버시티 Compositions and methods for phagocyte delivery of anti-staphylococcal agents
US9944694B2 (en) 2013-12-13 2018-04-17 Rijksuniversiteit Groningen Antibodies against Staphylococcus aureus and uses therof
WO2015095423A2 (en) 2013-12-17 2015-06-25 Genentech, Inc. Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
KR102447878B1 (en) 2013-12-17 2022-09-26 제넨테크, 인크. Methods of treating cancers using pd-1 axis binding antagonists and taxanes
WO2015095410A1 (en) 2013-12-17 2015-06-25 Genentech, Inc. Methods of treating cancer using pd-1 axis binding antagonists and an anti-cd20 antibody
AU2014366047B2 (en) 2013-12-19 2021-03-25 Novartis Ag Human mesothelin chimeric antigen receptors and uses thereof
EP3083933A1 (en) 2013-12-20 2016-10-26 Biogen MA Inc. Use of perfusion seed cultures to improve biopharmaceutical fed-batch production capacity and product quality
JP7325166B2 (en) 2013-12-20 2023-08-14 ジェネンテック， インコーポレイテッド Bispecific antibody
DK3087098T3 (en) 2013-12-24 2020-06-08 Janssen Pharmaceutica Nv Anti-Vista antibodies and fragments
US10391081B2 (en) 2013-12-27 2019-08-27 Chugai Seiyaku Kabushiki Kaisha FGFR gatekeeper mutant gene and drug targeting same
CA3233584A1 (en) 2013-12-27 2015-07-02 Chugai Seiyaku Kabushiki Kaisha Method for purifying antibody having low isoelectric point
EP2893939A1 (en) 2014-01-10 2015-07-15 Netris Pharma Anti-netrin-1 antibody
JP2017507118A (en) 2014-01-16 2017-03-16 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ Compositions and methods for the treatment and detection of cancer
US10150818B2 (en) 2014-01-16 2018-12-11 Academia Sinica Compositions and methods for treatment and detection of cancers
WO2016114819A1 (en) 2015-01-16 2016-07-21 Academia Sinica Compositions and methods for treatment and detection of cancers
WO2015116902A1 (en) 2014-01-31 2015-08-06 Genentech, Inc. G-protein coupled receptors in hedgehog signaling
JP6736467B2 (en) 2014-02-04 2020-08-05 ジェネンテック， インコーポレイテッド Smoothing mutant and method of using the same
US10106623B2 (en) 2014-02-12 2018-10-23 Michael Uhlin Bispecific antibodies for use in stem cell transplantation
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
WO2015143194A2 (en) 2014-03-19 2015-09-24 Dana-Farber Cancer Institute, Inc. Immunogenetic restriction on elicitation of antibodies
WO2015148515A1 (en) 2014-03-24 2015-10-01 Biogen Ma Inc. Methods for overcoming glutamine deprivation during mammalian cell culture
EP3778702B1 (en) 2014-03-25 2023-06-28 F. Hoffmann-La Roche AG Methods of preparing a poloxamer for use in cell culture medium
CN106415244B (en) 2014-03-27 2020-04-24 中央研究院 Reactive marker compounds and uses thereof
SG10201808565QA (en) 2014-03-31 2018-11-29 Debiopharm Int Sa Fgfr fusions
AU2015241038A1 (en) 2014-03-31 2016-10-13 Genentech, Inc. Combination therapy comprising anti-angiogenesis agents and OX40 binding agonists
US9546214B2 (en) 2014-04-04 2017-01-17 Bionomics, Inc. Humanized antibodies that bind LGR5
WO2015158765A1 (en) 2014-04-15 2015-10-22 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Differential diagnosis of eczema and psoriasis
EP4112070A1 (en) 2014-04-25 2023-01-04 Dana Farber Cancer Institute, Inc. Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof
CA2983794A1 (en) 2014-04-25 2015-10-29 The Brigham And Women's Hospital, Inc. Methods to manipulate alpha-fetoprotein (afp)
AU2015254596B2 (en) 2014-04-30 2020-10-22 Klinikum Rechts Der Isar Der Technischen Universitat Munchen Diagnosis of multiple sclerosis
WO2015175874A2 (en) 2014-05-16 2015-11-19 Medimmune, Llc Molecules with altered neonate fc receptor binding having enhanced therapeutic and diagnostic properties
US10118969B2 (en) 2014-05-27 2018-11-06 Academia Sinica Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
WO2015184004A1 (en) 2014-05-27 2015-12-03 Academia Sinica Anti-cd20 glycoantibodies and uses thereof
EP3149045B1 (en) 2014-05-27 2023-01-18 Academia Sinica Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
JP7062361B2 (en) 2014-05-27 2022-05-06 アカデミア シニカ Anti-HER2 sugar-manipulated antibody group and its use
CA2950433A1 (en) 2014-05-28 2015-12-03 Academia Sinica Anti-tnf-alpha glycoantibodies and uses thereof
KR102433464B1 (en) 2014-05-28 2022-08-17 아게누스 인코포레이티드 Anti-gitr antibodies and methods of use thereof
US20170137824A1 (en) 2014-06-13 2017-05-18 Indranil BANERJEE New treatment against influenza virus
TWI695011B (en) 2014-06-18 2020-06-01 美商梅爾莎納醫療公司 Monoclonal antibodies against her2 epitope and methods of use thereof
TWI831106B (en) 2014-06-20 2024-02-01 日商中外製藥股份有限公司 Pharmaceutical compositions for the prevention and/or treatment of diseases that develop and/or progress due to reduced or deficient activity of coagulation factor VIII and/or activated coagulation factor VIII
EP3157535A1 (en) 2014-06-23 2017-04-26 Friedrich Miescher Institute for Biomedical Research Methods for triggering de novo formation of heterochromatin and or epigenetic silencing with small rnas
WO2016001830A1 (en) 2014-07-01 2016-01-07 Friedrich Miescher Institute For Biomedical Research Combination of a brafv600e inhibitor and mertk inhibitor to treat melanoma
KR102355306B1 (en) 2014-07-09 2022-01-24 제넨테크, 인크. Ph adjustment to improve thaw recovery of cell banks
EP3169801A1 (en) 2014-07-14 2017-05-24 F. Hoffmann-La Roche AG Diagnostic methods and compositions for treatment of glioblastoma
SG10202007111TA (en) 2014-07-15 2020-09-29 Genentech Inc Compositions for treating cancer using pd-1 axis binding antagonists and mek inhibitors
RS65136B1 (en) 2014-07-17 2024-02-29 Novo Nordisk As Site directed mutagenesis of trem-1 antibodies for decreasing viscosity.
WO2018140026A1 (en) 2017-01-27 2018-08-02 Memorial Sloan Kettering Cancer Center Bispecific her2 and cd3 binding molecules
AU2015295441B2 (en) 2014-07-29 2020-05-14 Neurimmune Holding Ag Human-derived anti-huntingtin (HTT) antibodies and uses thereof
CA2952540C (en) 2014-07-31 2022-06-21 Amgen Research (Munich) Gmbh Bispecific single chain antibody construct with enhanced tissue distribution
EP3174901B1 (en) 2014-07-31 2019-06-26 Amgen Research (Munich) GmbH Optimized cross-species specific bispecific single chain antibody constructs
AR101669A1 (en) 2014-07-31 2017-01-04 Amgen Res (Munich) Gmbh ANTIBODY CONSTRUCTS FOR CDH19 AND CD3
EP4066859A1 (en) 2014-08-08 2022-10-05 Alector LLC Anti-trem2 antibodies and methods of use thereof
EP3180359A1 (en) 2014-08-14 2017-06-21 Novartis AG Treatment of cancer using gfr alpha-4 chimeric antigen receptor
US20170362304A1 (en) 2014-08-20 2017-12-21 Chugai Seiyaku Kabushiki Kaisha Method for measuring viscosity of protein solution
EP3183002B1 (en) 2014-08-21 2021-03-03 Walter Reed Army Institute of Research Monoclonal antibodies for treatment of microbial infections
CA2958882A1 (en) 2014-09-02 2016-03-10 Immunogen, Inc. Methods for formulating antibody drug conjugate compositions
EP3191500A4 (en) 2014-09-08 2018-04-11 Academia Sinica HUMAN iNKT CELL ACTIVATION USING GLYCOLIPIDS
WO2016040767A2 (en) 2014-09-12 2016-03-17 Amgen Inc. Chrdl-1 epitopes and antibodies
MX2017003121A (en) 2014-09-15 2017-08-02 Genentech Inc Antibody formulations.
EP3197557A1 (en) 2014-09-24 2017-08-02 Friedrich Miescher Institute for Biomedical Research Lats and breast cancer
MA40764A (en) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd THERAPEUTIC AGENT INDUCING CYTOTOXICITY
BR112017006598A2 (en) 2014-09-30 2018-04-17 Neurimmune Holding Ag human derived antidipeptide repeat antibody (dprs)
RU2017115315A (en) 2014-10-03 2018-11-08 Дана-Фарбер Кэнсер Инститьют, Инк. ANTIBODIES TO A GLUCCORTICOID-INDUCED TUMOR NECROSIS FACTOR (GITR) RECEPTOR AND METHODS OF APPLICATION
WO2016057488A1 (en) 2014-10-06 2016-04-14 Dana-Farber Cancer Institute, Inc. Humanized cc chemokine receptor 4 (ccr4) antibodies and methods of use thereof
MA41685A (en) 2014-10-17 2017-08-22 Biogen Ma Inc COPPER SUPPLEMENT FOR THE REGULATION OF GLYCOSYLATION IN A MAMMAL CELL CULTURE PROCESS
US9789197B2 (en) 2014-10-22 2017-10-17 Extend Biosciences, Inc. RNAi vitamin D conjugates
EP3220961B1 (en) 2014-10-22 2023-07-05 Extend Biosciences, Inc. Therapeutic vitamin d conjugates
US9616109B2 (en) 2014-10-22 2017-04-11 Extend Biosciences, Inc. Insulin vitamin D conjugates
CN114836385A (en) 2014-10-31 2022-08-02 宾夕法尼亚大学董事会 Altering gene expression in CART cells and uses thereof
ES2832711T3 (en) 2014-10-31 2021-06-11 Abbvie Biotherapeutics Inc Anti-CS1 Antibodies and Antibody Drug Conjugates
CA2966035A1 (en) 2014-10-31 2016-05-06 The Trustees Of The University Of Pennsylvania Compositions and methods of stimulating and expanding t cells
MA40864A (en) 2014-10-31 2017-09-05 Biogen Ma Inc HYPOTAURINE, GABA, BETA-ALANINE AND CHOLINE FOR THE REGULATION OF THE ACCUMULATION OF RESIDUAL BY-PRODUCTS IN MAMMAL CELL CULTURE PROCESSES
EP4295911A3 (en) 2014-11-05 2024-03-27 Annexon, Inc. Humanized anti-complement factor c1q antibodies and uses thereof
CA2966558C (en) 2014-11-05 2024-03-12 Genentech, Inc. Methods of producing two chain proteins in bacteria
EP3753948A1 (en) 2014-11-05 2020-12-23 Genentech, Inc. Methods of producing two chain proteins in bacteria
WO2016073157A1 (en) 2014-11-06 2016-05-12 Genentech, Inc. Anti-ang2 antibodies and methods of use thereof
AU2015343494A1 (en) 2014-11-06 2017-04-27 Genentech, Inc. Combination therapy comprising OX40 binding agonists and TIGIT inhibitors
DK3218005T5 (en) 2014-11-12 2024-10-14 Seagen Inc GLYCAN INTERACTING COMPOUNDS AND METHODS OF USING
US9879087B2 (en) 2014-11-12 2018-01-30 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
CN106999583A (en) 2014-11-17 2017-08-01 豪夫迈·罗氏有限公司 Combination treatment comprising OX40 combinations activator and the axle binding antagonists of PD 1
SG11201704058TA (en) 2014-11-18 2017-06-29 Janssen Pharmaceutica Nv Cd47 antibodies, methods, and uses
RU2758608C2 (en) 2014-11-19 2021-11-01 Конинклейке Филипс Н.В. Diagnostics method using hnl
US10517898B2 (en) 2014-11-20 2019-12-31 The Regents Of The University Of California Compositions and methods related to hematologic recovery
WO2016081835A2 (en) 2014-11-21 2016-05-26 University Of Maryland, Baltimore Targeted structure-specific particulate delivery systems
US20160158360A1 (en) 2014-12-05 2016-06-09 Genentech, Inc. Methods and compositions for treating cancer using pd-1 axis antagonists and hpk1 antagonists
WO2016094881A2 (en) 2014-12-11 2016-06-16 Abbvie Inc. Lrp-8 binding proteins
US10766959B2 (en) 2014-12-11 2020-09-08 Pierre Fabre Medicament Anti-C10ORF54 antibodies and uses thereof
EP3233897B1 (en) 2014-12-19 2021-02-17 Universite de Nantes Anti il-34 antibodies
ES2862701T3 (en) 2014-12-22 2021-10-07 Univ Rockefeller Anti-MERTK Agonist Antibodies and Uses Thereof
CA2973266A1 (en) 2015-01-08 2016-07-14 Biogen Ma Inc. Lingo-1 antagonists and uses for treatment of demyelinating disorders
GB2557389B (en) 2015-01-14 2020-12-23 Brigham & Womens Hospital Inc Treatment of cancer with anti-lap monoclonal antibodies
US9975965B2 (en) 2015-01-16 2018-05-22 Academia Sinica Compositions and methods for treatment and detection of cancers
US10495645B2 (en) 2015-01-16 2019-12-03 Academia Sinica Cancer markers and methods of use thereof
CA2974699A1 (en) 2015-01-23 2016-07-28 Icahn School Of Medicine At Mount Sinai Influenza virus vaccination regimens
EP3248005B1 (en) 2015-01-24 2020-12-09 Academia Sinica Novel glycan conjugates and methods of use thereof
EP3248013B1 (en) 2015-01-24 2020-07-15 Academia Sinica Cancer markers and methods of use thereof
EP3250927B1 (en) 2015-01-28 2020-02-19 H. Hoffnabb-La Roche Ag Gene expression markers and treatment of multiple sclerosis
DK3250590T3 (en) 2015-01-30 2021-10-18 Academia Sinica Compositions and Methods relating to universal glycoforms for enhanced anti-SSEA4 antibody efficacy
WO2016122738A1 (en) 2015-01-31 2016-08-04 The Trustees Of The University Of Pennsylvania Compositions and methods for t cell delivery of therapeutic molecules
EP3253784B1 (en) 2015-02-04 2020-05-06 Genentech, Inc. Mutant smoothened and methods of using the same
EP3253778A1 (en) 2015-02-05 2017-12-13 Chugai Seiyaku Kabushiki Kaisha Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses therof
US10988534B2 (en) 2015-02-09 2021-04-27 Memorial Sloan Kettering Cancer Center Multi-specific antibodies with affinity for human A33 antigen and DOTA metal complex and uses thereof
SG10201810615VA (en) 2015-02-26 2019-01-30 Merck Patent Gmbh Pd-1 / pd-l1 inhibitors for the treatment of cancer
CN107249637A (en) 2015-02-27 2017-10-13 中外制药株式会社 Composition for treating the relevant diseases of IL 6
BR112017015880A2 (en) 2015-03-03 2018-07-31 Kymab Ltd antibodies, uses and methods
US10711067B2 (en) 2015-03-03 2020-07-14 Xoma (Us) Llc Treatment of post-prandial hyperinsulinemia and hypoglycemia after bariatric surgery
DK3265483T3 (en) 2015-03-06 2020-03-02 CSL Behring Lengnau AG Modified von Willebrand factor with improved half-life
RU2733496C2 (en) 2015-03-16 2020-10-02 Гельмгольц Центрум Мюнхен - Дойчес Форшунгсцентрум Фюр Гезундхайт Унд Умвельт (Гмбх) Trispecific binding molecules for treating viral hepatitis b infection and bound states
KR102618312B1 (en) 2015-03-17 2023-12-28 메모리얼 슬로안 케터링 캔서 센터 Anti-MUC16 antibody and use thereof
CN108368169A (en) 2015-03-18 2018-08-03 约翰霍普金斯大学 Target the new monoclonal antibody inhibitors of potassium channel KCNK9
US20180074077A1 (en) 2015-03-25 2018-03-15 Alexion Pharmaceuticals, Inc. A method for measuring the protease activity of factor d of the alternative complement pathway
EP3274468B1 (en) 2015-03-25 2019-02-20 Alexion Pharmaceuticals, Inc. A method for measuring the protease activity of c3 and c5 convertase of the alternative complement pathway
WO2016161410A2 (en) 2015-04-03 2016-10-06 Xoma Technology Ltd. Treatment of cancer using inhibitors of tgf-beta and pd-1
IL254887B2 (en) 2015-04-07 2023-11-01 Alector Llc Anti-sortilin antibodies and methods of use thereof
WO2016164608A1 (en) 2015-04-07 2016-10-13 Alector Llc Methods of screening for sortilin binding antagonists
US11135282B2 (en) 2015-04-08 2021-10-05 Dana-Farber Cancer Institute, Inc. Humanized influenza monoclonal antibodies and methods of use thereof
EP4276116A3 (en) 2015-04-17 2024-01-17 Amgen Research (Munich) GmbH Bispecific antibody constructs for cdh3 and cd3
CN107454906B (en) 2015-04-17 2022-05-27 豪夫迈·罗氏有限公司 Combination therapy using coagulation factors and multispecific antibodies
CN107995863A (en) 2015-04-20 2018-05-04 特雷罗药物股份有限公司 Response of the prediction to Avobenzene west ground is analyzed by mitochondria
CA2983024A1 (en) 2015-04-27 2016-11-03 Dana-Farber Cancer Institute, Inc. Compositions and methods for assessing toxicity using dynamic bh3 profiling
JP6956639B2 (en) 2015-05-01 2021-11-02 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Method of mediating cytokine expression using anti-CCR4 antibody
AU2016256911B2 (en) 2015-05-07 2022-03-31 Agenus Inc. Anti-OX40 antibodies and methods of use thereof
EP3294771A1 (en) 2015-05-11 2018-03-21 H. Hoffnabb-La Roche Ag Compositions and methods of treating lupus nephritis
SI3294770T2 (en) 2015-05-12 2024-06-28 F. Hoffmann-La Roche Ag Therapeutic and diagnostic methods for cancer
HRP20231392T1 (en) 2015-05-15 2024-04-26 The General Hospital Corporation Antagonistic anti-tumor necrosis factor receptor superfamily antibodies
AU2016264212B2 (en) 2015-05-18 2020-10-22 Sumitomo Pharma Oncology, Inc. Alvocidib prodrugs having increased bioavailability
AU2016267059B2 (en) 2015-05-22 2020-08-13 Translational Drug Development Llc Benzamide and active compound compositions and methods of use
MA53355A (en) 2015-05-29 2022-03-16 Agenus Inc ANTI-CTLA-4 ANTIBODIES AND METHODS OF USE THEREOF
DK3303395T3 (en) 2015-05-29 2020-01-27 Abbvie Inc ANTI-CD40 ANTIBODIES AND APPLICATIONS THEREOF
ES2789500T5 (en) 2015-05-29 2023-09-20 Hoffmann La Roche Therapeutic and diagnostic procedures for cancer
AU2016269839B2 (en) 2015-06-03 2021-07-08 The University Of Queensland Mobilizing agents and uses therefor
KR20180033502A (en) 2015-06-12 2018-04-03 알렉터 엘엘씨 Anti-CD33 antibodies and methods of use thereof
EP3307779A2 (en) 2015-06-12 2018-04-18 Alector LLC Anti-cd33 antibodies and methods of use thereof
TW201710286A (en) 2015-06-15 2017-03-16 艾伯維有限公司 Binding proteins against VEGF, PDGF, and/or their receptors
CN107750166B (en) 2015-06-16 2022-02-11 默克专利股份有限公司 PD-L1 antagonist combination therapy
CN107771076A (en) 2015-06-17 2018-03-06 豪夫迈·罗氏有限公司 Use the axle binding antagonists of PD 1 and the method for Taxane treatment Locally Advanced or metastatic breast cancer
CA2990360C (en) 2015-06-24 2024-02-13 Janssen Pharmaceutica Nv Anti-vista antibodies and fragments
AU2016285596A1 (en) 2015-06-29 2018-01-18 Genentech, Inc. Type II anti-CD20 antibody for use in organ transplantation
TWI744242B (en) 2015-07-31 2021-11-01 德商安美基研究（慕尼黑）公司 Antibody constructs for egfrviii and cd3
TWI829617B (en) 2015-07-31 2024-01-21 德商安美基研究（慕尼黑）公司 Antibody constructs for flt3 and cd3
TWI796283B (en) 2015-07-31 2023-03-21 德商安美基研究（慕尼黑）公司 Antibody constructs for msln and cd3
TW202346349A (en) 2015-07-31 2023-12-01 德商安美基研究（慕尼黑）公司 Antibody constructs for dll3 and cd3
TWI717375B (en) 2015-07-31 2021-02-01 德商安美基研究（慕尼黑）公司 Antibody constructs for cd70 and cd3
WO2017024073A1 (en) 2015-08-03 2017-02-09 Tolero Pharmaceuticals, Inc. Combination therapies for treatment of cancer
TW202330904A (en) 2015-08-04 2023-08-01 美商再生元醫藥公司 Taurine supplemented cell culture medium and methods of use
US10253101B2 (en) 2015-08-06 2019-04-09 Xoma (Us) Llc Antibody fragments against the insulin receptor and uses thereof to treat hypoglycemia
MA45352A (en) 2015-08-07 2018-06-13 Univ Birmingham IDENTIFICATION OF GLYCOPEPTIDES ASSOCIATED WITH CATEGORY I HCM AS TARGETS FOR CANCER IMMUNOTHERAPY
CN105384825B (en) 2015-08-11 2018-06-01 南京传奇生物科技有限公司 A kind of bispecific chimeric antigen receptor and its application based on single domain antibody
WO2017031353A1 (en) 2015-08-19 2017-02-23 Rutgers, The State University Of New Jersey Novel methods of generating antibodies
CN117491623A (en) 2015-08-20 2024-02-02 豪夫迈·罗氏有限公司 Particle-based immunoassays using pegylated analyte-specific binding agents
KR20180054639A (en) 2015-08-28 2018-05-24 알렉터 엘엘씨 Anti-SIGLEC-7 Antibodies and Methods of Use Thereof
PE20181322A1 (en) 2015-09-01 2018-08-14 Agenus Inc ANTI-PD1 ANTIBODY AND ITS METHODS OF USE
CN108350605A (en) 2015-09-04 2018-07-31 台湾浩鼎生技股份有限公司 Glycan array and application method
KR101920175B1 (en) 2015-09-18 2018-11-19 추가이 세이야쿠 가부시키가이샤 Antibodies that bind to IL-8 and uses thereof
CN113912724A (en) 2015-09-25 2022-01-11 豪夫迈·罗氏有限公司 anti-TIGIT antibodies and methods of use
CA3000386A1 (en) 2015-09-30 2017-04-06 Merck Patent Gmbh Combination of a pd-1 axis binding antagonist and an alk inhibitor for treating alk-negative cancer
JP2018537956A (en) 2015-10-06 2018-12-27 アレクトル エルエルシー Anti-TREM2 antibody and method of use thereof
US20180348224A1 (en) 2015-10-28 2018-12-06 Friedrich Miescher Institute For Biomedical Resear Ch Tenascin-w and biliary tract cancers
CN108431041B (en) 2015-10-29 2022-08-16 艾利妥 anti-SIGLEC-9 antibodies and methods of use thereof
TW201720459A (en) 2015-11-02 2017-06-16 妮翠斯製藥公司 Combination therapy of NTN1 neutralizing agent with drugs inhibiting epigenetic control
JP2019500011A (en) 2015-11-03 2019-01-10 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ Bispecific antibodies with enhanced tumor selectivity and inhibition and uses thereof
IL302822A (en) 2015-11-12 2023-07-01 Seagen Inc Glycan-interacting compounds and methods of use
EP3378487B1 (en) 2015-11-18 2022-03-16 Chugai Seiyaku Kabushiki Kaisha Combination therapy using t cell redirection antigen binding molecule against cell having immunosuppressing function
WO2017086419A1 (en) 2015-11-18 2017-05-26 中外製薬株式会社 Method for enhancing humoral immune response
EP4335851A3 (en) 2015-11-25 2024-06-05 ImmunoGen, Inc. Pharmaceutical formulations and methods of use thereof
WO2017095808A1 (en) 2015-11-30 2017-06-08 Abbvie Inc. ANTI-huLRRC15 ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE
US10188660B2 (en) 2015-11-30 2019-01-29 Abbvie Inc. Anti-huLRRC15 antibody drug conjugates and methods for their use
US11253590B2 (en) 2015-12-02 2022-02-22 Stsciences, Inc. Antibodies specific to glycosylated BTLA (B- and T- lymphocyte attenuator)
WO2017096051A1 (en) 2015-12-02 2017-06-08 Stcube & Co., Inc. Antibodies and molecules that immunospecifically bind to btn1a1 and the therapeutic uses thereof
EP3184544A1 (en) 2015-12-23 2017-06-28 Julius-Maximilians-Universität Würzburg Glycoprotein v inhibitors for use as coagulants
EP3395835B1 (en) 2015-12-25 2021-02-03 Chugai Seiyaku Kabushiki Kaisha Antibody having enhanced activity, and method for modifying same
SG11201804951SA (en) 2015-12-30 2018-07-30 Genentech Inc Use of tryptophan derivatives for protein formulations
IL299759A (en) 2015-12-30 2023-03-01 Genentech Inc Formulations with reduced degradation of polysorbate
EA037027B1 (en) 2015-12-31 2021-01-27 Прогастрин Э Кансер С.А Р.Л. Use and method for preventing or treating gastric cancer using a composition comprising a monoclonal progastrin-binding antibody
AU2017204683B2 (en) 2015-12-31 2023-03-16 Syncerus S.À R.L. Compositions and methods for assessing the risk of cancer occurrence
AU2017204682B2 (en) 2015-12-31 2021-07-29 Progastrine Et Cancers S.À R.L. Compositions and methods for detecting and treating ovarian cancer
CA3193481A1 (en) 2015-12-31 2017-07-06 Progastrine Et Cancers S.A R.L. Compositions and methods for detecting and treating esophageal cancer
WO2017120536A1 (en) 2016-01-08 2017-07-13 Apg Therapeutics, Inc. Polyethylenimine (pei)-polypeptide conjugates and methods of use thereof
MX2018008347A (en) 2016-01-08 2018-12-06 Hoffmann La Roche Methods of treating cea-positive cancers using pd-1 axis binding antagonists and anti-cea/anti-cd3 bispecific antibodies.
EA201891753A1 (en) 2016-02-03 2019-01-31 Эмджен Рисерч (Мюник) Гмбх BISPECIFIC CONSTRUCTIONS OF ANTIBODIES TO PSMA AND CD3, INVOLVING T-CELLS
EA039859B1 (en) 2016-02-03 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Bispecific antibody constructs binding egfrviii and cd3
KR20240118898A (en) 2016-02-03 2024-08-05 암젠 리서치 (뮌헨) 게엠베하 BCMA and CD3 Bispecific T Cell Engaging Antibody Constructs
JP2019509721A (en) 2016-02-04 2019-04-11 キュリス，インコーポレイテッド Mutant smoothened and method of using the same
JP7033082B2 (en) 2016-02-05 2022-03-09 ナノビュー バイオサイエンシズ インコーポレイテッド Detection of exosomes with surface markers
WO2017137830A1 (en) 2016-02-12 2017-08-17 Janssen Pharmaceutica Nv Anti-vista (b7h5) antibodies
CN114395624A (en) 2016-02-29 2022-04-26 基因泰克公司 Methods for treatment and diagnosis of cancer
WO2017152102A2 (en) 2016-03-04 2017-09-08 Alector Llc Anti-trem1 antibodies and methods of use thereof
US11357849B2 (en) 2016-03-07 2022-06-14 Musc Foundation For Research Development Anti-nucleolin antibodies
CA3016170A1 (en) 2016-03-08 2017-09-14 Academia Sinica Methods for modular synthesis of n-glycans and arrays thereof
US11072666B2 (en) 2016-03-14 2021-07-27 Chugai Seiyaku Kabushiki Kaisha Cell injury inducing therapeutic drug for use in cancer therapy
AU2017233121B2 (en) 2016-03-15 2023-12-21 Itabmed (Hk) Limited Multispecific Fab fusion proteins and use thereof
MX2018011204A (en) 2016-03-15 2019-03-07 Mersana Therapeutics Inc Napi2b-targeted antibody-drug conjugates and methods of use thereof.
WO2017159699A1 (en) 2016-03-15 2017-09-21 Chugai Seiyaku Kabushiki Kaisha Methods of treating cancers using pd-1 axis binding antagonists and anti-gpc3 antibodies
CN108884156B (en) 2016-03-17 2021-10-01 努玛创新有限公司 anti-TNF alpha antibodies and functional fragments thereof
DK3219727T3 (en) 2016-03-17 2021-01-04 Tillotts Pharma Ag Anti-THF alpha antibodies and functional fragments thereof
KR102571700B1 (en) 2016-03-17 2023-08-29 누맙 세러퓨틱스 아게 Anti-TNFα antibodies and functional fragments thereof
PL3219726T3 (en) 2016-03-17 2021-07-19 Tillotts Pharma Ag Anti-tnf alpha-antibodies and functional fragments thereof
MA43716A (en) 2016-03-17 2018-11-28 Numab Innovation Ag ANTI-TNF ANTIBODIES AND FUNCTIONAL FRAGMENTS OF THEM
CN108697799A (en) 2016-03-22 2018-10-23 生态学有限公司 The application of anti-LGR5 monoclonal antibodies
US11549099B2 (en) 2016-03-23 2023-01-10 Novartis Ag Cell secreted minibodies and uses thereof
CA3019560A1 (en) 2016-03-29 2017-10-05 Obi Pharma, Inc. Antibodies, pharmaceutical compositions and methods
EA201892190A1 (en) 2016-03-29 2019-04-30 Янссен Байотек, Инк. TREATMENT OF PSORIASIS WITH ANTI-BODY TO IL-12 AND / OR IL-23 WITH THE GROWTH OF THE INTERVAL BETWEEN THE INTRODUCTION OF DOSE
US10980894B2 (en) 2016-03-29 2021-04-20 Obi Pharma, Inc. Antibodies, pharmaceutical compositions and methods
WO2017175058A1 (en) 2016-04-07 2017-10-12 Janssen Pharmaceutica Nv Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
JP2019515670A (en) 2016-04-15 2019-06-13 ジェネンテック， インコーポレイテッド Methods for monitoring and treating cancer
CN109154613A (en) 2016-04-15 2019-01-04 豪夫迈·罗氏有限公司 For monitoring and the method for the treatment of cancer
JOP20170091B1 (en) 2016-04-19 2021-08-17 Amgen Res Munich Gmbh Administration of a bispecific construct binding to CD33 and CD3 for use in a method for the treatment of myeloid leukemia
US11583577B2 (en) 2016-04-22 2023-02-21 Obi Pharma, Inc. Cancer immunotherapy by immune activation or immune modulation via Globo series antigens
AU2017264754A1 (en) 2016-05-10 2018-12-13 Genentech, Inc. Methods of decreasing trisulfide bonds during recombinant production of polypeptides
TWI808055B (en) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Combination therapies of hdac inhibitors and pd-1 inhibitors
WO2017194568A1 (en) 2016-05-11 2017-11-16 Sanofi Treatment regimen using anti-muc1 maytansinoid immunoconjugate antibody for the treatment of tumors
TWI794171B (en) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Combination therapies of hdac inhibitors and pd-l1 inhibitors
PT3626273T (en) 2016-05-17 2021-03-09 Abbvie Inc Anti-cmet antibody drug conjugates and methods for their use
CN116333130A (en) 2016-05-24 2023-06-27 英斯梅德股份有限公司 Antibodies and methods of making the same
CA3025391A1 (en) 2016-05-26 2017-11-30 Merck Patent Gmbh Pd-1 / pd-l1 inhibitors for cancer treatment
NZ749355A (en) 2016-05-27 2023-04-28 Agenus Inc Anti-tim-3 antibodies and methods of use thereof
PT3464361T (en) 2016-05-27 2021-12-27 Abbvie Biotherapeutics Inc Anti-cd40 antibodies and their uses
EP3464362B1 (en) 2016-05-27 2020-12-09 AbbVie Biotherapeutics Inc. Anti-4-1bb antibodies and their uses
WO2017215590A1 (en) 2016-06-13 2017-12-21 I-Mab Anti-pd-l1 antibodies and uses thereof
WO2017218624A1 (en) 2016-06-15 2017-12-21 Icahn School Of Medicine At Mount Sinai Influenza virus hemagglutinin proteins and uses thereof
EP3481864A1 (en) 2016-07-08 2019-05-15 Staten Biotechnology B.V. Anti-apoc3 antibodies and methods of use thereof
JP2018035137A (en) 2016-07-13 2018-03-08 マブイミューン ダイアグノスティックス エイジーＭａｂｉｍｍｕｎｅ Ｄｉａｇｎｏｓｔｉｃｓ Ａｇ Novel anti-fibroblast activated protein (FAP) binding agent and use thereof
WO2018014260A1 (en) 2016-07-20 2018-01-25 Nanjing Legend Biotech Co., Ltd. Multispecific antigen binding proteins and methods of use thereof
EP3487521A4 (en) 2016-07-21 2020-07-01 Emory University Ebola virus antibodies and binding agents derived therefrom
CN109689689B (en) 2016-07-22 2022-12-06 丹娜法伯癌症研究所公司 Glucocorticoid-induced tumor necrosis factor receptor (GITR) antibodies and methods of use thereof
US20190330318A1 (en) 2016-07-25 2019-10-31 Biogen Ma Inc. Anti-hspa5 (grp78) antibodies and uses thereof
US11642400B2 (en) 2016-07-27 2023-05-09 Obi Pharma, Inc. Immunogenic/therapeutic glycan compositions and uses thereof
EP3491026A4 (en) 2016-07-29 2020-07-29 OBI Pharma, Inc. Human antibodies, pharmaceutical compositions and methods
NL2017267B1 (en) 2016-07-29 2018-02-01 Aduro Biotech Holdings Europe B V Anti-pd-1 antibodies
WO2018026748A1 (en) 2016-08-01 2018-02-08 Xoma (Us) Llc Parathyroid hormone receptor 1 (pth1r) antibodies and uses thereof
NL2017270B1 (en) 2016-08-02 2018-02-09 Aduro Biotech Holdings Europe B V New anti-hCTLA-4 antibodies
JP7250674B2 (en) 2016-08-08 2023-04-03 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト CANCER TREATMENT AND DIAGNOSTIC METHOD
MX2019001635A (en) 2016-08-12 2019-06-10 Genentech Inc Combination therapy with a mek inhibitor, a pd-1 axis inhibitor, and a vegf inhibitor.
KR102588027B1 (en) 2016-08-22 2023-10-12 초 파마 인크. Antibodies, binding fragments and methods of use
EP3507305A1 (en) 2016-09-02 2019-07-10 Dana-Farber Cancer Institute, Inc. Composition and methods of treating b cell disorders
CN109661241A (en) 2016-09-06 2019-04-19 中外制药株式会社 Use the method for identification plasma thromboplastin component and/or the bispecific antibody of activated clotting factor IX and Stuart factor and/or activated clotting factor X
US20190233505A1 (en) 2016-09-06 2019-08-01 Dana-Farber Cancer Institute, Inc. Methods of treating or preventing zika virus infection
EP3510046A4 (en) 2016-09-07 2020-05-06 The Regents of the University of California Antibodies to oxidation-specific epitopes
TW201825674A (en) 2016-09-09 2018-07-16 美商艾斯合顧問有限公司 Oncolytic virus expressing bispecific engager molecules
KR102561356B1 (en) 2016-09-14 2023-08-03 애브비 바이오테라퓨틱스 인크. Anti-PD-1 Antibodies and Uses Thereof
UA126565C2 (en) 2016-09-19 2022-11-02 Ай-Маб Байофарма (Ханчжоу) Ко., Лтд. Anti-gm-csf antibodies and uses thereof
JOP20190009A1 (en) 2016-09-21 2019-01-27 Alx Oncology Inc Antibodies against signal-regulatory protein alpha and methods of use
EP4360714A3 (en) 2016-09-21 2024-07-24 Nextcure, Inc. Antibodies for siglec-15 and methods of use thereof
DK3515478T3 (en) 2016-09-21 2024-05-21 Nextcure Inc Antibodies to SIGLEC-15 and methods of use thereof
CN110087681A (en) 2016-09-28 2019-08-02 佐马美国有限公司 The antibody of bind interleukin -2 and its purposes
CN109862917A (en) 2016-09-29 2019-06-07 基因泰克公司 Mek inhibitor, PD-1 axis inhibitor, and the combination treatment of taxane
JP2020500152A (en) 2016-09-30 2020-01-09 ヤンセン バイオテツク，インコーポレーテツド Safe and effective method of treating psoriasis with anti-IL23 specific antibody
BR112019006710A2 (en) 2016-10-03 2019-06-25 Abbott Lab improved methods for uch-l1 status assessment in patient samples
CA3038712A1 (en) 2016-10-06 2018-04-12 Genentech, Inc. Therapeutic and diagnostic methods for cancer
CA3039451A1 (en) 2016-10-06 2018-04-12 Pfizer Inc. Dosing regimen of avelumab for the treatment of cancer
WO2018068201A1 (en) 2016-10-11 2018-04-19 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against ctla-4
CA3037380A1 (en) 2016-10-11 2018-04-19 Agenus Inc. Anti-lag-3 antibodies and methods of use thereof
KR102136742B1 (en) 2016-10-20 2020-07-23 아이-맵 바이오파마 유에스 리미티드 New CD47 monoclonal antibodies and uses
WO2018081531A2 (en) 2016-10-28 2018-05-03 Ariad Pharmaceuticals, Inc. Methods for human t-cell activation
ES2908239T3 (en) 2016-10-28 2022-04-28 Astute Medical Inc Use of antibodies against timp-2 for the improvement of renal function
CN110300600A (en) 2016-11-02 2019-10-01 伊缪诺金公司 Utilize the combined therapy of antibody-drug conjugates and PARP inhibitor
EP3534947A1 (en) 2016-11-03 2019-09-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
AU2017353936A1 (en) 2016-11-04 2019-05-02 Novimmune Sa Anti-CD19 antibodies and methods of use thereof
AU2017353939A1 (en) 2016-11-07 2019-06-06 Neuracle Science Co., Ltd. Anti-family with sequence similarity 19, member A5 antibodies and method of use thereof
EP3541422A4 (en) 2016-11-16 2020-05-06 Janssen Biotech, Inc. Method of treating psoriasis with anti-il-23 specific antibody
EP3541847A4 (en) 2016-11-17 2020-07-08 Seattle Genetics, Inc. Glycan-interacting compounds and methods of use
WO2018094275A1 (en) 2016-11-18 2018-05-24 Tolero Pharmaceuticals, Inc. Alvocidib prodrugs and their use as protein kinase inhibitors
TWI767959B (en) 2016-11-21 2022-06-21 台灣浩鼎生技股份有限公司 Conjugated biological molecules, pharmaceutical compositions and methods
AU2017363337B2 (en) 2016-11-23 2021-07-01 Translational Drug Development, Llc Benzamide and active compound compositions and methods of use
TW202235438A (en) 2016-11-28 2022-09-16 日商中外製藥股份有限公司 Ligand-binding molecule having adjustable ligand binding activity
SI3551660T1 (en) 2016-12-07 2024-02-29 Agenus Inc. Anti-ctla-4 antibodies and methods of use thereof
BR112019011582A2 (en) 2016-12-07 2019-10-22 Agenus Inc. antibodies and their methods of use
JP6772385B2 (en) 2016-12-15 2020-10-21 アッヴィ・バイオセラピューティクス・インコーポレイテッド Anti-OX40 Antibodies and Their Use
WO2018119000A1 (en) 2016-12-19 2018-06-28 Tolero Pharmaceuticals, Inc. Profiling peptides and methods for sensitivity profiling
CN110088129A (en) 2016-12-27 2019-08-02 豪夫迈·罗氏有限公司 New biotin monoclonal antibody specific and application thereof
EP3562841A1 (en) 2016-12-27 2019-11-06 H. Hoffnabb-La Roche Ag Novel biotin-specific monoclonal antibody and use thereof
KR20210126136A (en) 2016-12-27 2021-10-19 에프. 호프만-라 로슈 아게 Novel biotin-specific monoclonal antibody and use thereof
US11773182B2 (en) 2017-01-05 2023-10-03 The Johns Hopkins University Development of new monoclonal antibodies recognizing human prostate-specific membrane antigen (PSMA)
JP7211952B2 (en) 2017-01-05 2023-01-24 ネトリス ファーマ Combination treatment with netrin-1 inhibitors and immune checkpoint inhibitors
CN110291109B (en) 2017-01-20 2023-01-31 大有华夏生物医药集团有限公司 Monoclonal antibodies to human programmed death receptor PD-1 and fragments thereof
ES2908662T3 (en) 2017-01-24 2022-05-03 I Mab Biopharma Us Ltd Anti-CD73 antibodies and uses thereof
WO2018140510A1 (en) 2017-01-25 2018-08-02 Biogen Ma Inc. Compositions and methods for treatment of stroke and other cns disorders
KR20190113858A (en) 2017-01-30 2019-10-08 얀센 바이오테크 인코포레이티드 Anti-TNF Antibodies, Compositions, and Methods for the Treatment of Active Psoriatic Arthritis
WO2018141768A1 (en) 2017-02-02 2018-08-09 Roche Diagnostics Gmbh Immunoassay using at least two pegylated analyte-specific binding agents
JOP20190189A1 (en) 2017-02-02 2019-08-01 Amgen Res Munich Gmbh Low ph pharmaceutical composition comprising t cell engaging antibody constructs
MX2019009377A (en) 2017-02-07 2019-12-11 Janssen Biotech Inc Anti-tnf antibodies, compositions, and methods for the treatment of active ankylosing spondylitis.
CN108456251A (en) 2017-02-21 2018-08-28 上海君实生物医药科技股份有限公司 Anti- PD-L1 antibody and its application
EP3589754B1 (en) 2017-03-01 2023-06-28 F. Hoffmann-La Roche AG Diagnostic and therapeutic methods for cancer
KR20240044544A (en) 2017-03-03 2024-04-04 씨젠 인크. Glycan-interacting compounds and methods of use
TWI808963B (en) 2017-03-22 2023-07-21 法商賽諾菲公司 Treatment of lupus using humanized anti-cxcr5 antibodies
JP7346300B2 (en) 2017-03-23 2023-09-19 アボット・ラボラトリーズ Methods for aiding in the diagnosis and determination of the extent of traumatic brain injury in human subjects using the early biomarker ubiquitin carboxy-terminal hydrolase L1
KR20190133005A (en) 2017-03-24 2019-11-29 젠야쿠코교가부시키가이샤 Anti IgM / B Cell Surface Antigen Bispecific Antibodies
US11614448B2 (en) 2017-03-30 2023-03-28 Ecs-Progastrin Sa Compositions and methods for detecting prostate cancer
KR102616819B1 (en) 2017-03-30 2023-12-21 프로가스트린 에 캔서스 에스.에이 알.엘. Compositions and methods for treating lung cancer
IL269718B2 (en) 2017-03-30 2024-10-01 Merck Patent Gmbh Combination of an anti-pd-l1 antibody and a dna-pk inhibitor for the treatment of cancer
TW201836636A (en) 2017-03-31 2018-10-16 公立大學法人奈良縣立醫科大學 Medicinal composition usable for preventing and/or treating blood coagulation factor ix abnormality, comprising multispecific antigen binding molecule replacing function of blood coagulation factor viii
US10722589B2 (en) 2017-04-03 2020-07-28 Covagen Ag FGFR3 binding molecules
JP7315466B2 (en) 2017-04-05 2023-07-26 アスチュート メディカル，インコーポレイテッド Assays for TIMP2 with improved performance in biological samples
CA3058652A1 (en) 2017-04-07 2018-10-11 Icahn School Of Medicine At Mount Sinai Anti-influenza b virus neuraminidase antibodies and uses thereof
KR102629972B1 (en) 2017-04-13 2024-01-29 아게누스 인코포레이티드 Anti-CD137 antibody and methods of using the same
AU2018250688B2 (en) 2017-04-15 2024-07-04 Abbott Laboratories Methods for aiding in the hyperacute diagnosis and determination of traumatic brain injury in a human subject using early biomarkers
MA50958A (en) 2017-04-21 2020-10-14 Staten Biotechnology B V ANTI-APOC3 ANTIBODIES AND THEIR METHODS OF USE
CN110799529A (en) 2017-04-22 2020-02-14 免疫治疗有限公司 Improved LAMP constructs
US20230140818A1 (en) 2017-04-27 2023-05-04 The University Of Hong Kong Use of hcn inhibitors for treatment of cancer
JP7261739B2 (en) 2017-04-27 2023-04-20 中外製薬株式会社 Blood Coagulation Factor IX with Improved Pharmacokinetics
AU2018256845B2 (en) 2017-04-28 2024-03-14 Abbott Laboratories Methods for aiding in the hyperacute diagnosis and determination of traumatic brain injury using early biomarkers on at least two samples from the same human subject
US11021537B2 (en) 2017-05-01 2021-06-01 Agenus Inc. Anti-TIGIT antibodies and methods of use thereof
BR112019023014A2 (en) 2017-05-02 2020-05-19 Immunomic Therapeutics Inc improved lamp constructs comprising cancer antigens
US11851486B2 (en) 2017-05-02 2023-12-26 National Center Of Neurology And Psychiatry Method for predicting and evaluating therapeutic effect in diseases related to IL-6 and neutrophils
US11918650B2 (en) 2017-05-05 2024-03-05 Amgen Inc. Pharmaceutical composition comprising bispecific antibody constructs for improved storage and administration
US10865238B1 (en) 2017-05-05 2020-12-15 Duke University Complement factor H antibodies
JOP20190256A1 (en) 2017-05-12 2019-10-28 Icahn School Med Mount Sinai Newcastle disease viruses and uses thereof
WO2018213316A1 (en) 2017-05-16 2018-11-22 Alector Llc Anti-siglec-5 antibodies and methods of use thereof
US10914729B2 (en) 2017-05-22 2021-02-09 The Trustees Of Princeton University Methods for detecting protein binding sequences and tagging nucleic acids
WO2018215535A1 (en) 2017-05-23 2018-11-29 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Novel cd73 antibody, preparation and uses thereof
WO2018218169A1 (en) 2017-05-25 2018-11-29 Abbott Laboratories Methods for aiding in the determination of whether to perform imaging on a human subject who has sustained or may have sustained an injury to the head using early biomarkers
WO2018215835A1 (en) 2017-05-26 2018-11-29 Novimmune Sa Anti-cd47 x anti-mesothelin antibodies and methods of use thereof
BR112019025387A2 (en) 2017-05-30 2020-07-07 Abbott Laboratories methods to assist in the diagnosis and evaluation of a mild traumatic brain injury in a human subject using cardiac troponin i and early biomarkers
EP3630834A1 (en) 2017-05-31 2020-04-08 STCube & Co., Inc. Methods of treating cancer using antibodies and molecules that immunospecifically bind to btn1a1
KR20200015602A (en) 2017-05-31 2020-02-12 주식회사 에스티큐브앤컴퍼니 Antibodies and molecules immunospecifically binding to BTN1A1 and therapeutic uses thereof
CN110997724A (en) 2017-06-06 2020-04-10 斯特库伯株式会社 Methods of treating cancer using antibodies and molecules that bind BTN1A1 or BTN1A 1-ligands
WO2019000223A1 (en) 2017-06-27 2019-01-03 Nanjing Legend Biotech Co., Ltd. Chimeric antibody immune effctor cell engagers and methods of use thereof
CR20200076A (en) 2017-07-14 2020-06-10 Pfizer Antibodies to madcam
WO2019018757A1 (en) 2017-07-21 2019-01-24 Genentech, Inc. Therapeutic and diagnostic methods for cancer
WO2020159504A1 (en) 2019-01-30 2020-08-06 Nomocan Pharmaceuticals Llc Antibodies to m(h)dm2/4 and their use in diagnosing and treating cancer
AU2018306436A1 (en) 2017-07-27 2020-02-13 Nomocan Pharmaceuticals Llc Antibodies to M(H)DM2/4 and their use in diagnosing and treating cancer
CN110662765B (en) 2017-08-03 2023-09-29 艾利妥 anti-CD 33 antibodies and methods of use thereof
TW202342547A (en) 2017-08-03 2023-11-01 美商阿列克特有限責任公司 Anti-trem2 antibodies and methods of use thereof
KR20200054209A (en) 2017-08-21 2020-05-19 아다진 인크. Dynamic human antibody light chain library
EP3673101A4 (en) 2017-08-21 2021-03-24 Adagene Inc. Dynamic human heavy chain antibody libraries
MX2020002612A (en) 2017-09-07 2020-07-13 Univ Res Inst Inc Augusta Antibodies to programmed cell death protein 1.
WO2019055579A1 (en) 2017-09-12 2019-03-21 Tolero Pharmaceuticals, Inc. Treatment regimen for cancers that are insensitive to bcl-2 inhibitors using the mcl-1 inhibitor alvocidib
WO2019059411A1 (en) 2017-09-20 2019-03-28 Chugai Seiyaku Kabushiki Kaisha Dosage regimen for combination therapy using pd-1 axis binding antagonists and gpc3 targeting agent
BR112020005737A2 (en) 2017-09-22 2020-11-17 F. Hoffmann-La Roche Ag multivalent recombinant antibody and its use, kit and method to detect an antigen
TW201922780A (en) 2017-09-25 2019-06-16 美商健生生物科技公司 Safe and effective method of treating Lupus with anti-IL12/IL23 antibody
US11230601B2 (en) 2017-10-10 2022-01-25 Tilos Therapeutics, Inc. Methods of using anti-lap antibodies
CA3185107A1 (en) 2017-10-12 2019-04-18 Immunowake Inc. Vegfr-antibody light chain fusion protein
JP7235249B2 (en) 2017-10-20 2023-03-08 学校法人兵庫医科大学 Pharmaceutical composition for suppressing postoperative adhesion containing anti-IL-6 receptor antibody
WO2019083904A1 (en) 2017-10-23 2019-05-02 Chan Zuckerberg Biohub, Inc. Measurement of afucosylated igg fc glycans and related treatment methods
AU2018354189A1 (en) 2017-10-24 2020-04-23 Crispr Therapeutics Ag Compositions and methods for the depletion of CD117+ cells
JP7403164B2 (en) 2017-10-26 2023-12-22 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Inhibition of oxidation-specific epitopes to treat ischemic reperfusion injury
WO2019089594A1 (en) 2017-10-31 2019-05-09 Immunogen, Inc. Combination treatment with antibody-drug conjugates and cytarabine
CN111315772A (en) 2017-10-31 2020-06-19 斯塔顿生物技术有限公司 anti-APOC 3 antibodies and methods of use thereof
MX2020004567A (en) 2017-11-06 2020-08-13 Genentech Inc Diagnostic and therapeutic methods for cancer.
JP7165193B2 (en) 2017-11-27 2022-11-02 パーデュー、ファーマ、リミテッド、パートナーシップ Humanized antibody targeting human tissue factor
TWI818934B (en) 2017-11-28 2023-10-21 日商中外製藥股份有限公司 Ligand-binding molecules with adjustable ligand-binding activity
KR102461238B1 (en) 2017-12-05 2022-11-01 프로가스트린 에 캔서스 에스.에이 알.엘. Combination therapy between anti-progastrin antibodies and immunotherapy to treat cancer
IL275077B1 (en) 2017-12-06 2024-10-01 Magenta Therapeutics Inc Dosing Regimens for the Mobilization of Hematopoietic Stem and Progenitor Cells
CA3067055A1 (en) 2017-12-09 2019-06-13 Abbott Laboratories Methods for aiding in diagnosing and evaluating a traumatic brain injury in a human subject using a combination of gfap and uch-l1
BR112019028254A2 (en) 2017-12-09 2020-07-14 Abbott Laboratories methods to assist in the diagnosis and evaluation of a patient who has suffered an orthopedic injury and who has suffered or may have suffered a head injury, such as a mild traumatic brain injury (lct), using glial fibrillar acid protein (gfap) and / or the carboxy-terminal hydrolase of ubiquitin l1 (uch-l1)
AU2018383679A1 (en) 2017-12-11 2020-05-07 Amgen Inc. Continuous manufacturing process for bispecific antibody products
CA3085861C (en) 2017-12-20 2023-09-26 Harbour Biomed (Shanghai) Co., Ltd Antibodies binding ctla-4 and uses thereof
EP3732196A4 (en) 2017-12-28 2022-01-05 Astute Medical, Inc. Antibodies and assays for ccl14
KR20200104333A (en) 2017-12-28 2020-09-03 난징 레전드 바이오테크 씨오., 엘티디. Single-domain antibodies to TIGIT and variants thereof
WO2019131988A1 (en) 2017-12-28 2019-07-04 Chugai Seiyaku Kabushiki Kaisha Cytotoxicity-inducing therapeutic agent
CA3078849A1 (en) 2017-12-28 2019-07-04 Nanjing Legend Biotech Co., Ltd. Antibodies and variants thereof against pd-l1
UY38041A (en) 2017-12-29 2019-06-28 Amgen Inc CONSTRUCTION OF BIESPECFIC ANTIBODY DIRECTED TO MUC17 AND CD3
CN111699200B (en) 2018-01-15 2023-05-26 南京传奇生物科技有限公司 Single domain antibodies and variants thereof against PD-1
JP7542257B2 (en) 2018-01-25 2024-08-30 エイシーエム バイオラブズ プライベート リミテッド Polymersomes containing solubilized encapsulated antigens and methods of making and using same
TW201940881A (en) 2018-01-26 2019-10-16 瑞士商Ｅｃｓ前胃泌激素公司 Combining progastrin detection with other cancer biomarkers in cancer diagnosis
US20210363238A1 (en) 2018-01-31 2021-11-25 Motokazu Kato Therapeutic agent for asthma containing il-6 inhibitor
JP7391027B2 (en) 2018-02-26 2023-12-04 ジェネンテック， インコーポレイテッド Medication for treatment with anti-TIGIT and anti-PD-L1 antagonist antibodies
EP3759492A1 (en) 2018-02-27 2021-01-06 ECS-Progastrin SA Progastrin as a biomarker for immunotherapy
WO2019169229A1 (en) 2018-03-01 2019-09-06 Nextcure, Inc. Klrg1 binding compositions and methods of use thereof
NL2020520B1 (en) 2018-03-02 2019-09-12 Labo Bio Medical Invest B V Multispecific binding molecules for the prevention, treatment and diagnosis of neurodegenerative disorders
IL310216A (en) 2018-03-05 2024-03-01 Janssen Biotech Inc Methods of treating crohn's disease with anti-il23 specific antibody
BR112020017701A2 (en) 2018-03-12 2020-12-29 Zoetis Services Llc ANTI-NGF ANTIBODIES AND METHODS OF THE SAME
US11203646B2 (en) 2018-03-14 2021-12-21 Novimmune Sa Anti-CD3 epsilon antibodies and methods of use thereof
EP3765522A4 (en) 2018-03-14 2022-05-18 Beijing Xuanyi Pharmasciences Co., Ltd. Anti-claudin 18.2 antibodies
JP7393342B2 (en) 2018-03-21 2023-12-06 エーエルエックス オンコロジー インコーポレイテッド Antibodies against signal regulatory protein α and methods of use
WO2019180272A1 (en) 2018-03-23 2019-09-26 Fundación Instituto De Investigación Sanitaria De Santiago De Compostela Anti-leptin affinity reagents for use in the treatment of obesity and other leptin-resistance associated diseases
US20210048437A1 (en) 2018-03-26 2021-02-18 Glycanostiion , s.r.o. Means and methods for glycoprofiling of a protein
US11958903B2 (en) 2018-03-30 2024-04-16 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies against LAG-3 and uses thereof
AU2019248547A1 (en) 2018-04-02 2020-09-10 Bristol-Myers Squibb Company Anti-TREM-1 antibodies and uses thereof
CN112004558A (en) 2018-04-12 2020-11-27 米迪亚制药有限责任公司 LGALS3BP antibody-drug-conjugate and its use for the treatment of cancer
AU2019256383A1 (en) 2018-04-17 2020-11-26 Celldex Therapeutics, Inc. Anti-CD27 and anti-PD-L1 antibodies and bispecific constructs
EP3784274A1 (en) 2018-04-27 2021-03-03 Fondazione Ebri Rita Levi-Montalcini Antibody directed against a tau-derived neurotoxic peptide and uses thereof
JP2021522298A (en) 2018-05-04 2021-08-30 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ Simultaneous inhibition of PD-1 / PD-L1, TGFβ and DNA-PK for cancer treatment
JP7530638B2 (en) 2018-05-10 2024-08-08 ニューラクル サイエンス カンパニー リミテッド Antibody family with sequence similarity 19, member A5 antibodies and methods of use thereof
US20190345245A1 (en) 2018-05-11 2019-11-14 Janssen Biotech, Inc. Methods of Treating Crohn's Disease with Anti-IL23 Specific Antibody
JP2021523185A (en) 2018-05-15 2021-09-02 イミュノミック セラピューティックス， インコーポレイテッドＩｍｍｕｎｏｍｉｃ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． Improved LAMP constructs containing allergens
WO2019222130A1 (en) 2018-05-15 2019-11-21 Immunogen, Inc. Combination treatment with antibody-drug conjugates and flt3 inhibitors
TWI840360B (en) 2018-05-21 2024-05-01 日商中外製藥股份有限公司 Freeze-dried preparation sealed in glass container, kit, method for producing freeze-dried preparation, method for preventing or reducing fogging of freeze-dried preparation glass container, and glass container with ammonium sulfate treatment or VIST treatment on the inside of the container
CN112218893A (en) 2018-05-25 2021-01-12 艾利妥 anti-SIRPA antibodies and methods of use thereof
EP3803332A1 (en) 2018-06-01 2021-04-14 NanoView Biosciences, Inc. Compositions, systems, and methods for enhanced label-free and fluorescence - based detection of nanoparticles
EP3800999A4 (en) 2018-06-04 2022-06-01 Biogen MA Inc. Anti-vla-4 antibodies having reduced effector function
EP3802610A1 (en) 2018-06-05 2021-04-14 Amgen Inc. Modulating antibody dependent cellular phagocytosis
EA202092595A1 (en) 2018-06-08 2021-04-12 Алектор Ллс ANTIBODIES TO SIGLEC-7 AND METHODS OF THEIR APPLICATION
WO2019246494A1 (en) 2018-06-21 2019-12-26 Yumanity Therapeutics, Inc. Compositions and methods for the treatment and prevention of neurological disorders
MA52968A (en) 2018-06-23 2021-04-28 Hoffmann La Roche METHODS OF TREATMENT OF LUNG CANCER USING A PD-1 AXIS ANTAGONIST, PLATINUM AGENT AND TOPOISOMERASE II INHIBITOR
US11203645B2 (en) 2018-06-27 2021-12-21 Obi Pharma, Inc. Glycosynthase variants for glycoprotein engineering and methods of use
WO2020003210A1 (en) 2018-06-29 2020-01-02 Kangwon National University University-Industry Cooperation Foundation Anti-l1cam antibodies and uses thereof
US11396546B2 (en) 2018-07-13 2022-07-26 Alector Llc Anti-Sortilin antibodies and methods of use thereof
AU2019302603A1 (en) 2018-07-13 2021-01-14 Nanjing Legend Biotech Co., Ltd. Co-receptor systems for treating infectious diseases
WO2020016838A2 (en) 2018-07-18 2020-01-23 Janssen Biotech, Inc. Sustained response predictors after treatment with anti-il23 specific antibody
EP3823611A1 (en) 2018-07-18 2021-05-26 Genentech, Inc. Methods of treating lung cancer with a pd-1 axis binding antagonist, an antimetabolite, and a platinum agent
BR112021000934A2 (en) 2018-07-20 2021-04-27 Pierre Fabre Medicament receiver for sight
US20210395361A1 (en) 2018-07-27 2021-12-23 Alector Llc Anti-siglec-5 antibodies and methods of use thereof
EP3830121A1 (en) 2018-07-30 2021-06-09 Amgen Research (Munich) GmbH Prolonged administration of a bispecific antibody construct binding to cd33 and cd3
UY38326A (en) 2018-08-03 2020-01-31 Amgen Inc ANTIBODY CONSTRUCTS FOR CLDN18.2 AND CD3
AU2019319822A1 (en) 2018-08-08 2021-03-18 Genentech, Inc. Use of tryptophan derivatives and L-methionine for protein formulation
HRP20240821T1 (en) 2018-08-27 2024-09-27 Affimed Gmbh Cryopreserved nk cells preloaded with an antibody construct
KR20210055742A (en) 2018-09-06 2021-05-17 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 Humanized anti-C5 antibodies and uses thereof
CN112789293B (en) 2018-09-10 2024-05-10 南京传奇生物科技有限公司 Single domain antibodies to CLL1 and constructs thereof
MX2021002792A (en) 2018-09-11 2021-05-12 Amgen Inc Methods of modulating antibody-dependent cell-mediated cytotoxicity.
WO2020053325A1 (en) 2018-09-12 2020-03-19 Acm Biolabs Pte Ltd Polymersomes comprising a covalently bound antigen as well as methods of making and uses thereof
WO2020061060A1 (en) 2018-09-19 2020-03-26 Genentech, Inc. Therapeutic and diagnostic methods for bladder cancer
AU2019342133A1 (en) 2018-09-21 2021-04-22 Genentech, Inc. Diagnostic methods for triple-negative breast cancer
LT3883606T (en) 2018-09-24 2023-09-11 Janssen Biotech, Inc. Safe and effective method of treating ulcerative colitis with anti-il12/il23 antibody
JP2022502399A (en) 2018-09-26 2022-01-11 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung Combination of PD-1 antagonist, ATR inhibitor, and platinum product for the treatment of cancer
AR116548A1 (en) 2018-09-28 2021-05-19 Amgen Inc ANTIBODIES AGAINST SOLUBLE BCMA
MA53811A (en) 2018-10-03 2022-03-16 Staten Biotechnology B V ANTIBODIES SPECIFIC TO HUMAN APOC3 AND CYNOMOLGUS AND METHODS FOR THE USE THEREOF
EP3863722A2 (en) 2018-10-10 2021-08-18 Tilos Theapeutics, Inc. Anti-lap antibody variants and uses thereof
AU2019356564A1 (en) 2018-10-11 2021-04-29 Amgen Inc. Downstream processing of bispecific antibody constructs
CA3116234A1 (en) 2018-10-15 2020-04-23 Merck Patent Gmbh Combination therapy utilizing dna alkylating agents and atr inhibitors
CN113196061A (en) 2018-10-18 2021-07-30 豪夫迈·罗氏有限公司 Methods of diagnosis and treatment of sarcoma-like renal cancer
WO2020086408A1 (en) 2018-10-26 2020-04-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A high-yield perfusion-based transient gene expression bioprocess
US20220170097A1 (en) 2018-10-29 2022-06-02 The Broad Institute, Inc. Car t cell transcriptional atlas
JP7499760B2 (en) 2018-11-02 2024-06-14 アネクソン，インコーポレーテッド Compositions and methods for treating brain injury
CN113260626B (en) 2018-11-05 2024-09-13 豪夫迈·罗氏有限公司 Method for producing double-stranded proteins in prokaryotic host cells
WO2020099533A1 (en) 2018-11-16 2020-05-22 F. Hoffmann-La Roche Ag Streptavidin-coated solid phases with a member of a binding pair
WO2020104943A2 (en) 2018-11-20 2020-05-28 Janssen Biotech, Inc. Safe and effective method of treating psoriasis with anti-il-23 specific antibody
EP3890749A4 (en) 2018-12-04 2022-08-03 Sumitomo Dainippon Pharma Oncology, Inc. Cdk9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
US20220098310A1 (en) 2018-12-06 2022-03-31 Alexion Pharmaceuticals, Inc. Anti-alk2 antibodies and uses thereof
US20220026445A1 (en) 2018-12-07 2022-01-27 Georgia Tech Research Corporation Antibodies that bind to natively folded myocilin
EP3897722A4 (en) 2018-12-18 2022-09-14 Janssen Biotech, Inc. Safe and effective method of treating lupus with anti-il12/il23 antibody
AU2020208193A1 (en) 2019-01-14 2021-07-29 BioNTech SE Methods of treating cancer with a PD-1 axis binding antagonist and an RNA vaccine
BR112021013903A2 (en) 2019-01-15 2021-09-21 Janssen Biotech, Inc. COMPOSITIONS AND METHODS OF ANTI-TNF ANTIBODIES FOR THE TREATMENT OF JUVENILE IDIOPATHIC ARTHRITIS
EP3914615A1 (en) 2019-01-23 2021-12-01 F. Hoffmann-La Roche AG Methods of producing multimeric proteins in eukaryotic host cells
CA3127748A1 (en) 2019-01-23 2020-07-30 Janssen Biotech, Inc. Anti-tnf antibody compositions for use in methods for the treatment of psoriatic arthritis
WO2020153467A1 (en) 2019-01-24 2020-07-30 中外製薬株式会社 Novel cancer antigens and antibodies of said antigens
EP3917515A1 (en) 2019-01-29 2021-12-08 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Treating the causative agent in adhesiogenesis
EP3921443A1 (en) 2019-02-08 2021-12-15 F. Hoffmann-La Roche AG Diagnostic and therapeutic methods for cancer
US11028176B2 (en) 2019-02-13 2021-06-08 The Brigham And Women's Hospital, Inc. Anti-peripheral lymph node addressin antibodies and uses thereof
EP3928790A4 (en) 2019-02-22 2023-01-11 Wuhan Yzy Biopharma Co., Ltd. Cd3 antigen binding fragment and application thereof
MX2021010003A (en) 2019-02-26 2021-12-10 Inspirna Inc High-affinity anti-mertk antibodies and uses thereof.
MX2021010313A (en) 2019-02-27 2021-09-23 Genentech Inc Dosing for treatment with anti-tigit and anti-cd20 or anti-cd38 antibodies.
BR112021016619A2 (en) 2019-02-28 2021-11-03 Juntendo Educational Found Antibody capable of binding to cleaved mutant calreticulin and diagnostic, prophylactic or therapeutic agent for myeloproliferative neoplasms
KR20210141990A (en) 2019-03-14 2021-11-23 얀센 바이오테크 인코포레이티드 Methods of Preparation for Generating Anti-IL12/IL23 Antibody Compositions
KR20210142002A (en) 2019-03-14 2021-11-23 얀센 바이오테크 인코포레이티드 Methods of Preparation for Producing Anti-TNF Antibody Compositions
WO2020183270A1 (en) 2019-03-14 2020-09-17 Janssen Biotech, Inc. Methods for producing anti-tnf antibody compositions
MA55284A (en) 2019-03-14 2022-01-19 Janssen Biotech Inc METHODS FOR PRODUCING ANTI-TNF ANTIBODY COMPOSITIONS
IL285909B2 (en) 2019-03-15 2023-04-01 Cartesian Therapeutics Inc Anti-bcma single chain variable fragments
WO2020188466A1 (en) 2019-03-18 2020-09-24 Janssen Biotech, Inc. Method of treating psoriasis in pediatric subjects with anti-il12/il23 antibody
JPWO2020189748A1 (en) 2019-03-19 2020-09-24
WO2020191326A1 (en) 2019-03-20 2020-09-24 Sumitomo Dainippon Pharma Oncology, Inc. Treatment of acute myeloid leukemia (aml) with venetoclax failure
US11090336B2 (en) 2019-03-27 2021-08-17 The Trustees Of The University Of Pennsylvania Tn-MUC1 chimeric antigen receptor (CAR) T cell therapy
EP3947442A2 (en) 2019-03-28 2022-02-09 Danisco US Inc. Engineered antibodies
TW202104244A (en) 2019-04-10 2021-02-01 日商中外製藥股份有限公司 Method for purifying fc region-modified antibody
KR20220019670A (en) 2019-04-17 2022-02-17 고쿠리츠다이가쿠호진 히로시마다이가쿠 A therapeutic agent for urinary cancer, characterized in that it is administered in combination with an IL-6 inhibitor and a CCR2 inhibitor
SG11202110287QA (en) 2019-04-24 2021-10-28 Heidelberg Pharma Res Gmbh Amatoxin antibody-drug conjugates and uses thereof
EP3962947A2 (en) 2019-05-03 2022-03-09 F. Hoffmann-La Roche AG Methods of treating cancer with an anti-pd-l1 antibody
AU2020279987A1 (en) 2019-05-23 2021-11-18 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to IL-23 and TNF alpha
US20200369759A1 (en) 2019-05-23 2020-11-26 Fibrogen, Inc. Methods of treatment of muscular dystrophies
AU2020289070A1 (en) 2019-06-03 2022-02-03 Janssen Biotech, Inc. Anti-TNF antibody compositions, and methods for the treatment of Psoriatic Arthritis
CA3142580A1 (en) 2019-06-03 2020-12-10 Janssen Biotech, Inc. Anti-tnf antibodies, compositions, and methods for the treatment of active ankylosing spondylitis
EP4023230A4 (en) 2019-06-05 2023-11-15 Chugai Seiyaku Kabushiki Kaisha Antibody cleavage site-binding molecule
TW202045711A (en) 2019-06-13 2020-12-16 美商安進公司 Automated biomass-based perfusion control in the manufacturing of biologics
EP4004041A1 (en) 2019-07-26 2022-06-01 Amgen Inc. Anti-il13 antigen binding proteins
WO2021028752A1 (en) 2019-08-15 2021-02-18 Janssen Biotech, Inc. Anti-tfn antibodies for treating type i diabetes
WO2021042019A1 (en) 2019-08-30 2021-03-04 Agenus Inc. Anti-cd96 antibodies and methods of use thereof
WO2021043206A1 (en) 2019-09-03 2021-03-11 百奥泰生物制药股份有限公司 Anti-tigit immunosuppressant and application thereof
JP2022547483A (en) 2019-09-04 2022-11-14 ジェネンテック， インコーポレイテッド CD8 binding agents and uses thereof
AU2020345787A1 (en) 2019-09-10 2022-03-24 Amgen Inc. Purification method for bispecific antigen-binding polypeptides with enhanced protein L capture dynamic binding capacity
KR20220062304A (en) 2019-09-12 2022-05-16 제넨테크, 인크. Compositions and methods for treating lupus nephritis
EP4041767A1 (en) 2019-09-26 2022-08-17 StCube & Co. Antibodies specific to glycosylated ctla-4 and methods of use thereof
EP4424321A2 (en) 2019-09-27 2024-09-04 F. Hoffmann-La Roche AG Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
WO2021072277A1 (en) 2019-10-09 2021-04-15 Stcube & Co. Antibodies specific to glycosylated lag3 and methods of use thereof
CN114641306A (en) 2019-10-18 2022-06-17 免疫治疗有限公司 Improved LAMP constructs comprising cancer antigens
EP4051298A1 (en) 2019-11-01 2022-09-07 Magenta Therapeutics, Inc. Dosing regimens for the mobilization of hematopoietic stem and progentor cells
JP2023501971A (en) 2019-11-01 2023-01-20 アレス トレーディング ソシエテ アノニム Combinatorial inhibition of PD-1, TGFβ, and ATM with radiotherapy for the treatment of cancer
BR112022008295A2 (en) 2019-11-05 2022-07-26 Merck Patent Gmbh COMBINED INHIBITION OF PD-1, TGFBETA AND TIGIT FOR THE TREATMENT OF CANCER
CN115066613A (en) 2019-11-06 2022-09-16 基因泰克公司 Diagnostic and therapeutic methods for treating hematologic cancers
US20220396599A1 (en) 2019-11-13 2022-12-15 Amgen Inc. Method for Reduced Aggregate Formation in Downstream Processing of Bispecific Antigen-Binding Molecules
EP3825330A1 (en) 2019-11-19 2021-05-26 International-Drug-Development-Biotech Anti-cd117 antibodies and methods of use thereof
AU2020397888A1 (en) 2019-12-05 2022-06-09 Alector Llc Methods of use of anti-TREM2 antibodies
US11897950B2 (en) 2019-12-06 2024-02-13 Augusta University Research Institute, Inc. Osteopontin monoclonal antibodies
JP2023504748A (en) 2019-12-09 2023-02-06 ジェネンテック， インコーポレイテッド Anti-PD-L1 antibody formulation
EP4073119A1 (en) 2019-12-12 2022-10-19 Alector LLC Methods of use of anti-cd33 antibodies
MX2022007688A (en) 2019-12-20 2022-07-19 Amgen Inc Mesothelin-targeted cd40 agonistic multispecific antibody constructs for the treatment of solid tumors.
JP2023508366A (en) 2019-12-27 2023-03-02 アフィメッド ゲゼルシャフト ミット ベシュレンクテル ハフツンク Methods for producing bispecific FCYRIIIxCD30 antibody constructs
EP4087657A1 (en) 2020-01-08 2022-11-16 Synthis Therapeutics, Inc. Alk5 inhibitor conjugates and uses thereof
US20230093169A1 (en) 2020-01-22 2023-03-23 Amgen Research (Munch) Gmbh Combinations of antibody constructs and inhibitors of cytokine release syndrome and uses thereof
WO2021194481A1 (en) 2020-03-24 2021-09-30 Genentech, Inc. Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
WO2022050954A1 (en) 2020-09-04 2022-03-10 Genentech, Inc. Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
JP2023512654A (en) 2020-01-31 2023-03-28 ジェネンテック， インコーポレイテッド Methods for Inducing Neoepitope-Specific T Cells Using PD-1 Axis Binding Antagonists and RNA Vaccines
CN113248611A (en) 2020-02-13 2021-08-13 湖南华康恒健生物技术有限公司 anti-BCMA antibody, pharmaceutical composition and application thereof
WO2021173565A1 (en) 2020-02-24 2021-09-02 Alector Llc Methods of use of anti-trem2 antibodies
WO2021177980A1 (en) 2020-03-06 2021-09-10 Genentech, Inc. Combination therapy for cancer comprising pd-1 axis binding antagonist and il6 antagonist
CA3174103A1 (en) 2020-03-06 2021-09-10 Go Therapeutics, Inc. Anti-glyco-cd44 antibodies and their uses
KR20220167276A (en) 2020-03-10 2022-12-20 매사추세츠 인스티튜트 오브 테크놀로지 Compositions and methods for immunotherapy of NPM1c-positive cancers
TW202200615A (en) 2020-03-12 2022-01-01 美商安進公司 Method for treatment and prophylaxis of crs in patients
WO2021188851A1 (en) 2020-03-19 2021-09-23 Amgen Inc. Antibodies against mucin 17 and uses thereof
JP7329288B2 (en) 2020-03-27 2023-08-18 株式会社PhotoQ3 Drugs to kill tumor cells
US20230203191A1 (en) 2020-03-30 2023-06-29 Danisco Us Inc Engineered antibodies
EP4130035A4 (en) 2020-03-31 2024-06-26 Bio-Thera Solutions, Ltd. Antibody and fusion protein for treating coronaviruses and use thereof
CA3172451A1 (en) 2020-04-03 2021-10-07 Robert Paul Methods of use of anti-trem2 antibodies
WO2021202959A1 (en) 2020-04-03 2021-10-07 Genentech, Inc. Therapeutic and diagnostic methods for cancer
US20230149555A1 (en) 2020-04-06 2023-05-18 PhotoQ3 Inc. Medicament for killing tumor cells
WO2021207449A1 (en) 2020-04-09 2021-10-14 Merck Sharp & Dohme Corp. Affinity matured anti-lap antibodies and uses thereof
EP4136459A1 (en) 2020-04-13 2023-02-22 Abbott Laboratories Methods, complexes and kits for detecting or determining an amount of a ss-coronavirus antibody in a sample
WO2021209458A1 (en) 2020-04-14 2021-10-21 Ares Trading S.A. Combination treatment of cancer
JP2023106635A (en) 2020-04-17 2023-08-02 中外製薬株式会社 Bispecific antigen binding molecules and compositions related thereto, uses, kits and methods for producing compositions
AU2021263754A1 (en) 2020-04-27 2022-12-01 Ensoma, Inc. Methods and compositions for transducing hematopoietic stem and progenitor cells in vivo
JP2023523145A (en) 2020-04-27 2023-06-02 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Isotype-independent antibody against lipoprotein (a)
EP4143345A1 (en) 2020-04-28 2023-03-08 Genentech, Inc. Methods and compositions for non-small cell lung cancer immunotherapy
MX2022014636A (en) 2020-05-19 2023-02-23 Amgen Inc Mageb2 binding constructs.
JPWO2021235537A1 (en) 2020-05-22 2021-11-25
EP3915641A1 (en) 2020-05-27 2021-12-01 International-Drug-Development-Biotech Anti-cd5 antibodies and methods of use thereof
WO2021243320A2 (en) 2020-05-29 2021-12-02 Amgen Inc. Adverse effects-mitigating administration of a bispecific antibody construct binding to cd33 and cd3
CN115803062A (en) 2020-06-03 2023-03-14 博泰康医药公司 Antibodies to trophoblast cell surface antigen 2 (TROP-2)
WO2021249969A1 (en) 2020-06-10 2021-12-16 Merck Patent Gmbh Combination product for the treatment of cancer diseases
IL299039A (en) 2020-06-16 2023-02-01 Genentech Inc Methods and compositions for treating triple-negative breast cancer
KR20230024368A (en) 2020-06-18 2023-02-20 제넨테크, 인크. Treatment with anti-TIGIT antibodies and PD-1 axis binding antagonists
EP4174071A4 (en) 2020-06-24 2024-09-11 Univ Tokyo Photosensitizing dye
WO2022006562A1 (en) 2020-07-03 2022-01-06 Dana-Farber Cancer Institute, Inc. Multispecific coronavirus antibodies
CA3189336A1 (en) 2020-07-24 2022-01-27 Amgen Inc. Immunogens derived from sars-cov2 spike protein
KR20230047397A (en) 2020-07-28 2023-04-07 추가이 세이야쿠 가부시키가이샤 Needle-added pre-filled syringe formulation with a needle shield containing a novel modified antibody
IL300225A (en) 2020-07-31 2023-03-01 Chugai Pharmaceutical Co Ltd Pharmaceutical composition including cell expressing chimeric receptor
IL300133A (en) 2020-07-31 2023-03-01 Genentech Inc Anti-integrin beta7 antibody formulations and devices
CN116568824A (en) 2020-08-03 2023-08-08 基因泰克公司 Method for diagnosing and treating lymphoma
WO2022031804A1 (en) 2020-08-04 2022-02-10 Abbott Laboratories Improved methods and kits for detecting sars-cov-2 protein in a sample
WO2022028608A1 (en) 2020-08-07 2022-02-10 百奥泰生物制药股份有限公司 Anti pd-l1 antibody and application thereof
WO2022036146A1 (en) 2020-08-12 2022-02-17 Genentech, Inc. Diagnostic and therapeutic methods for cancer
CN114106173A (en) 2020-08-26 2022-03-01 上海泰槿生物技术有限公司 anti-OX 40 antibodies, pharmaceutical compositions and uses thereof
WO2022045247A1 (en) 2020-08-27 2022-03-03 学校法人順天堂 Anti-truncated mutant calr-cd3 bispecific antibody and pharmaceutical composition
WO2022047381A1 (en) 2020-08-31 2022-03-03 Genentech, Inc. Methods for producing antibodies
WO2022051549A1 (en) 2020-09-04 2022-03-10 Rutgers, The State University Of New Jersey Sars-cov-2 vaccines and antibodies
EP4210832A1 (en) 2020-09-14 2023-07-19 Vor Biopharma, Inc. Chimeric antigen receptors for treatment of cancer
WO2022074206A1 (en) 2020-10-08 2022-04-14 Affimed Gmbh Trispecific binders
US12006550B2 (en) 2020-10-12 2024-06-11 University Of South Carolina Targeting treatment for ADAM30 in pathological cells
EP4229081A1 (en) 2020-10-15 2023-08-23 The United States of America, as represented by The Secretary, Department of Health and Human Services Antibody specific for sars-cov-2 receptor binding domain and therapeutic methods
WO2022087274A1 (en) 2020-10-21 2022-04-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibodies that neutralize type-i interferon (ifn) activity
WO2022093981A1 (en) 2020-10-28 2022-05-05 Genentech, Inc. Combination therapy comprising ptpn22 inhibitors and pd-l1 binding antagonists
CA3196550A1 (en) 2020-11-02 2022-05-05 Yan Lan Combination treatment of cancer
AU2021372815A1 (en) 2020-11-02 2023-06-22 Ares Trading S.A. Combination treatment of cancer
US20230406909A1 (en) 2020-11-02 2023-12-21 Roche Diagnostics Operations, Inc. Sars-cov-2 nucleocapsid antibodies
EP4240770A1 (en) 2020-11-06 2023-09-13 Amgen Research (Munich) GmbH Polypeptide constructs selectively binding to cldn6 and cd3
JP2023549116A (en) 2020-11-06 2023-11-22 アムジエン・インコーポレーテツド Multitarget bispecific antigen binding molecules with increased selectivity
AU2021373318A1 (en) 2020-11-06 2023-05-25 Amgen Inc. Antigen binding domain with reduced clipping rate
JP2023547661A (en) 2020-11-06 2023-11-13 アムジエン・インコーポレーテツド Polypeptide constructs that bind to CD3
JP2023551113A (en) 2020-11-06 2023-12-07 バイオ－テラ ソリュ－ションズ，エルティーディー． Bispecific antibodies and their applications
US20230406921A1 (en) 2020-11-12 2023-12-21 Mabwell (shanghai) Bioscience Co., Ltd. Antibody and preparation method therefor
WO2022119841A1 (en) 2020-12-01 2022-06-09 Abbott Laboratories Use of one or more biomarkers to determine traumatic brain injury (tbi) in a subject having received a head computerized tomography scan that is negative for a tbi
WO2023102384A1 (en) 2021-11-30 2023-06-08 Abbott Laboratories Use of one or more biomarkers to determine traumatic brain injury (tbi) in a subject having received a head computerized tomography scan that is negative for a tbi
WO2022140797A1 (en) 2020-12-23 2022-06-30 Immunowake Inc. Immunocytokines and uses thereof
WO2022147147A1 (en) 2020-12-30 2022-07-07 Abbott Laboratories Methods for determining sars-cov-2 antigen and anti-sars-cov-2 antibody in a sample
EP4301782A1 (en) 2021-03-05 2024-01-10 Go Therapeutics, Inc. Anti-glyco-cd44 antibodies and their uses
CA3211581A1 (en) 2021-03-10 2022-09-15 Ellen WU Immunomodulatory molecules and uses thereof
EP4305061A1 (en) 2021-03-12 2024-01-17 Janssen Biotech, Inc. Safe and effective method of treating psoriatic arthritis with anti-il23 specific antibody
WO2022191306A1 (en) 2021-03-12 2022-09-15 中外製薬株式会社 Pharmaceutical composition for treatment or prevention of myasthenia gravis
BR112023018400A2 (en) 2021-03-12 2023-12-12 Janssen Biotech Inc METHOD FOR TREATMENT OF PSORIATIC ARTHRITIS PATIENTS WITH INADEQUATE RESPONSE TO TNF THERAPY WITH SPECIFIC ANTI-IL23 ANTIBODY
BR112023018621A2 (en) 2021-03-15 2023-10-24 Hoffmann La Roche METHODS TO TREAT LUPUS NEPHRITIS, DEPLETION OF PERIPHERAL B CELLS, KITS TO TREAT LUPUS NEPHRITIS AND ANTI-CD20 TYPE II ANTIBODIES
EP4308694A1 (en) 2021-03-16 2024-01-24 Magenta Therapeutics, Inc. Dosing regimens for hematopoietic stem cell mobilization for stem cell transplants in multiple myeloma patients
AU2022241935A1 (en) 2021-03-22 2023-09-28 Novimmune S.A. Bispecific antibodies targeting cd47 and pd-l1 and methods of use thereof
US20220315655A1 (en) 2021-03-22 2022-10-06 Novimmune Sa Bispecific antibodies targeting cd47 and pd-l1 and methods of use thereof
EP4314068A1 (en) 2021-04-02 2024-02-07 The Regents Of The University Of California Antibodies against cleaved cdcp1 and uses thereof
MX2023011690A (en) 2021-04-02 2023-12-15 Amgen Inc Mageb2 binding constructs.
US20240239895A1 (en) 2021-04-09 2024-07-18 Genentech, Inc. Combination therapy with a raf inhibitor and a pd-1 axis inhibitor
EP4322922A1 (en) 2021-04-12 2024-02-21 ACM Biolabs Pte Ltd Polymersomes comprising a soluble encapsulated polynucleotide and an ionizable lipid as well as methods of making and uses thereof
WO2022233718A2 (en) 2021-05-03 2022-11-10 Merck Patent Gmbh Her2 targeting fc antigen binding fragment-drug conjugates
WO2022235628A1 (en) 2021-05-04 2022-11-10 Regeneron Pharmaceuticals, Inc. Multispecific fgf21 receptor agonists and their uses
WO2022235940A1 (en) 2021-05-06 2022-11-10 Dana-Farber Cancer Institute, Inc. Antibodies against alk and methods of use thereof
CA3217180A1 (en) 2021-05-06 2022-11-10 Amgen Research (Munich) Gmbh Cd20 and cd22 targeting antigen-binding molecules for use in proliferative diseases
WO2022245920A1 (en) 2021-05-18 2022-11-24 Abbott Laboratories Methods of evaluating brain injury in a pediatric subject
CA3221411A1 (en) 2021-05-25 2022-12-01 Merck Patent Gmbh Egfr targeting fc antigen binding fragment-drug conjugates
AU2022288571A1 (en) 2021-06-07 2024-01-04 Ares Trading S.A. Combination treatment of cancer
CA3218481A1 (en) 2021-06-14 2022-12-22 argenx BV Anti-il-9 antibodies and methods of use thereof
JP2024521476A (en) 2021-06-14 2024-05-31 アボット・ラボラトリーズ Methods for diagnosing or aiding in the diagnosis of brain injury caused by acoustic energy, electromagnetic energy, overpressure waves and/or blast waves
JP2024526315A (en) 2021-07-09 2024-07-17 ヤンセン バイオテツク，インコーポレーテツド Method for producing anti-TNF antibody composition
CN117916260A (en) 2021-07-09 2024-04-19 詹森生物科技公司 Methods of manufacture for preparing anti-IL 12/IL23 antibody compositions
WO2023281462A1 (en) 2021-07-09 2023-01-12 Janssen Biotech, Inc. Manufacturing methods for producing anti-tnf antibody compositions
WO2023010118A1 (en) 2021-07-29 2023-02-02 Vor Biopharma Inc. Nfat-responsive reporter systems for assessing chimeric antigen receptor activation and methods of making and using the same
JP2024529381A (en) 2021-07-30 2024-08-06 アフィメド ゲーエムベーハー Duplex Body
AU2022324456A1 (en) 2021-08-05 2024-02-15 Go Therapeutics, Inc. Anti-glyco-muc4 antibodies and their uses
WO2023018803A1 (en) 2021-08-10 2023-02-16 Byomass Inc. Anti-gdf15 antibodies, compositions and uses thereof
CA3229526A1 (en) 2021-08-16 2023-02-23 Hemogenyx Pharmaceuticals Llc Anti-flt3 antibodies, cars, car t cells and methods of use
AU2022328625A1 (en) 2021-08-17 2024-03-21 Eli Lilly And Company Bispecific anti-flt3/cd3 antibodies and methods of use
CN118715440A (en) 2021-08-31 2024-09-27 雅培实验室 Method and system for diagnosing brain injury
CA3230038A1 (en) 2021-08-31 2023-03-09 Hongwei Zhang Methods and systems of diagnosing brain injury
CA3230934A1 (en) 2021-09-03 2023-03-09 Go Therapeutics, Inc. Anti-glyco-cmet antibodies and their uses
JP2024534910A (en) 2021-09-03 2024-09-26 ジーオー セラピューティクス，インコーポレイテッド Anti-glycolic LAMP1 antibodies and uses thereof
EP4406556A1 (en) 2021-09-24 2024-07-31 PhotoQ3 Inc. Medicine for killing tumor cells
CA3232176A1 (en) 2021-09-30 2023-04-06 Beth MCQUISTON Methods and systems of diagnosing brain injury
EP4410839A1 (en) 2021-09-30 2024-08-07 Bio-Thera Solutions, Ltd. Anti-b7-h3 antibody and application thereof
WO2023057871A1 (en) 2021-10-04 2023-04-13 Novartis Ag Surfactant stabilizers
JPWO2023058723A1 (en) 2021-10-08 2023-04-13
CN118451101A (en) 2021-10-18 2024-08-06 百欧麦斯公司 Anti-activin A antibodies, compositions and uses thereof
WO2023072904A1 (en) 2021-10-26 2023-05-04 F. Hoffmann-La Roche Ag Monoclonal antibodies specific for sars-cov-2 rbd
IL312401A (en) 2021-10-29 2024-06-01 Janssen Biotech Inc Methods of treating crohn's disease with anti-il23 specific antibody
AR127568A1 (en) 2021-11-03 2024-02-07 Affimed Gmbh CD16A BISPECIFIC LIGANDS
CA3237018A1 (en) 2021-11-03 2023-05-11 Joachim Koch Bispecific cd16a binders
AU2022383057A1 (en) 2021-11-05 2024-05-16 Abviro Llc Human broadly crossreactive influenza monoclonal antibodies and methods of use thereof
WO2023081898A1 (en) 2021-11-08 2023-05-11 Alector Llc Soluble cd33 as a biomarker for anti-cd33 efficacy
US20230151087A1 (en) 2021-11-15 2023-05-18 Janssen Biotech, Inc. Methods of Treating Crohn's Disease with Anti-IL23 Specific Antibody
IL313021A (en) 2021-11-23 2024-07-01 Janssen Biotech Inc Method of treating ulcerative colitis with anti-il23 specific antibody
EP4436998A1 (en) 2021-11-24 2024-10-02 Dana-Farber Cancer Institute, Inc. Antibodies against ctla-4 and methods of use thereof
JP7367262B1 (en) 2021-12-01 2023-10-23 中外製薬株式会社 Method for preparing antibody-containing preparations
WO2023114978A1 (en) 2021-12-17 2023-06-22 Abbott Laboratories Systems and methods for determining uch-l1, gfap, and other biomarkers in blood samples
EP4448564A1 (en) 2021-12-17 2024-10-23 F. Hoffmann-La Roche AG A novel antibody for detection of amyloid beta 42 (a-beta42)
WO2023114543A2 (en) 2021-12-17 2023-06-22 Dana-Farber Cancer Institute, Inc. Platform for antibody discovery
CA3241395A1 (en) 2021-12-17 2023-06-22 Barbel SCHROFELBAUER Antibodies and uses thereof
WO2023122213A1 (en) 2021-12-22 2023-06-29 Byomass Inc. Targeting gdf15-gfral pathway cross-reference to related applications
WO2023144973A1 (en) 2022-01-27 2023-08-03 中外製薬株式会社 Pharmaceutical composition containing anti-pd-l1 antibody to be used in combination with anti-vegf antibody and paclitaxel
WO2023147107A1 (en) 2022-01-31 2023-08-03 Byomass Inc. Myeloproliferative conditions
AU2023216317A1 (en) 2022-02-04 2024-09-05 Abbott Laboratories Lateral flow methods, assays, and devices for detecting the presence or measuring the amount of ubiquitin carboxy-terminal hydrolase l1 and/or glial fibrillary acidic protein in a sample
CN118765204A (en) 2022-02-23 2024-10-11 艾利妥 Methods of using anti-TREM 2 antibodies
AU2023226293A1 (en) 2022-02-25 2024-09-05 Juntendo Educational Foundation Medicine comprising combination of anti-mutant-calr antibody and another drug
AU2023229884A1 (en) 2022-03-09 2024-10-10 Astrazeneca Ab BINDING MOLECULES AGAINST FRα
WO2023170216A1 (en) 2022-03-11 2023-09-14 Astrazeneca Ab A SCORING METHOD FOR AN ANTI-FRα ANTIBODY-DRUG CONJUGATE THERAPY
AU2023236386A1 (en) 2022-03-18 2024-10-10 Evolveimmune Therapeutics, Inc. Bispecific antibody fusion molecules and methods of use thereof
EP4245772A1 (en) 2022-03-18 2023-09-20 Netris Pharma Anti-netrin-1 antibody to treat liver inflammation
EP4249509A1 (en) 2022-03-22 2023-09-27 Netris Pharma Anti-netrin-1 antibody against arthritis-associated pain
WO2023186968A1 (en) 2022-03-29 2023-10-05 Netris Pharma Novel mcl-1 inhibitor and combination of mcl-1 and a bh3 mimetic, such as a bcl-2 inhibitor
WO2023187707A1 (en) 2022-03-30 2023-10-05 Janssen Biotech, Inc. Method of treating mild to moderate psoriasis with il-23 specific antibody
WO2023194539A1 (en) 2022-04-07 2023-10-12 Heidelberg Pharma Research Gmbh Methods of improving the therapeutic index of amatoxin-antibody conjugates
AU2023254186A1 (en) 2022-04-10 2024-10-17 Immunomic Therapeutics, Inc. Bicistronic lamp constructs comprising immune response enhancing genes and methods of use thereof
WO2023215498A2 (en) 2022-05-05 2023-11-09 Modernatx, Inc. Compositions and methods for cd28 antagonism
WO2023218027A1 (en) 2022-05-12 2023-11-16 Amgen Research (Munich) Gmbh Multichain multitargeting bispecific antigen-binding molecules of increased selectivity
WO2023223265A1 (en) 2022-05-18 2023-11-23 Janssen Biotech, Inc. Method for evaluating and treating psoriatic arthritis with il23 antibody
WO2023235415A1 (en) 2022-06-01 2023-12-07 Genentech, Inc. Method to identify a patient with an increased likelihood of chemotherapy-induced peripheral neuropathy
WO2023240109A1 (en) 2022-06-07 2023-12-14 Regeneron Pharmaceuticals, Inc. Multispecific molecules for modulating t-cell activity, and uses thereof
WO2023240058A2 (en) 2022-06-07 2023-12-14 Genentech, Inc. Prognostic and therapeutic methods for cancer
WO2023240124A1 (en) 2022-06-07 2023-12-14 Regeneron Pharmaceuticals, Inc. Pseudotyped viral particles for targeting tcr-expressing cells
WO2024006876A1 (en) 2022-06-29 2024-01-04 Abbott Laboratories Magnetic point-of-care systems and assays for determining gfap in biological samples
WO2024015953A1 (en) 2022-07-15 2024-01-18 Danisco Us Inc. Methods for producing monoclonal antibodies
WO2024039670A1 (en) 2022-08-15 2024-02-22 Dana-Farber Cancer Institute, Inc. Antibodies against cldn4 and methods of use thereof
WO2024039672A2 (en) 2022-08-15 2024-02-22 Dana-Farber Cancer Institute, Inc. Antibodies against msln and methods of use thereof
WO2024038165A1 (en) 2022-08-18 2024-02-22 Immunocore Ltd T cell receptor fusion proteins specific for mage a4
WO2024059675A2 (en) 2022-09-14 2024-03-21 Amgen Inc. Bispecific molecule stabilizing composition
WO2024059708A1 (en) 2022-09-15 2024-03-21 Abbott Laboratories Biomarkers and methods for differentiating between mild and supermild traumatic brain injury
US20240254234A1 (en) 2022-10-21 2024-08-01 Novimmune Sa PD-L1xCD28 BISPECIFIC ANTIBODIES FOR IMMUNE CHECKPOINT-DEPENDENT T CELL ACTIVATION
WO2024097639A1 (en) 2022-10-31 2024-05-10 Modernatx, Inc. Hsa-binding antibodies and binding proteins and uses thereof
WO2024097796A1 (en) 2022-11-02 2024-05-10 Kira Pharmaceuticals (Us) Llc Anti-c5 antibody fused to factor h for use in the treatment of complement-mediated diseases
WO2024097441A1 (en) 2022-11-02 2024-05-10 Kira Pharmaceuticals (Us) Llc Anti-c5 antibody fused to factor h for use in the treatment of complement-mediated diseases
WO2024102734A1 (en) 2022-11-08 2024-05-16 Genentech, Inc. Compositions and methods of treating childhood onset idiopathic nephrotic syndrome
US20240199734A1 (en) 2022-11-22 2024-06-20 Janssen Biotech, Inc. Method of Treating Ulcerative Colitis with Anti-IL23 Specific Antibody
WO2024118866A1 (en) 2022-12-01 2024-06-06 Modernatx, Inc. Gpc3-specific antibodies, binding domains, and related proteins and uses thereof
WO2024137589A2 (en) 2022-12-20 2024-06-27 Genentech, Inc. Methods of treating pancreatic cancer with a pd-1 axis binding antagonist and an rna vaccine
WO2024133858A1 (en) 2022-12-22 2024-06-27 Julius-Maximilians-Universität-Würzburg Antibodies for use as coagulants
WO2024152014A1 (en) 2023-01-13 2024-07-18 Regeneron Pharmaceuticals, Inc. Fgfr3 binding molecules and methods of use thereof
WO2024167898A1 (en) 2023-02-07 2024-08-15 Go Therapeutics, Inc. ANTIBODY FUSION PROTEINS COMPRISING ANTI-GLYCO-MUC4 ANTIBODIES AND MIC PROTEIN α1-α2 DOMAINS, AND THEIR USES
WO2024173607A2 (en) 2023-02-14 2024-08-22 Evolveimmune Therapeutics, Inc. Combination of bispecific antibodies and chimeric antigen receptor t cells for treatment
WO2024170660A1 (en) 2023-02-16 2024-08-22 Astrazeneca Ab Combination therapies for treatment of cancer with therapeutic binding molecules
WO2024178305A1 (en) 2023-02-24 2024-08-29 Modernatx, Inc. Compositions of mrna-encoded il-15 fusion proteins and methods of use thereof for treating cancer
WO2024180085A1 (en) 2023-02-27 2024-09-06 Netris Pharma Anti-netrin-1 monoclonal antibody for treating endometriosis and associated pains
WO2024187062A1 (en) 2023-03-08 2024-09-12 Amgen Inc. Controlled-ice nucleation lyophilization process for bispecific molecules
EP4431526A1 (en) 2023-03-16 2024-09-18 Emfret Analytics GmbH & Co. KG Anti-gpvi antibodies and functional fragments thereof
WO2024188355A1 (en) 2023-03-16 2024-09-19 Itabmed Biopharmaceutical (Shanghai) Co., Ltd. Multispecific antigen binding proteins and uses thereof
WO2024188356A1 (en) 2023-03-16 2024-09-19 Inmagene Biopharmaceuticals (Hangzhou) Co., Ltd. Ilt7-targeting antibodies and uses thereof
WO2024194686A2 (en) 2023-03-17 2024-09-26 Oxitope Pharma B.V. Anti-phosphocholine antibodies and methods of use thereof
WO2024194685A2 (en) 2023-03-17 2024-09-26 Oxitope Pharma B.V. Anti-phosphocholine antibodies and methods of use thereof
WO2024206126A1 (en) 2023-03-27 2024-10-03 Modernatx, Inc. Cd16-binding antibodies and uses thereof
WO2024211475A1 (en) 2023-04-04 2024-10-10 Abbott Laboratories Use of biomarkers to determine whether a subject has sustained, may have sustained or is suspected of sustaining a subacute acquired brain injury (abi)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994002602A1 (en) * 1992-07-24 1994-02-03 Cell Genesys, Inc. Generation of xenogeneic antibodies
WO1994025585A1 (en) * 1993-04-26 1994-11-10 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1996033735A1 (en) * 1995-04-27 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5204244A (en) * 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
WO1991000906A1 (en) * 1989-07-12 1991-01-24 Genetics Institute, Inc. Chimeric and transgenic animals capable of producing human antibodies

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994002602A1 (en) * 1992-07-24 1994-02-03 Cell Genesys, Inc. Generation of xenogeneic antibodies
WO1994025585A1 (en) * 1993-04-26 1994-11-10 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1996033735A1 (en) * 1995-04-27 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JAKOBOVITS A ET AL: "PRODUCTION OF ANTIGEN-SPECIFIC HUMAN ANTIBODIES FROM MICE ENGINEERED WITH HUMAN HEAVY AND LIGHT CHAIN YACS", ANNALS OF THE NEW YORK ACADEMY OF SCIENCES,US,NEW YORK ACADEMY OF SCIENCES, NEW YORK, NY, vol. 764, 29 September 1995 (1995-09-29), pages 525 - 535, XP002067728, ISSN: 0077-8923 *
See also references of WO9634096A1 *

Also Published As

Publication number Publication date
AU2466895A (en) 1996-11-18
EP0823941A1 (en) 1998-02-18
CA2219486A1 (en) 1996-10-31
WO1996034096A1 (en) 1996-10-31

Similar Documents

Publication Publication Date Title
EP0823941A4 (en) Human antibodies derived from immunized xenomice
IL136335A0 (en) Monoclonal human natural antibodies
PL311926A1 (en) Anti-alphav-integrinic monoclonal antibodies
IL128406A0 (en) Monoclonal antibodies
IL104620A (en) Humanized monoclonal antibodies against human interleukin-5
HK1015282A1 (en) High affinity human monoclonal antibodies specificfor rsv f-protein.
IL130143A0 (en) Humanized anti-CD11a antibodies
AU5365296A (en) Human monoclonal antibody against lung carcinoma
PL349266A1 (en) Human monoclonal antibodies to ctla-4
IL130864A0 (en) Monoclonal antibodies to human cd6
IL108199A0 (en) Monoclonal antibodies against the human il-4 receptor and hybridomas producing the same
ZA962280B (en) RAGE tumor rejection antigens
HUP9800613A3 (en) Humanized antibody against human fas-antigene
AU6155896A (en) Humanized antibodies to e-selectin
EP0977590A4 (en) Human monoclonal antibodies
AU5021796A (en) Recombinant human anti-lewis b antibodies
ZA9510195B (en) Monoclonal antibody fragments having immunosuppressant activity
EP0871641A4 (en) Multiple administrations of anti-tnf antibody
HUP9601394A1 (en) Two-function brassiere
IL102088A0 (en) Me20:monoclonal antibodies and antigen for human melanoma
ZA941645B (en) Antibodies specifically reactive against human prostate specific antigen.
ZA951113B (en) Tumor assosiated monoclonal antibody 123av16
AU2828795A (en) Monoclonal antibodies for the reduction of anti-xenogeneic immune responses
AU4775899A (en) Human monoclonal antibodies against the tumor antigen uk114 and lymphocyte cellsand hybridomas for their production
ZA912136B (en) Anti-oncostatin m monoclonal antibodies

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19971128

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 20010806

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

RIC1 Information provided on ipc code assigned before grant

Free format text: 7C 12N 15/00 A, 7C 07K 16/00 B

17Q First examination report despatched

Effective date: 20020205

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20030308

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1009153

Country of ref document: HK